0001527728
false
0001527728
2023-09-28
2023-09-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 28, 2023
Renovaro
Biosciences Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-54478 |
|
45-2559340 |
(State
or other jurisdiction |
|
(Commission
File Number) |
|
(I.R.S.
Employer |
of
incorporation) |
|
|
|
Identification
No.) |
2080
Century Park East, Suite 906
Los
Angeles, CA 90067
(Address
of principal executive offices)
+1(305)
918-1980
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☒ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
Common
Stock, par value $0.0001 per share |
|
ENOB |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01.
Entry into a Material Definitive Agreement
On September 28, 2023, Renovaro Biosciences Inc. (NASDAQ:
RENB) (“Renovaro”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GEDi
Cube Intl Ltd., a private company formed under the laws of England and Wales (“GEDi Cube”). Upon the terms and subject
to the conditions set forth in the Purchase Agreement, Renovaro will acquire 100% of the equity interests of GEDi Cube from its equity
holders (the “Sellers”) and GEDi Cube will become a wholly-owned subsidiary of Renovaro (the “Transaction”).
On September 28, 2023, the board of directors of Renovaro, and the board of managers of GEDi Cube unanimously approved the Purchase Agreement.
At the effective time of the Transaction (the
“Effective Time”), each ordinary share of GEDi Cube (each, a “GEDi
Cube Share”) issued and outstanding as of immediately prior to the Effective Time will be exchanged for (i) shares of common
stock of Renovaro, par value $0.0001 (the “Renovaro Shares”) such that the
total number of Renovaro Shares issued to the holders of GEDi Cube Shares shall equal 50% of the total number of Renovaro Shares outstanding
as of the Effective Time, subject to certain adjustments (the “Closing Consideration”)
and (ii) earn-out Renovaro Shares to be issued pro rata to the Sellers upon the exercise or conversion of any of Renovaro’s derivative
securities (subject to certain exceptions) which are outstanding at the Effective Time (the “Earnout
Shares”).
Each of Renovaro and GEDi Cube has agreed,
subject to certain exceptions with respect to unsolicited proposals, not to directly or indirectly solicit competing acquisition proposals
or to enter into discussions concerning, or provide confidential information in connection with, any unsolicited alternative acquisition
proposals.
The completion of the Transaction is subject
to the satisfaction or waiver of customary closing conditions, including: (i) adoption of the Purchase Agreement by holders of all
of the outstanding GEDi Cube Shares, (ii) approval of the issuance of Renovaro Shares in connection with the Transaction by a majority
of the votes cast at the shareholder meeting of Renovaro, (iii) absence of any court order or regulatory injunction prohibiting completion
of the Transaction, (iv) subject to specified materiality standards, the accuracy of the representations and warranties of the other
party, (v) the authorization for listing of Renovaro Shares to be issued in the Transaction on the Nasdaq, (vi) compliance by
the other party in all material respects with its covenants, and (vii) the entry by the parties into a registration rights agreement,
to become effective as of the Effective Time, pursuant to which Renvoaro will provide registration rights to the Sellers with respect
to (a) the Renovaro Shares issued to the Sellers as Closing Consideration at the Effective Time and (b) any Earnout Shares that they receive
after the Closing.
Renovaro and GEDi Cube have each made customary
representations and warranties in the Purchase Agreement. The Purchase Agreement also contains customary covenants and agreements, including
covenants and agreements relating to (i) the conduct of each of Renovaro’s and GEDi Cube’s business between the date
of the signing of the Purchase Agreement and the closing date of the Transaction and (ii) the efforts of the parties to cause the
Transaction to be completed.
The Purchase Agreement contains certain termination
rights for both Renovaro and GEDi Cube.
The Purchase Agreement is attached hereto as Exhibit
2.1 and is incorporated by reference. The foregoing summary has been included to provide investors and security holders with information
regarding the terms of the Purchase Agreement and is qualified in its entirety by the terms and conditions of the Purchase Agreement.
It is not intended to provide any other factual information about Renovaro, GEDi Cube or their respective subsidiaries and affiliates.
The Purchase Agreement contains representations and warranties by each of the parties to the Purchase Agreement, which were made only
for purposes of the Purchase Agreement and as of specified dates. The representations, warranties and covenants in the Purchase Agreement
were made solely for the benefit of the parties to the Purchase Agreement; may be subject to limitations agreed upon by the contracting
parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties
to the Purchase Agreement instead of establishing these matters as facts; and may be subject to standards of materiality applicable to
the contracting parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and
covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Renovaro, GEDi Cube or any of
their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and
covenants may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in Renovaro’s
public disclosures.
Item 3.02.
Unregistered Shares of Equity Securities.
Pursuant to the Purchase Agreement described above
in Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference, Renovaro has agreed to deliver
the Renovaro Shares to the holders of GEDi Shares at the closing of the Transaction, subject to the satisfaction of the closing conditions
set forth in the Purchase Agreement. The issuance of the Renovaro Shares by Renovaro to the holders of GEDi Cube Shares will be made pursuant
to the exemption from registration provided by Section 4(a)(2) and Regulation S of the Securities Act of 1933, as amended.
Item 8.01.
Other Events.
On September 29, 2023, Renovaro issued a release announcing the entry into
the Purchase Agreement. A copy of the joint press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Cautionary Statement Regarding Forward-Looking
Statements
This report contains “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included in this communication that address activities, events or developments that Renovaro
or GEDi Cube expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as “estimate,”
“project,” “predict,” “believe,” “expect,” “anticipate,” “potential,”
“create,” “intend,” “could,” “would,” “may,” “plan,” “will,”
“guidance,” “look,” “goal,” “future,” “build,” “focus,” “continue,”
“strive,” “allow” or the negative of such terms or other variations thereof and words and terms of similar substance
used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of
these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to,
statements regarding the proposed Transaction, the expected closing of the proposed Transaction and the timing thereof and as adjusted
descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital
expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance. Information adjusted
for the proposed Transaction should not be considered a forecast of future results. There are a number of risks and uncertainties that
could cause actual results to differ materially from the forward-looking statements included in this communication. These include the
risk that cost savings, synergies and growth from the proposed Transaction may not be fully realized or may take longer to realize than
expected; the possibility that shareholders of Renovaro may not approve the issuance of new shares of Renovaro common stock in the proposed
Transaction; the risk that a condition to closing of the proposed Transaction may not be satisfied, that either party may terminate the
Transaction Agreement or that the closing of the proposed Transaction might be delayed or not occur at all; potential adverse reactions
or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed Transaction;
the occurrence of any other event, change or other circumstances that could give rise to the termination of the stock purchase agreement
relating to the proposed Transaction; the risk that changes in Renovaro’s capital structure and governance could have adverse effects
on the market value of its securities and its ability to access the capital markets; the ability of Renovaro to retain its Nasdaq listing;
the ability of GEDi Cube to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers
and on GEDi Cube’s operating results and business generally; the risk the proposed Transaction could distract management from ongoing
business operations or cause Renovaro and/or GEDi Cube to incur substantial costs; the risk that GEDi Cube may be unable to reduce expenses;
the impact of the COVID-19 pandemic, any related economic downturn; the risk of changes in regulations effecting the healthcare industry;
and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult
to predict and are beyond Renovaro’s or GEDi Cube’s control, including those detailed in Renovaro’s Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on Renovaro’s website at www.renovarobio.com
and on the website of the Securities and Exchange Commission (the “SEC”) at
www.sec.gov. All forward-looking statements are based on assumptions that Renovaro and GEDi Cube believe to be reasonable but that may
not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither Renovaro
nor GEDi Cube undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future
events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
No Offer or Solicitation
This report is not intended to and shall not constitute
an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any
vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except
by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Important Additional Information Regarding the
Merger Will Be Filed with the SEC and Where to Find It
In connection with the proposed Transaction, Renovaro
intends to file a proxy statement (the “proxy statement”), and will file other documents regarding the proposed Transaction
with the SEC. INVESTORS AND SECURITYHOLDERS OF RENOVARO ARE URGED TO CAREFULLY AND THOROUGHLY READ, WHEN THEY BECOME AVAILABLE,
THE PROXY STATEMENT, AS MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY RENOVARO WITH THE SEC
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RENOVARO, GEDI CUBE AND THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND
RELATED MATTERS.
Once complete, a definitive proxy statement will be
mailed to stockholders of Renovaro. Investors will be able to obtain free copies of the proxy statement, as may be amended from time to
time, and other relevant documents filed by Renovaro with the SEC (when they become available) through the website maintained by the SEC
at www.sec.gov. Copies of documents filed with the SEC by Renovaro, including the proxy statement (when it becomes available), will be
available free of charge from Renovaro’s website at www.renovarobio.com under the “Financials” tab.
Participants in the Solicitation
Renovaro and its directors and executive officers
may be deemed to be participants in the solicitation of proxies from the stockholders of Renovaro in connection with the proposed Transaction.
Information about Renovaro’s directors and executive officers is set forth in Renovaro’s definitive proxy statement for the
2023 annual meeting of stockholders filed with the SEC on May 16, 2023, and the proxy statement (when it becomes available). Other information
regarding the interests of such individuals, as well as information regarding other persons who may be deemed participants in the proposed
Transaction, will be set forth in the proxy statement and other relevant materials to be filed with the SEC when they become available.
Stockholders of Renovaro, potential investors, and other readers should read the proxy statement carefully when it becomes available before
making any voting or investment decisions.
Item 9.01.
Financial Statements and Exhibits
2.1* |
|
Stock Purchase Agreement, dated as of September 28, 2023, by and among Renovaro Biosciences Inc., GEDi Cube Intl Ltd., Yalla Yalla Ltd., in its capacity as Sellers’ Representative, and the Sellers party thereto |
|
|
99.1 |
|
Press Release, dated September 29, 2023, issued by Renovaro |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* |
Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(2). Renovaro agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
RENOVARO BIOSCIENCES, INC. |
|
|
|
By: |
/s/ Luisa Puche |
|
|
Name: Luisa Puche |
|
|
Title: Chief Financial Officer |
|
Date: September 29, 2023
EXHIBIT 2.1
EXECUTION VERSION
Renovaro
Biosciences Inc., as Buyer,
GEDi
Cube Intl Ltd., as Company
The
Sellers SIGNATORIES Hereto
and
Yalla
Yalla Ltd., in its capacity as Sellers’ Representative
Stock
Purchase AGREEMENT
Dated as of September 28, 2023
|
TABLE OF CONTENTS |
|
|
|
Page |
|
|
|
ARTICLE I DEFINITIONS |
2 |
|
|
|
1.1 |
Certain Defined Terms |
2 |
|
|
|
1.2 |
Definitions |
14 |
|
|
|
ARTICLE II PURCHASE AND SALE; CLOSING |
17 |
|
|
|
2.1 |
Purchase and Sale of Shares |
17 |
|
|
|
2.2 |
Exchange Consideration |
17 |
|
|
|
2.2.1 |
Earnout; Earnout Stock |
17 |
|
|
|
2.3 |
Amended Buyer Organizational Documents |
18 |
|
|
|
2.4 |
Surrender of Purchased Shares |
19 |
|
|
|
2.5 |
Termination of Certain Agreements |
19 |
|
|
|
2.6 |
Taking of Necessary Action |
19 |
|
|
|
2.7 |
Closing |
19 |
|
|
|
ARTICLE III REPRESENTATIONS AND WARRANTIES |
19 |
|
|
|
3.1 |
Representations and Warranties Relating to Target Companies |
19 |
|
|
|
3.1.1 |
Organization, Standing, and Power |
20 |
|
|
|
3.1.2 |
Capital Structure |
20 |
|
|
|
3.1.3 |
Authority |
22 |
|
|
|
3.1.4 |
No Conflicts; Consents, Notices and Approvals |
22 |
|
|
|
3.1.5 |
Financial Statements |
22 |
|
|
|
3.1.6 |
Litigation |
23 |
|
|
|
3.1.7 |
Absence of Undisclosed Liabilities |
24 |
|
|
|
3.1.8 |
No Violations |
24 |
|
|
|
3.1.9 |
Compliance with Healthcare Laws |
24 |
|
|
|
3.1.10 |
Ethical Practices |
24 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
3.1.11 |
Employment Matters |
25 |
|
|
|
3.1.12 |
Employee Benefit Plans |
26 |
|
|
|
3.1.13 |
Real Property; Leases |
27 |
|
|
|
3.1.14 |
Environmental |
27 |
|
|
|
3.1.15 |
Company Material Contracts |
27 |
|
|
|
3.1.16 |
Taxes. |
29 |
|
|
|
3.1.17 |
Intellectual Property Rights |
30 |
|
|
|
3.1.18 |
Artificial Intelligence |
31 |
|
|
|
3.1.19 |
Privacy and Information Security. |
32 |
|
|
|
3.1.20 |
Brokers and Other Fees |
33 |
|
|
|
3.1.21 |
Insurance |
33 |
|
|
|
3.1.22 |
Affiliate Transactions |
34 |
|
|
|
3.1.23 |
Absence of Certain Changes |
34 |
|
|
|
3.1.24 |
Disclosure |
34 |
|
|
|
3.1.25 |
Independent Investigation |
34 |
|
|
|
3.1.26 |
Information Supplied |
35 |
|
|
|
3.2 |
Representations and Warranties of Buyer |
35 |
|
|
|
3.2.1 |
Organization; Standing and Power |
35 |
|
|
|
3.2.2 |
Capitalization |
36 |
|
|
|
3.2.3 |
Authority |
38 |
|
|
|
3.2.4 |
Valid Issuance of Shares |
39 |
|
|
|
3.2.5 |
No Conflicts; Consents, Notices and Approvals |
39 |
|
|
|
3.2.6 |
SEC Documents; Financial Statements |
39 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
3.2.7 |
Litigation |
40 |
|
|
|
3.2.8 |
Absence of Undisclosed Liabilities |
40 |
|
|
|
3.2.9 |
No Violations |
40 |
|
|
|
3.2.10 |
Compliance with Healthcare Laws |
41 |
|
|
|
3.2.11 |
Ethical Practices |
42 |
|
|
|
3.2.12 |
Employment Matters |
42 |
|
|
|
3.2.13 |
Employee Benefit Plans |
44 |
|
|
|
3.2.14 |
Real Property; Lease |
44 |
|
|
|
3.2.15 |
Environmental |
45 |
|
|
|
3.2.16 |
Buyer Material Contracts |
45 |
|
|
|
3.2.17 |
Tax Returns and Payments |
47 |
|
|
|
3.2.18 |
Intellectual Property Rights |
48 |
|
|
|
3.2.19 |
Privacy and Information Security. |
49 |
|
|
|
3.2.20 |
Brokers and Other Fees |
49 |
|
|
|
3.2.21 |
Insurance |
50 |
|
|
|
3.2.22 |
D&O Policy |
50 |
|
|
|
3.2.23 |
Affiliate Transactions |
50 |
|
|
|
3.2.24 |
Absence of Certain Changes |
50 |
|
|
|
3.2.25 |
Compliance with Regulation S |
51 |
|
|
|
3.2.26 |
Disclosure |
51 |
|
|
|
3.2.27 |
Independent Investigation |
51 |
|
|
|
3.2.28 |
Liens on Company and Company Shares |
51 |
|
|
|
3.2.29 |
Information Supplied |
51 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
3.3 |
Representations and Warranties with respect to Sellers |
52 |
|
|
|
3.3.1 |
Organization, Standing, and Power |
52 |
|
|
|
3.3.2 |
Authority |
52 |
|
|
|
3.3.3 |
Investment Representations |
53 |
|
|
|
ARTICLE IV COVENANTS OF COMPANY AND SELLER |
54 |
|
|
|
4.1 |
Conduct of Business |
54 |
|
|
|
4.1.1 |
Ordinary Course |
54 |
|
|
|
4.1.2 |
Seller Transfers |
56 |
|
|
|
4.1.3 |
Exclusivity; Acquisition Proposals |
57 |
|
|
|
4.1.4 |
Company Financial Statements |
58 |
|
|
|
4.1.5 |
No Trading |
59 |
|
|
|
4.2 |
Notification; Access to Information |
59 |
|
|
|
4.2.1 |
Cooperation |
59 |
|
|
|
4.2.2 |
Access to Information |
59 |
|
|
|
4.3 |
Consents and Notices |
60 |
|
|
|
4.4 |
Commercially Reasonable Efforts |
60 |
|
|
|
4.5 |
Proxy Statement |
60 |
|
|
|
4.6 |
Issuance of Company Oridinary Shares to Consultant and Employee |
60 |
|
|
|
ARTICLE V COVENANTS OF BUYER |
60 |
|
|
|
5.1 |
Conduct of Business |
60 |
|
|
|
5.1.1 |
Ordinary Course |
60 |
|
|
|
5.1.2 |
Exclusivity; Acquisition Proposals |
63 |
|
|
|
5.1.3 |
Buyer Public Filings |
63 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
5.2 |
Notification; Access to Information |
64 |
|
|
|
5.2.1 |
Cooperation |
64 |
|
|
|
5.2.2 |
Access to Information |
64 |
|
|
|
5.3 |
Consents and Notices |
64 |
|
|
|
5.4 |
Commercially Reasonable Efforts |
65 |
|
|
|
5.5 |
Proxy Statements; Buyer Stockholder Meeting |
65 |
|
|
|
5.5.1 |
Proxy Statements |
65 |
|
|
|
5.5.2 |
Buyer Stockholder Meeting |
65 |
|
|
|
5.5.3 |
Stockholder Approval of Amendment |
66 |
|
|
|
5.6 |
Fairness Opinion |
66 |
|
|
|
5.7 |
D&O Policy |
66 |
|
|
|
ARTICLE VI ADDITIONAL AGREEMENTS |
66 |
|
|
|
6.1 |
Confidentiality Agreement |
66 |
|
|
|
6.2 |
Expenses |
66 |
|
|
|
6.3 |
Further Assurances |
67 |
|
|
|
6.4 |
Public Announcements |
67 |
|
|
|
6.4.1 |
Prior Written Consent |
67 |
|
|
|
6.4.2 |
Press Releases and Filings |
67 |
|
|
|
6.5 |
Post-Closing Board of Directors |
68 |
|
|
|
6.6 |
Indemnification of Company’s Board and Officers |
68 |
|
|
|
6.7 |
Post-Closing Tax Matters |
68 |
|
|
|
6.7.1 |
Returns Filed |
68 |
|
|
|
6.7.2 |
Tax Cooperation |
69 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
6.7.3 |
No Amendments |
69 |
|
|
|
6.7.4 |
Transfer Taxes |
69 |
|
|
|
6.8 |
Efforts to Consummate; Regulatory Matters and Approvals |
69 |
|
|
|
6.8.1 |
Defense of Proceedings |
69 |
|
|
|
6.9 |
Securities Laws Compliance |
69 |
|
|
|
6.10 |
Delivery of Disclosure Schedules |
69 |
|
|
|
6.11 |
Additional Sellers |
70 |
|
|
|
ARTICLE VII CONDITIONS PRECEDENT |
70 |
|
|
|
7.1 |
Conditions to Each Party’s Obligation to Effect the Transactions |
70 |
|
|
|
7.1.1 |
Buyer Stockholder Approval |
70 |
|
|
|
7.1.2 |
Consents |
70 |
|
|
|
7.1.3 |
No Order |
70 |
|
|
|
7.1.4 |
Nasdaq Listing |
70 |
|
|
|
7.2 |
Conditions to Obligations of Buyer |
71 |
|
|
|
7.2.1 |
Representations and Warranties of Company and Sellers |
71 |
|
|
|
7.2.2 |
Agreements and Covenants |
71 |
|
|
|
7.2.3 |
No Company Material Adverse Effect |
72 |
|
|
|
7.2.4 |
Return of All Distributions |
72 |
|
|
|
7.2.5 |
Certain Transaction Documents |
72 |
|
|
|
7.2.6 |
Seller’s and Company’s Closing Deliverables |
72 |
|
|
|
7.2.7 |
Legal Action |
73 |
|
|
|
7.2.8 |
Financial Statements |
73 |
|
|
|
7.2.9 |
Fairness Opinion |
73 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
7.2.10 |
Termination of Certain Agreements |
73 |
|
|
|
7.3 |
Conditions to Obligation of Company and Sellers |
73 |
|
|
|
7.3.1 |
Representations and Warranties of Buyer |
73 |
|
|
|
7.3.2 |
Agreements and Covenants |
74 |
|
|
|
7.3.3 |
No Buyer Material Adverse Effect |
74 |
|
|
|
7.3.4 |
Certain Transaction Documents |
74 |
|
|
|
7.3.5 |
Buyer Organizational Documents |
74 |
|
|
|
7.3.6 |
Appointment to the Board |
74 |
|
|
|
7.3.7 |
Buyer Closing Deliverables |
74 |
|
|
|
7.4 |
Frustrations of Conditions |
75 |
|
|
|
ARTICLE VIII INDEMNIFICATION |
75 |
|
|
|
8.1 |
Indemnification by Sellers |
75 |
|
|
|
8.2 |
Indemnification by Buyer |
76 |
|
|
|
8.3 |
Third Party Claims |
77 |
|
|
|
8.4 |
Tax Contests |
78 |
|
|
|
8.5 |
Survival |
79 |
|
|
|
8.6 |
Limitations |
79 |
|
|
|
8.6.1 |
Threshold Amounts |
80 |
|
|
|
8.6.2 |
Caps |
80 |
|
|
|
8.7 |
Exclusive Remedy |
81 |
|
|
|
8.8 |
Value of Shares |
82 |
|
|
|
8.9 |
Losses Net of Insurance Coverage |
82 |
|
|
|
8.10 |
No Duplicative Recovery |
82 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
8.11 |
Straddle Period |
83 |
|
|
|
8.12 |
Tax Treatment of Indemnification Payments |
83 |
|
|
|
ARTICLE IX CLAIMS |
83 |
|
|
|
9.1 |
Notice of Claims and Expenses |
83 |
|
|
|
9.2 |
Resolution of Claims |
83 |
|
|
|
9.3 |
Arbitration |
84 |
|
|
|
ARTICLE X TERMINATION, AMENDMENT, AND WAIVER |
84 |
|
|
|
10.1 |
Termination |
84 |
|
|
|
10.1.1 |
Mutual Written Consent |
85 |
|
|
|
10.1.2 |
Written Notice by Buyer or Sellers’ Representatives |
85 |
|
|
|
10.1.3 |
Written Notice of Order |
85 |
|
|
|
10.1.4 |
Written Notice of Breach by Buyer |
85 |
|
|
|
10.1.5 |
Written Notice of Breach by Company or Seller |
85 |
|
|
|
10.1.6 |
Written Notice of Company Material Adverse Effect |
86 |
|
|
|
10.1.7 |
Written Notice of Buyer Stockholder Meeting |
86 |
|
|
|
10.1.8 |
Written Notice of Unsatisfactory Buyer Due Diligence |
86 |
|
|
|
10.1.9 |
Written Notice of Unsatisfactory Seller Due Diligence |
86 |
|
|
|
10.2 |
Effect of Termination |
86 |
|
|
|
ARTICLE XI GENERAL PROVISIONS |
86 |
|
|
|
11.1 |
Notices |
86 |
|
|
|
11.2 |
Disclosure Schedule |
88 |
|
|
|
11.3 |
Supplements to Disclosure Schedule |
88 |
|
|
|
11.4 |
Interpretation |
88 |
|
TABLE OF CONTENTS |
|
|
(continued) |
|
|
|
Page |
11.5 |
Counterparts |
89 |
|
|
|
11.6 |
Entire Understanding; No Third Party Beneficiaries |
89 |
|
|
|
11.7 |
Governing Law |
90 |
|
|
|
11.8 |
Amendment; Waiver |
90 |
|
|
|
11.9 |
Successors and Assigns |
90 |
|
|
|
11.10 |
Specific Performance |
90 |
|
|
|
11.11 |
Severability |
90 |
|
|
|
11.12 |
Submission to Jurisdiction |
91 |
|
|
|
11.13 |
Waiver of Jury Trial |
91 |
|
|
|
11.14 |
Sellers’ Representative |
91 |
|
|
|
11.14.1 |
Appointment of Seller’s Representative |
91 |
|
|
|
11.14.2 |
Reliance by the Sellers’ Representative |
92 |
|
|
|
11.14.3 |
Expenses of the Sellers’ Representative |
93 |
|
|
|
11.14.4 |
Indemnification of the Sellers’ Representative |
93 |
|
|
|
11.14.5 |
Resignation of the Sellers’ Representative |
93 |
|
|
|
11.15 |
Legal Representation |
93 |
STOCK PURCHASE AGREEMENT
This stock
purchase AGREEMENT (this “Agreement”), dated September 28, 2023 (the “Effective Date”),
is by and among Renovaro Biosciences Inc., a Delaware corporation (“Buyer”), GEDi Cube Intl Ltd., a private
company formed under the laws of England and Wales (“Company”), each of the
shareholders of the Company that are named on signature pages hereto that have executed and delivered a copy of this
Agreement as of the date hereof (collectively the “Signing Sellers”), each of the other shareholders of the
Company that after the Effective Date execute and deliver to the Buyer, the Company and the Seller Representative (as defined below)
a joinder agreement in substantially the form attached as Exhibit A hereto (each a “Seller Joinder”)
to become a party to this Agreement which Seller Joinder is accepted in writing and executed and delivered by Buyer, the Company
and the Seller Representative (collectively, the “Joining Sellers” and, together with the Signing Sellers, each
a “Seller” and collectively, the “Sellers”), and Yalla Yalla Ltd., a private limited liability
company registered and incorporated under the laws of Malta with company registration number C 103531 (“Yalla”),
in its capacity as representative to the Sellers (the “Sellers’ Representative”). Buyer, Company, Sellers
and the Sellers’ Representative are each referred to as a “Party” or collectively as the “Parties.”
WHEREAS, the Signing Sellers
own the issued shares and other equity interests in or of Company set forth opposite such Signing Seller’s name in Exhibit
B hereto (the “Company Shares”);
WHEREAS, Company holds the
legal and beneficial title to all issued and outstanding shares, with a nominal value of EUR 0.01 (one euro cent) each, in the
capital of Grace Systems B.V., a private limited liability company (een besloten vennootschap met beperkte aansprakelijkheid)
organized and existing under the laws of the Netherlands, having its corporate seat (statutaire zetel) in Amsterdam, the
Netherlands, with address at Park Oosterspaarn 48, 2036MB Haarlem, the Netherlands, registered with the Trade Register of the Dutch
Chamber of Commerce under number 58062203 (“Grace”), which such shares constitute the only issued and outstanding
equity interests of Grace;
WHEREAS, Company holds the
legal and beneficial title to all issued and outstanding shares, with a nominal value of EUR 0.01 (one euro cent) each, in the
capital of Gedi Cube B.V., a private limited liability company (een besloten vennootschap met beperkte aansprakelijkheid)
organized and existing under the laws of the Netherlands, having its corporate seat (statutaire zetel) in Amsterdam, the
Netherlands, with address at Park Oosterspaarn 48, 2036MB Haarlem, the Netherlands, registered with the Trade Register of the Dutch
Chamber of Commerce under number 91275237, “GC Sub”),
which such shares constitute the only issued and outstanding equity interests of GC Sub;
Whereas,
Grace and GC Sub are engaged in the business of artificial intelligence machine learning technology with validation in humans for
early diagnosis of lung cancers, as well as silico detection for additional cancers;
WHEREAS, Buyer is a biotechnology
company committed to developing advanced cell and gene therapies to promote stronger immune system responses potentially for long-term
or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such
as Human Immunodeficiency Virus and potentially Hepatitis B virus infection;
Whereas,
the Signing Sellers, and upon their execution and delivery of this Agreement, the Joining Sellers, desire to sell to Buyer, and
Buyer desires to purchase from the Signing Sellers, and upon their execution and delivery of this Agreement, from the Joining Sellers,
all of the issued and outstanding shares and any other equity interests in or of the Company
in exchange for newly issued shares of Buyer Common Stock (the “Share Exchange”), on the terms and conditions
set forth in this Agreement.
NOW,
Therefore, in consideration of the premises and the mutual representations, warranties, covenants, and agreements in this
Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties intending to be legally bound, agree as follows:
Article
I
DEFINITIONS
1.1 Certain Defined
Terms. The terms below are defined as follows:
“Acquisition Proposal”
means any inquiry, proposal or offer, or any indication of interest in making an offer or proposal, from any Person or group at
any time relating to an Alternative Transaction.
“AI”
collectively means the AI Inputs, AI Outputs and AI Technology;
“AI Inputs”
means any and all of the following generated by or derived from AI Technology which are, in whole or in part, used or relied upon,
or licensed, sold, otherwise provided or accessed, by or to Company or its subsidiaries, including but not limited to, data, writings,
works of authorship, graphics, pictures, recordings, any electronic or other information, text or numerals, audio or visual content,
or materials of any nature or description;
“AI Outputs”
means any and all services, products, data, writings, works of authorship, graphics, pictures, recordings, any electronic or other
information, text or numerals, audio or visual content, or materials of any nature or description generated or derived by or on
behalf of Company or its subsidiaries, from any AI Technology or AI Inputs, where such outputs are licensed, sold, provided to,
or otherwise made available or accessible by Company or its subsidiaries to any third party;
“AI Technology”
means any and all training, self-improving, or machine learning software, algorithms, hardware or other artificial intelligence
tools or aids of any kind.
“Accounting Principles”
means, (i) with respect to Buyer and the other Renovaro Group members, US GAAP, (ii) with respect to Company, UK GAAP, and
(iii) with respect to the Company’s subsidiaries, Dutch GAAP.
“Applicable Percentage”
means an amount, expressed as a percentage and calculated as of the Closing Date immediately prior to Closing, equal to the ratio
of (a) the aggregate number of Company Shares held by all Sellers, divided by (b) the aggregate Company Ordinary Shares
issued and outstanding.
“as converted basis”
means, as of any date of determination, all issued and outstanding shares of Buyer Common Stock and all Buyer Common Stock issuable
upon the conversion of any outstanding Convertible Securities of Buyer as of such date, whether or not such Buyer Convertible Security
is at the time convertible.
“Assets”
of any Person means all assets and properties of every kind, nature, character and description, that are owned, leased or licensed
by such Person.
“Buyer Common Stock”
means the common stock of Buyer, par value $0.0001 per share.
“Buyer IP Rights”
shall mean Buyer Patent Rights, Buyer Know-How Rights, Trade Secrets and any other Intellectual Property in or to the Buyer Technology.
“Buyer Know-How
Rights” shall mean all Know-How Rights in and to Buyer Technology.
“Buyer Material
Adverse Effect” means any event, circumstance, development, occurrence, fact, condition, effect, or change (each, an
“Effect”) that, individually or in the aggregate, is or would reasonably be expected to be materially adverse
to: (a) the business, results of operations, condition (financial or otherwise), or assets of Buyer and the Renovaro Group, taken
as a whole; or (b) the ability of Buyer to timely perform its obligations under this Agreement or consummate the Transactions contemplated
hereby on a timely basis; provided, however, that a Buyer Material Adverse Effect shall not be deemed to include any Effect
(alone or in combination) arising out of, relating to, or resulting from: (i) changes generally affecting the economy, financial
or securities markets, or political conditions; (ii) the execution and delivery, or consummation of the Transactions contemplated
by this Agreement (it being understood and agreed that this clause shall not apply with respect to any representation or warranty
that is intended to address the consequences of the execution and delivery or consummation of this Agreement); (iii) any changes
in applicable Law or Accounting Principles or other applicable accounting standards; (iv) acts of war or terrorism or the escalation
thereof; (v) natural disasters, epidemics, pandemics, or disease outbreaks (including the COVID-19 virus), public health emergencies
(as declared by the World Health Organization or the Health and Human Services Secretary of the United States), or other force
majeure events; (vi) general conditions in the industry in which Buyer operates; (vii) any failure, in and of itself, by Buyer
to meet any internal or published projections, forecasts, estimates,
or predictions in respect of revenues, earnings, or other
financial or operating metrics for any period (it being understood that any Effect underlying such failure may be deemed to constitute,
or be taken into account in determining whether there has been or would reasonably be expected to become, a Buyer Material Adverse
Effect, to the extent permitted by this definition and not otherwise excepted by another clause of this proviso); (viii) any change,
in and of itself, in the market price or trading volume of Buyer’s securities (it being understood that any Effect underlying
such change may be deemed to constitute, or be taken into account in determining whether there has been or would reasonably be
expected to become, a Buyer Material Adverse Effect, to the extent permitted by this definition and not otherwise excepted by another
clause of this proviso); or (ix) actions taken as required or specifically permitted by the Agreement or actions or omissions taken
with Company’s consent; provided further, however, that any Effect referred to in clauses (i), (iii), (iv),
(v), or (vi) immediately above shall be taken into account in determining whether a Buyer Material Adverse Effect has occurred
or would reasonably be expected to occur if it has a disproportionate effect on Buyer or the Renovaro Group, taken as a whole,
compared to other participants in the industries in which Buyer conducts its businesses.
“Buyer Patent Rights”
shall mean any and all current and future Patent Rights that claim or Cover Company Technology related to Buyer’s business,
including, but not limited to the Patent Rights set forth on Section 3.2.18(a) of the Buyer Disclosure Schedule.
“Buyer Special
Representations” means the representations and warranties set forth in Section 3.2.17 and Section 3.2.18.
“Buyer Technology”
shall mean all Technology that relates to Buyer’s business that is (i) owned by Renovaro Group or licensed to a Renovaro
Group member immediately prior to the Effective Date or (ii) conceived, created, generated, made, derived, developed, reduced to
practice or acquired by or on behalf of Renovaro Group, solely or jointly with any other Person.
“Code”
means the U.S. Internal Revenue Code of 1986, as amended.
“Company IP Rights”
shall mean Company Patent Rights, Company Know-How Rights, Trade Secrets and any other Intellectual Property in or to the Company
Technology.
“Company Know-How
Rights” shall mean all Know-How Rights in and to Company Technology.
“Company Loan Proceed
Shares” means any Renovaro Group Securities issued prior to Closing, the proceeds of which are used to finance the operations
of the Company; provided; however; that in the event any such loan made by Buyer to the Company is prepaid by the
Company prior to the Closing, such Renovaro Group Securities underlying the proceeds of such prepaid loan shall be reduced from
the Company Loan Proceed Shares.
“Company Material
Adverse Effect” means any Effect that, individually or in the aggregate, is or would reasonably be expected to be materially
adverse to: (a) the business, results of operations, condition (financial or otherwise), or assets of Target Companies, taken as
a whole; or (b) the ability of Company or Sellers to timely perform their obligations under this Agreement or consummate the transactions
contemplated hereby on a timely basis; provided, however, that a Company Material Adverse Effect shall not be deemed to
include any Effect (alone or in combination) arising out of, relating to, or resulting from: (i) changes generally affecting the
economy, financial or securities markets, or political conditions; (ii) the execution and delivery, or consummation of the transactions
contemplated by this Agreement (it being understood and agreed that this clause shall not apply with respect to any representation
or warranty that is intended to address the consequences of the execution and delivery or consummation of this Agreement); (iii) any
changes in applicable Law or Accounting Principles or other applicable accounting standards (iv) acts of war or terrorism or the
escalation thereof; (v) natural disasters, epidemics, pandemics, or disease outbreaks (including the COVID-19 virus), public health
emergencies (as declared by the World Health Organization or the Health and Human Services Secretary of the United States), or
other force majeure events; (vi) general conditions in the industry in which any Target Company operates; (vii) any failure, in
and of itself, by any Target Company to meet any internal or published projections, forecasts, estimates, or predictions in respect
of revenues, earnings, or other financial or operating metrics for any period (it being understood that any Effect underlying such
failure may be deemed to constitute, or be taken into account in determining whether there has been or would reasonably be expected
to become, a Company Material Adverse Effect, to the extent permitted by this definition and not otherwise excepted by another
clause of this proviso); or (viii) actions taken as required or specifically permitted by the Agreement or actions or omissions
taken with Buyer’s consent; provided further, however, that any Effect referred to in clauses (i), (iii), (iv),
(v), or (vi) immediately above shall be taken into account in determining whether a Company Material Adverse Effect has occurred
or would reasonably be expected to occur if it has a disproportionate effect on Target Companies, taken as a whole, compared to
other participants in the industries in which any Target Company conducts its business.
“Company Ordinary
Shares” means the 2,157 ordinary shares of £1.00 each in the capital of Company.
“Company Patent
Rights” shall mean any and all current and future Patent Rights that claim or Cover Company Technology related to Target
Companies’ businesses.
“Company Securities”
means, collectively, the Company Ordinary Shares and any Convertible Securities of the Company.
“Company Special
Representations” means the representations and warranties set forth in Section 3.1.16.
“Company Technology”
shall mean all Technology that is (i) owned by any Target Company or licensed to any Target Company (including by any Seller) immediately
prior to the Effective Date or (ii) conceived, created, generated, made, derived, developed, reduced to practice or acquired by
or on behalf of any Target Company, solely or jointly with any other Person.
“Confidential Information”
means any and all confidential or proprietary Information, whether communicated in writing or orally or by any other method, which
is provided by or on behalf of one Party to the other Party in connection with this Agreement or the Transactions, and which is
designated in writing as confidential at the time of such communication or which should, given the facts and circumstances surrounding
the communication reasonably be understood as confidential by the receiving Party, excluding any information that (i) was in the
public domain at the time of disclosure, (ii) is published or otherwise comes into the public domain after its disclosure through
no violation of this Agreement, (iii) is disclosed to the recipient by a third party not under an obligation of confidence, or
(iv) is already known by the recipient at the time of its disclosure as evidenced by written documentation of the recipient existing
prior to such disclosure.
“Consent”
means any consent, approval, waiver, authorization or Permit of, or notice to or declaration or filing with any Governmental Entity
or any other Person.
“Contract”
means any legally binding written or oral contract, lease, sublease, license, sublicense, loan agreement, master services agreement,
mortgage, security agreement, indemnity agreement, surety agreement, trust indenture or other agreement or instrument.
“Control”,
“Controls”, or “Controlled by” means, with respect to any Person, the power to direct or
cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract
or otherwise.
“Convertible Securities”
means, with respect to a Person, collectively, any options, warrants, convertible notes, convertible preferred stock (including,
in the case of Buyer, Preferred Stock) or other rights to subscribe for or purchase any capital stock of such Person or securities
convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire any equity interest of such Person.
For the avoidance of doubt, Convertible Securities shall include any securities, rights and/or profits interests, issued by any
Affiliate, plan, holding company, or other entity which, directly or indirectly, holds equity interests in such Person, and which
can cause the revaluation, valuation, issuance, profits or payment compensation in connection with, or conversion, exercise or
exchange of, any equity interests of such Person.
“Cover”
means, (a) with respect to Know-How Rights, that such Know-How Rights were used in making, having made, using, selling, offering
to sell, importing, having sold, exporting or making improvements to the product, and (b) with respect to a Patent Right, a Valid
Patent Claim would (absent a license thereunder or ownership thereof) be infringed by making, having made, using, selling, offering
to sell, importing, having sold, exporting or making improvements to the product, in each case, including research and development.
Grammatical variations of the word “Cover”, including “Covered”, shall have correlative meanings.
“Dutch GAAP”
means, the provisions of Title 9 of Book 2 of the Dutch Civil Code (Burgerlijk wetboek) and the Regulations for annual reporting
(Richtlijnen voor de Jaarverslaggeving).
“equity interest”
means (i) with respect to a corporation, any and all classes or series of shares of capital stock, (ii) with respect to a partnership,
limited liability company, trust or similar Person, any and all classes or series of units, interests or other partnership/limited
liability company interests and (iii) with respect to any other entity, any other security representing ownership interest, equity
or participation in such entity.
“Environmental
Laws” means any Law, required permit, license or other authorization relating to: (i) releases or threatened releases
of Hazardous Materials or materials containing Hazardous Materials; (ii) the presence, manufacture, refining, production, generation,
handling, transport, use, treatment, recycling, storage, importing, labeling, testing, disposal, cleanup or control of Hazardous
Materials or materials containing Hazardous Materials; (iii) pollution or protection of the environment or natural resources; or
(iv) public health and safety or, as it relates to the handling of or exposure to Hazardous Materials, worker/occupational health
and safety.
“Environmental
Professional” means an individual licensed by a Governmental Entity to act on behalf of such Governmental Entity to oversee
environmental site investigation and remediation.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Fraud”
means common law fraud under Delaware Law, including the elements of scienter and reliance, with respect to a representation or
warranty (i) that was untrue, (ii) which the Person making the representation knew to be untrue at the time such representation
was made, (iii) with the intent to deceive and for the purpose of inducing the recipient to act upon it.
“Governmental Entity”
means any federal, state, local or foreign government or political subdivision thereof, or any agency, commission, governmental
authority, or instrumentality of such government or political subdivision, or court, or any self-regulated organization or other
non-governmental regulatory authority or quasi-governmental authority.
“Hazardous Material”
means: (i) any substance, material or waste which is regulated by, or for which liability or standards of conduct may be imposed
under, any Environmental Law, including any substance, material or waste which is defined as a “hazardous substance,”
“hazardous material,” “hazardous waste,” “solid waste,” “pollutant,” “contaminant,”
“toxic substance,” “toxic waste” or other similar term or phrase under any applicable Environmental Law;
(ii) petroleum and petroleum products, including crude oil and any fractions thereof; (iii) natural gas, natural gas liquids, synthetic
gas, and any mixtures thereof; (iv) polychlorinated biphenyls, asbestos and asbestos-containing materials, urea formaldehyde, toxic
mold, and radon; and (v) per- or polyfluoroalkyl substances.
“Healthcare Law”
means any Law relating to the regulation of the healthcare or clinical laboratory industry or to the payment for services rendered
by healthcare providers, including, without limitation: Title XVIII of the SSA (Medicare); Title XIX of the SSA (Medicaid); Title
10, Chapter 55 of the U.S.C. (TRICARE); the Federal Anti-Kickback Law (42 U.S.C. § 1320a-7b); the Stark Law (42 U.S.C. §
1395nn); the Federal False Claims Act (31 U.S.C. §§ 3729, et seq.); the Federal Civil Monetary Penalties Law (42 U.S.C.
§ 1320a-7a); the Federal Program Fraud Civil Remedies Act (31 U.S.C. § 3801 et seq.); the Federal Health Care Fraud law
(18 U.S.C. § 1347); the criminal false claims statutes (e.g., 18 U.S.C. §§ 287 and 1001); the Medicare Secondary
Payor Statute (32 U.S.C. § 1395y(b)); the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 321 et seq.) and all regulations
promulgated thereunder; the Health Insurance Portability and Accountability Act of 1996 as amended by the Health Information Technology
for Economic and Clinical Health Act of 2009, and their implementing regulations and any state health care privacy, security or
confidentiality Laws; the Patient Protection and Affordable Care Act (Pub. L 111-148) as amended by the Health Care and Education
Reconciliation Act of 2010 (Pub. L. 111-152) and the regulations adopted thereunder; Laws pertaining to licensure, certification,
registration or operation requirements of healthcare facilities, services or equipment, including, but not limited to, the Clinical
Laboratory Improvement Amendments, as amended; CMS manual guidance, and applicable Medicare administrative contractor guidance
pertaining to coding, coverage, reimbursement, claims submission, billing and collections; state certificate of need or similar
Laws governing the establishment of healthcare facilities or service or the making of healthcare capital expenditures; state Laws
relating to fee-splitting, patient brokering or the corporate practice of medicine; and any state physician self-referral prohibition
or state anti-kickback Laws.
“In-License”
means all licenses and other agreements under which (i) any Target Company or (ii) any member of the Renovaro Group has been granted
a license to any Intellectual Property (other than for “shrink wrapped,” “click-through,” or other form
license-based “off-the-shelf” third party Intellectual Property that is otherwise commercially available on standard,
nondiscriminatory terms, for an annual or one-time license fee of no more than $50,000).
“Indebtedness”
of any Person means, without duplication, (i) all indebtedness of such Person for borrowed money (including the outstanding
principal and accrued but unpaid interest), (ii) all obligations for the deferred purchase price of property or services (other
than trade payables incurred in the ordinary course of business), (iii) any other indebtedness of such Person that is evidenced
by a note, bond, debenture, credit agreement or similar instrument, (iv) all obligations of such Person under leases that
should be classified as finance leases in accordance with its Accounting Principles, (v) all obligations of such Person for
the reimbursement of any obligor on any line or letter of credit, banker’s acceptance, guarantee or similar credit transaction,
in each case, that has been drawn or claimed against, (vi) all obligations of such Person in respect of acceptances issued
or created, (vii) all interest rate and currency swaps, caps, collars and similar agreements or hedging devices under which
payments are obligated to be made by such Person, whether periodically or upon the happening of a contingency, (viii) all
obligations secured by a Lien on any property of such Person, (ix) any premiums, prepayment fees or other penalties, fees,
costs or expenses associated with payment of any Indebtedness of such Person, and (x) all obligations described in clauses
(i) through (ix) above of any other Person which is directly or indirectly guaranteed by such Person or which such Person
has agreed (contingently or otherwise) to purchase or otherwise acquire or in respect of which it has otherwise assured a creditor
against loss.
“Information”
shall mean any and all data, information, materials and know-how (whether patentable or not), including, (a) ideas, discoveries,
inventions, improvements, Technology or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components,
or compositions, (c) methods, procedures, formulas, processes, tests, assays, techniques, regulatory requirements, business plans,
marketing plans, and competitive strategies, (d) biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical, clinical, safety, manufacturing, process and quality control data and information related thereto, (e) technical
and non-technical data and other information related to the foregoing, and (f) drawings, plans, designs, diagrams, sketches, specifications,
invention disclosures, patent applications or other documents containing or relating to such data, information, materials or know-how.
“Infringe”
means any infringement as determined by applicable law, including, without limitation, direct infringement, contributory infringement
or any inducement to infringe.
“Intellectual Property”
means any and all of the following and all rights in, relating to, arising out of, or associated with (whether provisional or non-provisional)
intellectual property and proprietary rights, whether protected, created, or arising under any Law or jurisdiction throughout the
world (including all applications or rights to apply for any of the following, and all registrations, renewals, extensions, future
equivalents, and restorations, now or hereafter in force and effect), including: all United States, international, and foreign:
(1) issued patents and patent applications, and all substitutions, reissues, divisions, reexaminations, provisionals, continuations,
continuations-in-part, revalidations, extensions, supplementary protection certificates, results of inter parties, post grant or
covered business method patent reviews and derivation proceedings, and equivalent or similar rights anywhere in the world in inventions,
discoveries, and designs, including invention disclosures or restorations of any of the foregoing, and
other Governmental Entity-issued indicia of invention ownership (including certificates of invention, petty patents, and patent
utility models) (“Patents”); (2) all Trade Secrets; (3) trademarks, service
marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with
the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of,
any of the foregoing; (4) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications
for registration, and renewals of any of the foregoing and all other rights corresponding thereto, (including moral rights),
throughout the world; (“Copyrights”); (5) mask works, and all registrations, applications
for registration, and renewals thereof; (6) industrial designs, and all Patents, registrations, applications for registration,
and renewals thereof, whether or not Copyrights; (7) computer programs, operating systems, applications, firmware, and other code,
including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and
other documentation thereof; (8) rights of publicity, privacy and personality; (9) all
rights in World Wide Web addresses, URLs, domain names, social media accounts and handles, other similar designations, and contract
rights therein and (10) all other intellectual or industrial property, proprietary rights, and
any similar, corresponding, or equivalent rights to any of the foregoing in items (1) through (10) above, anywhere in the world.
“Intellectual Property
Rights” means, collectively, Patent Rights, Know-How Rights, and any other Intellectual Property.
“IP Assignment”
means all agreements under which any Person has sold, conveyed, transferred, assigned or delivered any Intellectual Property to
(i) any Target Company or (ii) the Renovaro Group, as applicable.
“Know-How Rights”
means all Trade Secrets and other know-how rights (whether at law, in equity or otherwise) including, but not limited to, rights
in Confidential Information.
“Knowledge”
means, with respect to (i) Company, the actual knowledge of the executive officers or directors of any Target Company, including,
for the avoidance of a doubt, Frank Van Asch, after reasonable inquiry, or (ii) any other Party, (A) if an entity, the
actual knowledge of its directors and executive officers, after reasonable inquiry, or (B) if a natural person, the actual
knowledge of such Party after reasonable inquiry.
“Law”
means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement
or rule of law of any Governmental Entity.
“Liabilities”
means any and all liabilities, Indebtedness, Proceedings or obligations of any nature (whether absolute, accrued, contingent
or otherwise, whether known or unknown, whether direct or indirect, whether matured or unmatured, whether due or to become due
and whether or not required to be recorded or reflected on a balance sheet under Accounting Principles or other applicable accounting
standards), including Tax liabilities due or to become due.
“Lien”
means any mortgage, pledge, security interest, attachment, right of first refusal, option, proxy, voting trust, encumbrance, lien
or charge of any kind (including any conditional sale or other title retention agreement or lease in the nature thereof), restriction
(whether on voting, sale, transfer, disposition or otherwise), any subordination arrangement in favor of another Person, or any
filing or agreement to file a financing statement as debtor under any Law.
“Nasdaq”
shall mean The Nasdaq Stock Market.
“Order”
means any order, decree, ruling, judgment, injunction, writ, determination, binding decision, verdict, judicial award or other
action that is or has been made, entered, rendered, or otherwise put into effect by or under the authority of any Governmental
Entity.
“Organizational
Documents” means, with respect to any Person that is an entity, its certificate of incorporation or formation, bylaws,
operating agreement, memorandum and articles of association or similar organizational documents, in each case, as amended.
“Patent Rights”
shall mean (i) Patents (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications
for certificates of invention); (ii) any protection certificates, results of inter parties, post-grant, or covered business method
patent reviews and derivation proceedings, and the like of any such patents and patent applications; and (iii) any and all foreign
equivalents of the foregoing throughout the world.
“Permits”
means all permits, licenses, franchises, approvals, consents, permissions, clearances, exceptions, authorizations, registrations,
qualifications certificates, variances and similar rights obtained, or required to be obtained, from Governmental Entities.
“Person”
means any individual, corporation, limited or general partnership, limited liability company, limited liability partnership, trust,
association, estate, joint venture, een besloten vennootschap met beperkte aansprakelijkheid, Governmental Entity, or other
entity or group (which term will include a “group” as such term is defined in Section 13(d)(3) of the Exchange Act).
“Personal Information”
means all information that is defined as “personal information,” “personal data,” “personally identifiable
information,” “non-public information,” “protected health information,” or any similar term under
applicable Privacy Laws, including as applicable, names, addresses, telephone numbers, email addresses, financial information,
biometric information, personal health information, government-issued numbers, Internet Protocol addresses, device identifiers,
or other persistent identifiers, and other such information that identifies, can be used to identify or is otherwise associated
with an individual natural person or device.
“Pre-Closing Straddle
Period” means the portion of any Straddle Period ending on the Closing Date.
“Pre-Closing Tax
Period” means any taxable period ending on or before the Closing Date.
“Pre-Closing Taxes”
means (a) all Taxes imposed upon a Target Company (or for which such Target Company is liable) with respect to any Pre-Closing
Tax Period; (b) with respect to any Straddle Period, all Taxes imposed on any Target Company (or for which such Target Company
is liable) which are allocable, pursuant to Section 8.11, to a Pre-Closing Straddle Period; (c) all Taxes of any member
of an affiliated, consolidated, combined, or unitary group of which any Target Company (or any predecessor of any Target Company)
is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or any analogous
or similar Law; (d) all Taxes of any Person imposed on any Target Company (or for which such Target Company is liable) as a transferee
or successor, by contract or pursuant to any Law, which Taxes relate to an event, transaction, or agreement occurring or entered
into before the Closing.
“Privacy Laws”
means all applicable Laws, Orders, guidance issued by any Governmental Authority concerning the privacy, security, or Processing
of Personal Information and contractual and fiduciary obligations related to data privacy, biometric data, data protection, data
security or marketing.
“Proceeding”
means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,
citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at
law or in equity.
“Product”
shall mean any product or process that is Covered by, (i) in the case of Company, Company IP Rights, or that practices Company
Technology, or (ii) in the case of Buyer, Buyer IP Rights, or that practices Buyer Technology.
“Pro Rata Share”
means an amount, expressed as a percentage and calculated as of the Closing Date immediately prior to Closing, equal to the ratio
of (a) the aggregate number of Company Shares held by such Seller, divided by (b) the aggregate number of Company Shares
held by all Sellers.
“Regulatory Authority”
shall mean any country, federal, regional, supranational, state or local regulatory agency, department, bureau or other governmental
or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products
in any country or other jurisdiction, including, to the extent applicable, the United States Food and Drug Administration.
“Renovaro Denmark”
means Renovaro Biosciences Denmark ApS, a Danish limited company.
“Renovaro Group”
means, collectively, Buyer, Renovaro Denmark, Renovaro Biopharma, Inc., a Delaware corporation, and Renovaro Technologies, Inc.,
a Nevada corporation.
“Representatives”
means, as to any Person, such Person’s Affiliates and the respective managers, directors, officers, employees, independent
contractors, consultants, advisors (including financial advisors, counsel and accountants), agents and other legal representatives
of such Person or its Affiliates.
“SEC”
means the U.S. Securities and Exchange Commission.
“Securities Act”
means the Securities Act of 1933, as amended and the rules and regulations promulgated thereunder.
“Stockholder Approval”
means the approval of Buyer’s stockholders: (i) to amend its certificate of incorporation to increase the
number of authorized shares of Buyer Common Stock to allow for the issuance of the Exchange Consideration, (ii) as contemplated
by Nasdaq Rule 5635(a) with respect to the issuance of Buyer Common Stock in excess of the limitations imposed by such rule pursuant
to this Agreement and (iii) as contemplated by Nasdaq Rule 5635(c) with respect to the repricing of outstanding stock options.
“Straddle Period”
means, with respect to the Target Companies, any Tax period that begins before the Closing Date and ends after the Closing Date.
“Target Company”
means each of Company and its direct and indirect subsidiaries.
“Taxes”
(each, a “Tax”) means any and all taxes, fees, levies, duties, tariffs, imposts, and other charges of any kind
(together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by
any Governmental Entity, including taxes or other charges on or with respect to income, franchises, windfall or other profits,
gross receipts, property, sales, use, capital stock, abandoned and unclaimed property, escheat, payroll, employment, social security,
workers’ compensation, unemployment compensation, or net worth; taxes or other charges in the nature of excise, withholding,
ad valorem, stamp, transfer, value added, or gains taxes; license, registration and documentation fees; and customs’ duties,
tariffs, and similar charges, in each case together with any interest, additions or penalties with respect thereto and any interest
in respect of such additions or penalties.
“Tax Returns”
means any return, declaration, report, election, claim for refund or information return or other statement or form relating to
Taxes, including any schedule or attachment thereto or any amendment thereof.
“Technology”
means all discoveries, inventions (whether or not protectable under patent Laws), designs, developments, works of authorship, data,
information, methods of manufacture or use, know-how, procedures, protocols, techniques, results of experimentation and testing,
and other technology.
“Tax Contests”
any demand, claim, or notice of commencement of a claim, proposed adjustment, assessment, examination or other administrative or
court proceeding with respect to Taxes of the Target Companies for which Buyer may be liable.
“Trade Secrets”
means all trade secrets, know-how and confidential or proprietary ideas and information, including such rights in inventions (whether
or not), discoveries, improvements, Technology, and customer and supplier lists, business and technical information, proprietary
information, processes, formulae, databases and data compilations and collections, tools, methods, protocols, results, technical
data, methodologies, practices, techniques, and other confidential and proprietary information and rights therein.
“Transaction Documents”
means each agreement, instrument or document attached hereto as an exhibit, and the other agreements, certificates and instruments
to be executed or delivered by any of the Parties hereto in connection with or pursuant to this Agreement, including the Seller
Registration Rights Agreement, and the non-competition agreements to be entered into between certain Sellers and the Company.
“Treasury Regulations”
means the US Department of Treasury regulations promulgated under the Code.
“UK GAAP”
means United Kingdom generally accepted accounting principles, as consistently applied.
“US GAAP”
means United States generally accepted accounting principles, as consistently applied.
“Valid Patent Claim”
shall mean a claim of an issued and unexpired patent included within (i) Company Patent Rights, with respect to Company, or (ii)
Buyer Patent Rights, with respect to Buyer, which claim has not been revoked or held unenforceable or invalid by a decision of
a court or other governmental agency of competent jurisdiction (which decision is not appealable or has not been appealed within
the time allowed for appeal), and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through
reissue, re-examination or disclaimer or otherwise.
“VWAP”
means the volume-weighted average price per share, rounded to the nearest four decimal points, of Buyer Common Stock on the Nasdaq
(as reported on Bloomberg L.P. under the function “VWAP”), for the relevant period.
1.2 Definitions.
The following terms have the meanings set forth in the Sections set forth below:
Definition |
Location |
|
|
“Additional SEC Documents” |
5.1.3(a) |
“Affiliate” |
11.4 |
“Agreement” |
Preamble |
“Alternative Transaction” |
4.1.3 |
“Amended Buyer Organizational Documents” |
2.3 |
“Approved Indemnification Claim” |
9.2 |
“Authorizations” |
3.2.10(a) |
“beneficial ownership” |
11.4 |
“beneficially owned” |
11.4 |
“Benefit Plan” |
3.2.13 |
“business day” |
11.4 |
“Buyer” |
Preamble |
“Buyer Disclosure Schedule” |
3.2 |
“Buyer Employees” |
5.1.1(a) |
“Buyer Indemnified Person” |
8.1 |
“Buyer Lease” |
3.2.14 |
“Buyer Material Contracts” |
3.2.16(a) |
“Buyer Post-Closing Representation” |
11.15 |
“Buyer Stock” |
3.2.2 |
“Buyer Stockholder Meeting” |
5.5.1 |
“Claim” |
9.1 |
“Closing” |
2.7 |
“Closing Date” |
2.7 |
“Closing Derivative Securities” |
2.2.1(a) |
“Closing Filing” |
6.4.2 |
“Closing Press Release” |
6.4.2 |
“Company” |
Preamble |
“Company Certificates” |
2.4 |
“Company Disclosure Schedule” |
3.1 |
“Company Financials” |
3.1.5 |
“Company Lease” |
3.1.13 |
“Company Material Contracts” |
3.1.15(a) |
“Company Shares” |
Recitals |
“Confidentiality Agreement” |
6.1 |
“Copyrights” |
1.1 |
“Directors” |
6.5 |
“Dispute Period” |
9.2 |
“D&O Indemnified Persons” |
6.6 |
“D&O Policy” |
3.2.22 |
“Earnout Stock” |
2.2.1(b) |
“Effect” |
1.1 |
“Effective Date” |
Preamble |
“Employees” |
4.1.1(a) |
“Exchange Consideration” |
2.2 |
“Exchange Shares” |
2.2 |
“Federal Securities Laws” |
4.1.4(c) |
“hereof,” “herein,” “hereto,”
and “hereunder” |
11.4 |
“include,” “includes,” and
“including” |
11.4 |
“Indemnification Dispute Notice” |
9.2 |
“Indemnified Persons” |
8.2 |
“Indemnifying Seller” |
8.1 |
“Latest Balance Sheet Date” |
3.1.5 |
“Losses” |
8.1 |
“made available” or “provided to” |
11.4 |
“Majority Sellers” |
11.14.5 |
“Notice of Claim” |
9.1 |
“Notice of Meeting and Preliminary Proxy Statement” |
5.5.1 |
“OFAC” |
3.1.10(c) |
“Outside Date” |
10.1.2 |
“Party” and “Parties” |
Preamble |
“Patents” |
1.1 |
“PCAOB” |
4.1.4(a) |
“Post-Closing Board of Directors” |
6.5 |
“Preferred Stock” |
3.2.2(a) |
“Pro Rata Share” |
2.2 |
“Proxy Statements” |
5.5.1 |
“Record Date” |
5.5.2 |
“Record Stockholders” |
5.5.1 |
“Renovaro Group Securities” |
2.2.1(a) |
“Rules” |
9.3 |
“SEC Documents” |
3.2.6 |
“Security Breach” |
3.1.11(b) |
“Seller” and “Sellers” |
Preamble |
“Seller Indemnified Persons” |
8.2 |
“Seller Registration Rights Agreement” |
6.12 |
“Sellers’ Representative” |
Preamble |
“Share Exchange” |
Recitals |
“Signing Filing” |
6.4.2 |
“Signing Press Release” |
6.4.2 |
“subsidiary” and “subsidiaries” |
11.4 |
“Target Company Benefit Plan” |
3.1.12 |
“Third Party Claim” |
8.3 |
“Threshold Amount” |
8.6.1(a) |
“Transfer Taxes” |
6.7.4 |
“Trigger Date” |
2.2.1(b) |
“Transactions” |
3.1.4 |
“Violation” |
3.1.4 |
“Union” |
3.1.11(b) |
“Waiving Parties” |
11.15 |
“Yalla” |
Preamble |
“2022 Company Financials” |
4.1.4(a) |
“2023 Equity Incentive Plan” |
3.2.2(f) |
|
|
“2023 Interim Company Financials” |
4.1.4(a) |
Article
II
Purchase and Sale; Closing
2.1 Purchase and Sale
of Shares. At the Closing and subject to and upon the terms
and conditions of this Agreement, Sellers shall sell, transfer, convey, assign and deliver to Buyer, and Buyer shall purchase,
acquire and accept from Sellers, all of the Company Shares, free and clear of all Liens (other than potential restrictions on
resale under applicable securities Laws).
2.2 Exchange Consideration.
At the Closing, subject to and upon the terms and conditions of this Agreement, as consideration
for the Company Shares, Sellers collectively shall be entitled to have issued to them by Buyer, in the aggregate, (i) a number
of shares of Buyer Common Stock equal to (the “Exchange Shares”) the Applicable Percentage of the total
number of issued and outstanding shares of Buyer Common Stock as of the Closing Date (minus 1,000,000 shares of Buyer Common Stock
representing shares issued by Buyer to a consultant assisting the Parties on the Transaction (the “Consultant”))
and (ii) the right to receive from Buyer shares of Buyer Common Stock which may become issuable as Earnout Stock in accordance
with Section 2.2.1 below, if any (together with the Exchange Shares, the “Exchange Consideration”).
Each Seller shall receive its pro rata portion of the Exchange Consideration based on such Seller’s Pro Rata Share. Notwithstanding
anything to the contrary contained herein, no fraction of a share of Buyer Common Stock will be issued by Buyer by virtue of this
Agreement or the Transactions contemplated hereby, and each Seller who would otherwise be entitled to a fraction of a share of
Buyer Common Stock (after aggregating all fractional shares of Buyer Common Stock that would otherwise be received by such Seller)
shall instead have the number of shares of Buyer Common Stock issued to such Seller rounded down in the aggregate to the nearest
whole share of Buyer Common Stock.
2.2.1 Earnout; Earnout
Stock.
(a) Attached hereto
as Exhibit 2.2.1 is a complete list of all outstanding shares of Buyer Common Stock, Renovaro Group equity interests, Convertible
Securities of Renovaro Group, and any other subscriptions, calls, Contracts, commitments, understandings, restrictions, arrangements,
rights or phantom equity, including any rights plan, and any right of conversion or exchange under any outstanding security, instrument
or other agreement, obligating any Renovaro Group entity to issue, deliver, or sell, or cause to be issued, delivered or sold,
equity interests of any Renovaro Group entity or obligating any Renovaro Group entity to grant, extend, or enter into any such
agreement or commitment (collectively, “Renovaro Group Securities”). Buyer represents and warrants that there
are no Renovaro Group Securities, or other securities or other instruments outstanding that are convertible into or exercisable
for Buyer Common Stock or Renovaro Group equity interests, and there are no other obligations to issue Buyer Common Stock, Renovaro
Group equity interests or securities convertible into or exercisable for Buyer Common Stock or Renovaro Group equity interests,
and there will not be any such obligations at Closing except as listed on the certified list of Closing Derivative Securities as
defined below. On the Closing Date, Buyer shall deliver to the Sellers’ Representative an updated certified list of all shares
of Buyer Common Stock and Buyer Convertible Securities, including the name of the holder, the exercise price, and the term (the
“Closing Derivative Securities”).
(b) Upon the issuance
of any shares of Buyer Common Stock upon the exercise or conversion of any Closing Derivative Securities (other than any Company
Loan Proceed Shares) (each, a “Trigger Date”), Buyer shall issue to Sellers, excluding Consultant to the extent
Consultant becomes a Joining Seller (without the payment of any further consideration by Sellers) in the aggregate a number of
shares of Buyer Common Stock equal to the Applicable Percentage of such shares of Buyer Common Stock issued upon the exercise or
conversion of such Closing Derivative Securities on such Trigger Date (“Earnout Stock”), to be distributed proportionately
to such Sellers so that each such Seller receives his, her or its Pro Rata Share of such Earnout Stock
(calculated without taking into account Consultant’s Company Shares).
(c) The right of each
Seller to receive Earnout Stock pursuant to this Section 2.2.1 may only be assigned by operation of law, shall not be evidenced
by negotiable certificates of any kind and shall not be readily marketable.
(d) Delivery of Earnout
Stock shall be made on or before (i) the 10th full trading day following the Trigger Date if the Sellers’ Representative
gives Buyer notice that the Sellers wish to receive certificates representing such shares, or (ii) the 5th trading day following
the Trigger Date if the Sellers’ Representative gives Buyer notice that such shares are to be delivered via the Deposit Withdrawal
at Custodian (DWAC) process of the Depository Trust Company.
2.3 Amended Buyer Organizational
Documents. Effective upon the Closing, Buyer shall amend and restate its Organizational Documents to be
in a form to be mutually agreed upon by Buyer and Company, each acting reasonably (together, the “Amended Buyer Organizational
Documents”), which shall, among other matters, amend the Buyer’s Organizational Documents to (i) increase the number
of authorized shares of Buyer Common Stock to allow for the issuance of the Exchange Consideration, (ii) provide that the name of Buyer
shall be changed to “Renovaro AI”, or such other name as mutually agreed to by Buyer and Company and (iii) provide for
the size and structure of the Post-Closing Buyer Board in accordance with Section 6.5.
2.4 Surrender of Purchased
Shares. At the Closing, each Seller will deliver to Buyer,
a duly executed share transfer form in respect of its Company Ordinary Shares that are Company Shares, and the certificate(s)
representing Company Ordinary Shares (“Company Certificates”) for such Company Shares. In the event that any
Company Certificate shall have been lost, stolen or destroyed, in lieu of delivery of a Company Certificate to Buyer, Seller may
instead deliver to Buyer a statutory declaration of lost certificate and indemnity of loss in form and substance reasonably acceptable
to Buyer and Company; which at the reasonable discretion of Buyer may include a requirement that the owner of such lost, stolen
or destroyed Company Certificate deliver a bond in such sum as it may reasonably direct as indemnity against any claim that may
be made against Buyer or Company with respect to Company Shares represented by Company Certificates alleged to have been lost,
stolen or destroyed.
2.5 Termination of Certain
Agreements. Company and Sellers hereby agree that, effective
at the Closing, any agreement containing pre-emptive and special rights conferred to shareholders/stockholders, or shareholders’/stockholders’,
voting or similar agreement among Company and any of Sellers or among Sellers with respect to Company’s capital stock shall
automatically, and without any further action by any of the Parties, terminate in full and become null and void and of no further
force and effect. Further, each Seller and Company hereby waive any obligations of the parties under any of the foregoing agreements
or Company’s Organizational Documents with respect to the transactions contemplated by this Agreement and the Transaction
Documents, and any failure of the parties to comply with the terms thereof in connection with the Transactions and the Transaction
Documents.
2.6 Taking of Necessary
Action. If, at any time after the Closing, any further
action is necessary or desirable to carry out the purposes of this Agreement and to vest Buyer with full right, title and interest
in, to and under, and/or possession of, all assets, property, rights, privileges, powers and franchises of the Target Companies,
the officers and directors of Buyer are fully authorized in the name and on behalf of Company or any of its subsidiaries, to take
all lawful action necessary or desirable to accomplish such purpose or acts, so long as such action is not inconsistent with this
Agreement.
2.7 Closing.
The closing of the transaction contemplated by this Agreement (the “Closing”)
will take place as soon as practicable but no later than three (3) business days after satisfaction or waiver of the last to be
fulfilled of the conditions in Article VII (the date of such Closing, the “Closing Date”), at the offices
of K&L Gates LLP at 200 South Biscayne Boulevard, Suite 3900, Miami, Florida 33131, or remotely via electronic exchange of
signature counterparts, unless another date or place is agreed to in writing by the Parties. The Closing will be deemed effective
as of the closing of business on the Closing Date.
Article
III
REPRESENTATIONS AND WARRANTIES
3.1 Representations
and Warranties Relating to Target Companies. Except as
provided in a correspondingly numbered disclosure schedule delivered by Company and Sellers to Buyer pursuant to Section 6.10
(the “Company Disclosure Schedule”), Company and each Seller, severally and not jointly, represent to Buyer
as follows:
3.1.1 Organization,
Standing, and Power. Company is a corporation duly incorporated,
validly existing and in good standing under the Laws of England and Wales, and has all requisite corporate power and authority
to own, lease and operate its properties and to carry on its business as now being conducted. Each subsidiary of Company is a
private limited liability company (een besloten vennootschap met beperkte aansprakelijkheid) duly incorporated and validly
existing under the Laws of its jurisdiction of organization and has all requisite corporate power and authority to own, lease
and operate its properties and to carry on its business as now being conducted. Each Target Company is duly qualified or licensed
and in good standing in the jurisdiction in which it is incorporated or registered and in each other jurisdiction where it does
business or operates, to the extent applicable under the Laws of such jurisdictions and to the extent that the character of the
property owned, or leased or operated by it or the nature of the business conducted by it makes such qualification or licensing
necessary, except where the failure to be so qualified has not and would not have a Company Material Adverse Effect. Section
3.1.1 of the Company Disclosure Schedule lists all jurisdictions in which any Target Company is qualified to conduct business
and all names other than its legal name under which any Target Company does business. Company has provided to Buyer accurate and
complete copies of its Organizational Documents and the Organizational Documents of each of its subsidiaries, each as amended
to date and as currently in effect. No Target Company is in violation of any provision of its Organizational Documents in any
material respect.
3.1.2 Capital Structure.
(a) The Company Ordinary
Shares comprise all of the issued shares of the Company. No Company Ordinary Shares are held in treasury. All of the issued Company
Ordinary Shares have been duly authorized and validly issued, are fully paid except as set forth on Disclosure Schedule 3.1.2,
and have not been issued in violation of any purchase option, right of first refusal, preemptive right, subscription right or any
similar right under any provision of the laws of England and Wales, any other applicable Law, the Company Organizational Documents
or any contract to which Company is a party or by which it or its securities are bound. The legal (registered) and beneficial owners
of all of the issued and outstanding Company Ordinary Shares are set forth on Section 3.1.2 of the Company Disclosure Schedule,
all of which Company Shares are owned by the Persons set forth therein free and clear of any Liens, other than those imposed under
applicable securities Laws. No other class of shares or equity interests of Company is authorized or will be outstanding at Closing.
(b) There are no Convertible
Securities of the Company, or preemptive rights or rights of first refusal or first offer, nor are there any Contracts, commitments,
arrangements or restrictions to which Company or, to the Knowledge of Company, any of its stockholders is a party or bound relating
to any equity interests of Company, whether or not outstanding. There are no outstanding or authorized equity appreciation, phantom
equity or similar rights with respect to Company. There are no voting trusts, proxies, shareholder/stockholder agreements or any
other agreements or understandings with respect to the voting of Company’s equity interests. Except as set forth in the Company
Organizational Documents, there are no outstanding contractual obligations of Company to repurchase, redeem or otherwise acquire
any equity interests or securities of Company, nor has Company granted any registration rights to any Person with respect to Company’s
equity interests. All of Company Securities have been granted, offered, sold and issued in compliance with all applicable securities
Laws. As a result of the consummation of the Transactions contemplated by this Agreement, no equity interests of Company are issuable
and no rights in connection with any interests, warrants, rights, options or other securities of Company accelerate or otherwise
become triggered (whether as to vesting, exercisability, convertibility or otherwise).
(c) Except as disclosed
in the Company Financials, since its inception, Company has not declared or paid any distribution or dividend in respect of its
equity interests and has not repurchased, redeemed or otherwise acquired any equity interests of Company, and the board of directors
of Company has not authorized any of the foregoing.
(d) Section 3.1.2(d)
of the Company Disclosure Schedule sets forth the name of each subsidiary of Company, and with respect to each subsidiary (a) its
jurisdiction of organization, (b) its authorized shares or other equity interests (if applicable), (c) the number of issued and
outstanding shares or other equity interests and the record holders and beneficial owners thereof and (d) its Tax election to be
treated as a corporate or a disregarded entity under applicable non-U.S. Tax laws, if any. All of the outstanding equity interests
of each subsidiary of Company are duly authorized and validly issued, fully paid and non-assessable (if applicable), and were offered,
sold and delivered in compliance with all applicable securities Laws, and owned by one or more of Company or its subsidiaries free
and clear of all Liens, other than those imposed under applicable securities Laws. There are no Contracts to which Company or any
of its Affiliates is a party or bound with respect to the voting (including voting trusts or proxies) of the equity interests of
any subsidiary of Company other than the Organizational Documents of any such subsidiary. There are no outstanding or authorized
options, warrants, rights, agreements, subscriptions, convertible securities or commitments to which any subsidiary of Company
is a party or which are binding upon any subsidiary of Company providing for the issuance or redemption of any equity interests
of any subsidiary of Company. There are no outstanding equity appreciation, phantom equity, profit participation or similar rights
granted by any subsidiary of Company. Except as set forth in Section 3.1.2(d) of the Company Disclosure Schedules, no subsidiary
of Company has any limitation, whether by Contract, Order or applicable Law, on its ability to make any distributions or dividends
to its equity holders or repay any debt owed to another Target Company. Except for the equity interests of the subsidiaries of
the Company listed on Section 3.1.2(d) of the Company Disclosure Schedule, Company does not own or have any rights to acquire,
directly or indirectly, any equity interests of, or otherwise Control, any Person. None of Company or its subsidiaries is a participant
in any joint venture, partnership or similar arrangement. There are no outstanding contractual obligations of Company or its subsidiaries
to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, any other Person.
3.1.3 Authority.
Company has all requisite corporate power and authority to execute and deliver this Agreement
and each Transaction Document to which it is a party, to perform Company’s obligations hereunder and thereunder and to consummate
the Transactions contemplated hereby and thereby. The execution and delivery of this Agreement and each Transaction Document to
which Company is a party and the consummation of the Transactions contemplated hereby and thereby, (a) have been duly and validly
authorized by Company’s board of directors in accordance with the Company’s Organizational Documents, any applicable
Law or any Contract to which Company or any of its shareholders/stockholders is a party or by which it or its securities are bound
and (b) no other corporate proceedings on the part of Company are necessary to authorize the execution and delivery of this Agreement
and each Transaction Document to which it is a party or to consummate the Transactions contemplated hereby and thereby. This Agreement
has been, and each Transaction Document to which Company is or is required to be a party shall be when delivered, duly and validly
executed and delivered by Company and assuming the due authorization, execution and delivery of this Agreement and any such Transaction
Document by the other parties hereto and thereto, constitutes, or when delivered shall constitute, the legal, valid and binding
obligation of Company, enforceable against Company in accordance with its terms, except to the extent that enforceability may
be limited by the effect of (a) any applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws affecting
the enforcement of creditors rights generally, and (b) general equitable principles, regardless of whether such enforceability
is considered in a proceeding at law or in equity.
3.1.4 No Conflicts;
Consents, Notices and Approvals. The execution, delivery
and performance of this Agreement and the other Transaction Documents, and the consummation of the Transactions contemplated hereby
and thereby (the “Transactions”), do not and will not, conflict with or result in any violation of, or default
(with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, or acceleration
of any obligation or to loss of a material benefit under, or the creation of a Lien on assets (any such conflict, violation, default,
right, loss, or creation, a “Violation”), and no Target Company has received written notice that it would be,
with the passage of time, in Violation under: (a) any provision of their respective Organizational Documents; (b) any loan or
credit agreement, note, bond, mortgage, indenture, or other agreement or instrument including, without limitation each Company
Material Contract; or (c) any Law applicable to any Target Company or their properties or assets. Except as set forth in Section
3.1.4 of the Company Disclosure Schedule, no Consent of or with any Governmental Entity on the part of any Target Company
is required to be obtained or made in connection with the execution, delivery or performance of this Agreement or any Transaction
Documents or the consummation by Company of the Transactions contemplated hereby or thereby other than (a) such filings as
are expressly contemplated by this Agreement or (b) where the failure to obtain or make such Consents or to make such filings
or notifications, would not, individually or in the aggregate, have a Company Material Adverse Effect.
3.1.5 Financial Statements.
(a) As used herein,
the term “Company Financials” means (i) when delivered in accordance with Section 4.1.4 of
this Agreement, the 2022 Company Financials, and (ii) the 2023 Interim Company Financials. When delivered to Buyer pursuant
to Section 4.1.4, the Company Financials (i) shall accurately reflect the books and records of the Target Companies
as of the times and for the periods referred to therein, (ii) were prepared in accordance with US GAAP, consistently applied
throughout and among the periods involved, (iii) comply with all applicable accounting requirements under the Securities Act
and the rules and regulations of the SEC thereunder, and (iv) fairly present in all material respects the financial position
of the Target Companies as of the respective dates thereof. No Target Company has ever been subject to the reporting requirements
of Sections 13(a) and 15(d) of the Exchange Act.
(b) Each
Target Company maintains accurate books and records reflecting its assets and Liabilities and maintains proper and adequate internal
accounting controls that provide reasonable assurance that (i) such Target Company does not maintain any off-the-book accounts
and that such Target Company’s assets are used only in accordance with such Target Company’s management directives,
(ii) transactions are executed with management’s authorization, (iii) transactions are recorded as necessary to
permit preparation of the financial statements of such Target Company and to maintain accountability for such Target Company’s
assets, (iv) access to such Target Company’s assets is permitted only in accordance with management’s authorization,
(v) the reporting of such Target Company’s assets is compared with existing assets at regular intervals and verified
for actual amounts, and (vi) accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate
procedures are implemented to effect the collection of accounts, notes and other receivables on a current and timely basis. All
of the financial books and records of the Target Companies are complete and accurate in all material respects and have been maintained
in the ordinary course consistent with past practice and in accordance with applicable Laws. No Target Company has been subject
to or involved in any material fraud that involves management or other employees who have a significant role in the internal controls
over financial reporting of any Target Company. In the past three (3) years, no Target Company or its Representatives has
received any written complaint, allegation, assertion or claim regarding the accounting or auditing practices, procedures, methodologies
or methods of any Target Company or its internal accounting controls, including any material written complaint, allegation, assertion
or claim that any Target Company has engaged in questionable accounting or auditing practices.
(c) The Target Companies
do not have any Indebtedness other than the Indebtedness owed to Buyer.
3.1.6 Litigation.
Except as set forth in Section 3.1.6 of the Company Disclosure Schedule, there:
(a) are no Proceedings of any nature currently pending or, to Company’s Knowledge, threatened (and no such Proceeding has
been brought or, to Company’s Knowledge, threatened in the past three (3) years); or (b) is no Order now pending
or outstanding or that was rendered by a Governmental Entity, in either case of (a) or (b) by or against any Target
Company, its current or former directors, officers or equity holders (provided, that any litigation involving the directors, officers
or equity holders of a Target Company must be related to the Target Company’s business, equity securities or assets), its
business, equity securities or assets. In the past five (5) years, none of the current or former officers or directors of
any Target Company have been charged with, indicted for, arrested for, or convicted of any felony or any crime involving Fraud.
3.1.7 Absence of Undisclosed
Liabilities. No Target Company is subject to any Liabilities
or obligations which would be required to be reflected on or reserved against in the Company Financials under applicable Law or
Accounting Principles, except for those that are either (i) adequately reflected or reserved on or provided for in the consolidated
balance sheet of Company and its subsidiaries as of the Latest Balance Sheet Date contained in Company Financials or (ii) not
material and that were incurred after the Latest Balance Sheet Date in the ordinary course of business consistent with past practice
(other than Liabilities for breach of any Contract or violation of any Law).
3.1.8 No Violations.
(a) No Target Company
is or has been in material conflict or material non-compliance with, or in material default or violation of, nor has any Target
Company received, since January 1, 2020, any written or, to the Knowledge of Company, oral notice of any material conflict
or non-compliance with, or material default or violation of, any applicable Laws by which it or any of its properties, assets,
employees, business or operations are or were bound or affected.
(b) All Permits required
for the Target Companies to conduct their respective businesses have been obtained by them and are valid and in full force and
effect. All fees and charges with respect to such Permits as of the date hereof have been paid in full. Section 3.1.8(b)
of the Company Disclosure Schedule lists all current Permits issued to Target Company, including the names of the Permits and their
respective dates of issuance and expiration. No loss or expiration of any such Permit is pending or, to the Knowledge of the Target
Companies, threatened, other than expiration in accordance with the terms thereof.
3.1.9 Compliance with
Healthcare Laws.
(a) The Target Companies
are and have been since January 1, 2020, in compliance in all material respects with all applicable Healthcare Laws.
(b) To the extent that
any Target Company is participating in any research or clinical trials project, such research or clinical trials project is performed
in compliance in all material respects with applicable Healthcare Laws.
3.1.10 Ethical Practices.
(a) No Target Company,
nor, to the Target Company’s Knowledge, any of their respective Representatives acting on their behalf has (i) used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees, to foreign or domestic political parties or campaigns or violated
any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other local or foreign anti-corruption or bribery
Law or (iii) made any other unlawful payment. No Target Company, nor, to the Knowledge of the Target Companies, any of their respective
Representatives acting on their behalf has directly or indirectly, given or agreed to give any unlawful gift or similar benefit
in any material amount to any customer, supplier, governmental employee or other Person who is or may be in a position to help
or hinder any Target Company or assist any Target Company in connection with any actual or proposed transaction.
(b) The operations of
each Target Company are and have been conducted in compliance with anti-money laundering statutes in all applicable jurisdictions,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any Governmental Entity, and no Proceeding involving a Target Company with respect to any of the foregoing is pending
or, to the Knowledge of Company, threatened.
(c) No Target Company
or any of their respective directors or officers, or, to the Knowledge of Company, any other Representative acting on behalf of
a Target Company is currently identified on the specially designated nationals or other blocked person list or otherwise currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”),
and no Target Company has in the last five (5) fiscal years, directly or indirectly, used any funds, or loaned, contributed
or otherwise made available such funds to any subsidiary, joint venture partner or other Person, in connection with any sales or
operations in Cuba, Iran, Syria, Sudan, Myanmar, Russia or any other country sanctioned by OFAC or for the purpose of financing
the activities of any Person currently subject to, or otherwise in violation of, any U.S. sanctions administered by OFAC.
3.1.11 Employment Matters.
(a) Section 3.1.11(a)
of the Company Disclosure Schedule contains a list of all persons who are employees of any Target Company as of the date hereof,
including any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for
each such individual the following: (i) name; (ii) title or position (including whether full-time or part-time); (iii) hire or
retention date; (iv) current annual base compensation rate or contract fee; and (v) commission, bonus or other incentive-based
compensation. As of the date hereof, all compensation, including wages, commissions, bonuses, fees and other compensation, payable
to all employees, independent contractors or consultants of any Target Company for services performed on or prior to the date hereof
have been paid in full and there are no outstanding agreements, understandings or commitments of any Target Company with respect
to any compensation, commissions, bonuses or fees.
(b) No Target Company
is, nor has been for the past three (3) years, a party to, bound by, or negotiating any collective bargaining agreement or other
Contract with a union, works council or labor organization (collectively, “Union”), and there is not, and has
not been for the past three (3) years, any Union representing or purporting to represent any employee of a Target Company, and
no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining. There has
never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime
or other similar labor disruption or dispute affecting a Target Company or any of their employees. No Target Company has a duty
to bargain with any Union.
(c) Each Target Company
(i) is and has been in compliance in all material respects with all applicable Laws respecting employment and employment practices,
terms and conditions of employment, health and safety and wages and hours, and other Laws relating to discrimination, disability,
labor relations, hours of work, payment of wages and overtime wages, pay equity, immigration, workers compensation, working conditions,
employee scheduling, occupational safety and health, family and medical leave, and employee terminations, and has not received
written or, to the Knowledge of Company, oral notice that there is any pending Proceeding involving unfair labor practices against
a Target Company, (ii) is not liable for any material past due arrears of wages or any material penalty for failure to comply
with any of the foregoing, and (iii) is not liable for any material payment to any Governmental Entity with respect to unemployment
compensation benefits, social security or other benefits or obligations for employees, independent contractors or consultants (other
than routine payments to be made in the ordinary course of business and consistent with past practice). There are no Proceedings
pending or, to the Knowledge of Company, threatened against a Target Company brought by or on behalf of any applicant for employment,
any current or former employee, any Person alleging to be a current or former employee, or any Governmental Entity, relating to
any such Law or regulation, or alleging breach of any express or implied contract of employment, wrongful termination of employment,
or alleging any other discriminatory, wrongful or tortious conduct in connection with the employment relationship.
(d) Section 3.1.11(d)
of the Company Disclosure Schedule contains a list of all independent contractors (including consultants) currently engaged
by any Target Company, along with the position, the entity engaging such Person, date of retention, date of expiration and rate
of remuneration, most recent increase (or decrease) in remuneration and amount thereof, for each such Person. Except as set forth
on Section 3.1.11(d) of the Company Disclosure Schedule, all of such independent contractors are a party to a written Contract
with a Target Company. Except as set forth on Section 3.1.11(d) of the Company Disclosure Schedule, each such independent
contractor has entered into customary covenants regarding confidentiality, non-solicitation and assignment of inventions and copyrights
in such Person’s agreement with a Target Company, a copy of which has been provided to Buyer by Company.
3.1.12 Employee Benefit
Plans. Section 3.1.12 of the Company Disclosure
Schedule, contains a true and complete list of each pension, benefit, retirement, compensation, employment, consulting, profit-sharing,
deferred compensation, incentive, bonus, performance award, phantom equity, stock or stock-based, change in control, retention,
severance, vacation,
paid time off (PTO), medical, vision, dental, disability,
welfare, fringe benefit and other similar agreement, plan, policy, program or arrangement (and any amendments thereto), in each
case whether or not reduced to writing and whether funded or unfunded, which is or has been maintained, sponsored, contributed
to, or required to be contributed to by any Target Company for the benefit of any current or former employee, officer, director,
retiree, independent contractor or consultant of any Target Company or any spouse or dependent of such individual, or under which
any Target Company has or may have any Liability, or with respect to which Buyer or any of its Affiliates would reasonably be expected
to have any Liability, contingent or otherwise (as listed on Section 3.1.12 of the Company Disclosure Schedule, each, a
“Target Company Benefit Plan”). Each Target Company Benefit Plan is and has been operated at all times
in compliance with all applicable Laws in all material respects.
3.1.13 Real Property;
Leases. No Target Company owns, or has ever owned, real
property. Section 3.1.13 of the Company Disclosure Schedule sets forth each lease and sublease in effect on the date of
this Agreement under which any Target Company leases or subleases (a) real property (as either a tenant or subtenant), or (b)
personal property (in case of either clause (a) or (b), a “Company Lease”). No default by any Target Company,
or to Company’s Knowledge, by lessor or sublessor, exists under any Company Lease, and all payments of rent, operating expenses,
and other sums due under each Company Lease are current as of the date hereof. No Company Lease is terminable because of the execution
of this Agreement or the consummation of the Transactions. Each Company Lease is in full force and effect in accordance with its
respective terms. No consent is required from any party under any Company Lease in connection with the completion of the Transactions,
and no Target Company has received written notice that a party to any Company Lease intends to cancel, terminate, or refuse to
renew any Company Lease or to exercise any option or other right under such Company Lease, except where the failure to receive
such consent, or where such cancellation, termination, or refusal, would not result, or reasonably be expected to result, individually
or in the aggregate, in a Company Material Adverse Effect.
3.1.14 Environmental.
(a) Each Target Company
has complied in all material respects with all applicable Environmental Laws in effect on or before the date hereof in respect
of any real property leased or subleased by any Target Company.
(b) No Proceeding is
pending and, to Company’s Knowledge, no Proceeding has been threatened by any Governmental Entity against any Target Company
concerning any Environmental Law with respect to any real property leased or subleased at any point in time by any Target Company.
3.1.15 Company Material
Contracts.
(a) Section 3.1.15(a)
of the Company Disclosure Schedule lists all of the following Contracts to which a Target Company is a party (the “Company
Material Contracts”):
(i) any Contract with
an annual payment obligation by the Buyer of more than $300,000 (A) relating to the performance of services by, any employee, consultant,
or other Person, (B) in accordance with which a Target Company is or may become obligated to make any severance, termination, incentive,
or similar payment to any current or former officer, director, or employee, or (C) in accordance with which a Target Company may
be required to provide, or accelerate the vesting of, any payments, benefits, or equity rights upon the occurrence of any of the
Transactions;
(ii) any Contract imposing
any restriction on the right or ability of any Target Company, or that, after consummation of the Transactions, would impose a
restriction on the right or ability of Buyer, to compete in any line of business or in any geographic region with any other Person
or to transact business or deal in any other manner with any other Person;
(iii) any Contract that
provides for indemnification of any officer, director, employee, agent of any Target Company, except for Contracts containing standard
indemnification provisions entered into in the ordinary course of business;
(iv) any Contract with
a third party in accordance with which any Target Company (A) has paid or received $300,000 or more annually;
(v) any Contract or
agreement of partnership or joint venture, limited liability company or operating agreement that would give rise to an obligation
on the part of any Target Company to form a joint venture or to acquire securities of, or any other equity interest in, a third
party;
(vi) any Company Lease;
(vii) any Contract providing
for the development of any Technology or other Intellectual Property, independently or jointly, by or for any Target Company (other
than agreements with employees and independent contractors of any Target Company);
(viii) any settlement,
conciliation or similar agreement under which any Target Company or any counterparty to any such agreement has any outstanding
obligations in excess of $200,000;
(ix) any Contract relating
to the distribution, reselling, whole selling, advertising, marketing or sales of any Target Company’s services or products,
if any;
(x) any Contract that
grants any right of first refusal or right of first offer or similar right or that limits or purports to limit the ability of any
Target Company to own, operate, sell, transfer, pledge or otherwise dispose of any material amount of its assets and properties
or their respective businesses;
(xi) any Contract entered
into since the Latest Balance Sheet Date providing for the acquisition or sale, directly or indirectly, by merger or otherwise
of all or substantially all of the assets of another Person, the equity interests of another Person, or a business or division
of another Person;
(xii) any Contract between
any Target Company, on the one hand, and an Affiliate, on the other hand that provides for consideration in excess of $120,000;
(xiii) any Contract
with any Governmental Entity;
(xiv) any Contract with
a vendor to which total amounts payable exceed $300,000 annually;
(xv) except for trade
indebtedness incurred in the ordinary course of business and except as disclosed in the Company Financials, any instrument evidencing
or related in any way to indebtedness for borrowed money (either owed by or to any Target Company) by way of direct loan, sale
of debt securities, purchase money obligation, conditional sale, guarantee, or otherwise; and
(xvi) Any In-Licenses
or IP Assignments.
(b) Each Company Material
Contract is in full force and effect and is a valid and binding obligation of the applicable Target Company, and, to Company’s
Knowledge, against any other party to such Company Material Contract, except to the extent that enforceability may be limited by
the effect of (a) any applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws affecting the enforcement
of creditors rights generally, and (b) general equitable principles, regardless of whether enforceability is considered in a Proceeding
at law or in equity. No Target Company, nor, to Company’s Knowledge, any other party to the Company Material Contract, is
in material breach of or default under, any Company Material Contract. None of the parties to the Company Material Contracts has
expressed intent in writing to cancel, terminate, or refuse to renew any Company Material Contract. Company has made available
to Buyer complete copies of all Company Material Contracts.
3.1.16 Taxes.
(a) Each Target Company
has or will have timely filed, or caused to be timely filed, all income and other material Tax Returns required to be filed by
it (taking into account all available extensions), which Tax Returns are true, accurate, correct and complete in all material respects,
and has paid, collected or withheld and remitted, or caused to be paid, collected or withheld and remitted, all Taxes required
to be paid, collected or withheld and remitted (whether or not shown on any Tax Return), other than such Taxes for which adequate
reserves in the Company Financials have been established and which are not yet due and payable.
(b) There is no Proceeding
currently pending or, to the Knowledge of Company, threatened against any Target Company by a Governmental Entity in a jurisdiction
where the Target Company does not file Tax Returns that it is or may be subject to taxation by that jurisdiction.
(c) No Target Company
is being audited by any Tax authority or has been notified in writing or, to the Knowledge of Company, orally by any Tax authority
that any such audit is contemplated or pending. There are no claims, suits, assessments or, to the Knowledge of Company, audits,
examinations, investigations or other Proceedings, pending against any Target Company in respect of any Tax, and no Target Company
has been notified in writing of any proposed Tax claims or assessments against it (other than, in each case, claims or assessments
for which adequate reserves in the Company Financials have been established).
(d) There are no Liens
with respect to any Taxes upon any Target Company’s assets, other than Liens with respect to Taxes not yet due and payable
or Taxes being contested in good faith and for which adequate reserves in the Company Financials when delivered to Buyer have been
established.
(e) No Target Company
has any outstanding waivers or extensions of any applicable statute of limitations to assess any amount of Taxes. There are no
outstanding requests by a Target Company for any extension of time within which to file any Tax Return or within which to pay any
Taxes shown to be due on any Tax Return.
(f) No Target
Company has made any change in accounting method (except as required by a change in Law) or received a ruling from, or signed an
agreement with, any taxing authority that would reasonably be expected to have a material impact on its Taxes following the Closing.
(g) No
Target Company has any Liability for the Taxes of another Person (other than another Target Company) that are not adequately reflected
in the Company Financials (i) under any applicable Tax Law, (ii) as a transferee or successor, or (iii) by Contract
or indemnity (excluding commercial agreements entered into in the ordinary course of business the primary purpose of which is not
the sharing of Taxes). No Target Company is a party to or bound by any Tax indemnity agreement, Tax sharing agreement or Tax allocation
agreement or similar agreement (excluding commercial agreements entered into in the ordinary course of business the primary purpose
of which is not the sharing of Taxes) with respect to Taxes (including advance pricing agreements, closing agreements or other
agreements relating to Taxes with any Governmental Entity) that will be binding on any Target Company with respect to any period
following the Closing Date.
(h) No Target Company
has requested, or is it the subject of or bound by any private letter ruling, technical advice memorandum, closing agreement or
similar ruling, memorandum or agreement with any Governmental Entity with respect to any Taxes, nor is any such request outstanding.
3.1.17 Intellectual
Property Rights.
(a) Section 3.1.17(a)
of the Company Disclosure Schedule attached hereto contains a true and complete list of (i) the Company Patent Rights existing
on the Effective Date that are registered and applied-for with a Governmental Entity and owned by a Target Company and (ii) In-Licenses
relating to the Company Technology as of the Effective Date, excluding any licenses or sublicenses entered with any Target Company’s
suppliers or customers. The Company Patent Rights listed in Section 3.1.17(a) of the Company Disclosure Schedule include
all of the Patent Rights owned by the Target Companies and licenses relating to the Company Technology as of the Effective Date
that relate to the business and its operations.
(b) The Target Companies
are the owner or exclusive licensee of all Company Patent Rights listed in Section 3.1.17(b) of the Company Disclosure Schedule
and, to Company’s Knowledge as of the Effective Date, and Company has no knowledge that the Company Patent Rights are not
unpatentable or unenforceable.
(c) Company (i) is,
as of the Effective Date, the sole and exclusive owner or licensee of all right, title and interest in and to Company IP Rights
and as of the Effective Date free and clear of any Liens; (ii) has not granted to any third party any license or other right with
respect to Company IP Rights that conflicts with or limits in any way the licenses and rights granted to Company in or by any license;
and (iii) to the Company’s Knowledge has not disclosed to any third party any confidential Trade Secrets or Know-how listed
in Section 3.1.17(c) of the Company Disclosure Schedule.
(d) The manufacture,
use, sale, offer for sale or import of any Company Technology does not, to Company’s Knowledge as of the Effective Date,
Infringe any Patent Rights, Trade Secret, or any other Intellectual Property or proprietary right of any third party, and no Target
Company has received written, oral or other notice from any third party claiming that the manufacture, use, sale, testing, offer
for sale or import of any Product to the extent practicing Company Technology Infringes any Patent or other Intellectual Property
rights of any third party, nor to Company’s Knowledge as of the Effective Date is there any reasonable basis for such a claim.
(e) There are no claims,
judgments or settlements against or owed by Company or Sellers (or any of their Affiliates) with respect to Company IP Rights,
and neither Company nor any Seller is a party to any legal action, suit or proceeding relating to Company IP Rights, nor has Company
received any written, oral or other communication from any third party, including, without limitation, any Regulatory Authority
or other Governmental Entity, threatening such action, suit or proceeding or any other claim or proceeding alleging the unpatentability
or unenforceability of any Company Patent Rights; in each case, as of the Effective Date.
3.1.18 Artificial Intelligence.
(a) The Parties acknowledge
that Section 3.1.18(a) of the Company Disclosure Schedule sets forth all (a) AI Technologies, the owners or licensors thereof,
and the Contracts pursuant to which the Target Companies have a license to use or access such AI Technologies; (b) AI Inputs, the
owners or licensors thereof, and the Contracts pursuant to which the Target Companies have a license to use or access such AI Inputs;
and (c) AI Outputs, the recipients thereof, and the Contracts pursuant to which each such recipient have a license to use or access
such AI Outputs, and the means by which the AI Outputs have been provided to such recipient, including whether by remote access,
software as a service or on premises.
(b) The Target Companies
are not, and will not, be subject to any obligations that conflict with any terms in any contained herein which govern any Target
Company’s use or ownership of AI Inputs or AI Technology or its AI Outputs;
(c) The Target Companies
own or possess all rights and licenses required under applicable Law to use the AI Technology and AI Inputs and to generate the
AI Outputs, all as currently used and generated in its business;
(d) The Target Companies’
current use of the AI, does not Infringe any Intellectual Property rights or rights of likeness or publicity, and Target Companies
have acquired proper Consent from individuals where such Consent is necessary or required by applicable Privacy Laws;
(e) The Target Companies’
use of AI complies with all Laws and regulations (including those pertaining to Privacy Laws) as applicable to the Target Companies;
(f) Target Companies
use of AI and generation of AI Outputs conform to prevalent industry standards and practices;
(g) The consummation
of the contemplated Transactions will not adversely affect Target Companies rights in or use of any AI, and Target Companies will
be able to use the AI in a materially similar manner as prior to the Effective Date and Closing Date as it has prior to the Agreement.
(h) There have been
no errors, defects, failures or interruptions in the AI Technology or AI Inputs that have had a material effect on the , or to
Company’s Knowledge, in any Personal Information that may have been used to train the AI, or in the performance of its intended
purpose, and the AI has materially performed in accordance with its specifications and intended purpose.
(i) Target Companies
maintain commercially reasonable security measures, including access controls for the AI. There has been no unauthorized use of
or access to AI and, to the Company’s Knowledge, no AI has been used in violation of any applicable Laws.
3.1.19 Privacy and
Information Security.
(a) Target Companies
are in compliance with all Privacy Laws in the Processing of Personal Information (including employee information) applicable to
the Target Companies’ business;
(b) Target Companies
have not experienced any unauthorized access to: (i) any Personal Information Processed by the Targeted Companies; (ii) any databases,
computers, servers, storage media (e.g.) backup tapes, network devices or other devices or systems that collect or Process Personal
Information owned or maintained by the Target Companies (each, a “Security Breach”), where such Security Breach
resulted in the provision of notice to any Person as required by applicable Privacy Laws;
(c) Target Companies
are not subject to any contractual requirements or other legal obligations that, following the Closing of this Agreement, would
prohibit the Buyer from Processing any Personal Information in the manner in which the Target Companies Processed such Personal
Information;
(d) Target Companies
maintain commercially reasonable security measures, controls, technologies, policies and safeguards designed to protect Personal
Information and any proprietary information in possession of the Target Companies.
(e) Target Companies
have established one or more incident response and disaster recovery and business continuity plans to address any actual or threatened
Security Breach or other security incident or data breach.
3.1.20 Brokers and Other
Fees. Neither Target Companies, nor their stockholders,
officers, directors, or employees has employed any investment banker, broker, finder, or other intermediary that has been retained
by, or is authorized to act on behalf of, any Target Company that would be entitled to any fee or commission from any of the Target
Companies, or the holders of Company Shares in connection with or upon consummation of the Transactions.
3.1.21 Insurance.
(a) Section 3.1.21(a)
of the Company Disclosure Schedule lists all insurance policies (by policy number, insurer, coverage period, coverage amount, annual
premium and type of policy) held by any Target Company relating to a Target Company or a Target Company’s business, properties,
assets, directors, officers and employees, copies of which have been provided to Buyer. All premiums due and payable under all
such insurance policies have been paid and the Target Companies are otherwise in material compliance with the terms of such insurance
policies. Each such insurance policy (i) is legal, valid, binding,
enforceable and in full force and effect and (ii) will
continue to be legal, valid, binding, enforceable, and in full force and effect on identical terms following the Closing. No Target
Company has any self-insurance or co-insurance programs. In the past three (3) years, no Target Company has received any written
notice from, or on behalf of, any insurance carrier relating to or involving any adverse change or any change other than in the
ordinary course of business, in the conditions of insurance, any refusal to issue an insurance policy or non-renewal of a policy.
(b) The Target Companies
maintain and shall continue to maintain commercially reasonable insurance coverage for claims or losses pertaining to the AI. The
AI has not been subject to any claims, suits, demands, rulings, judgements, threats, fines, penalties, or a cease and desist letter
asserted against, or brought by, any Target Company pertaining to intellectual property or any other rights, violation or breach
of any applicable Law.
3.1.22 Affiliate Transactions.
Except for (a) relationships with any Target Company as an officer, director, employee
or consultant (and compensation by a Target Company in consideration of such services which is included in the Company Financials),
(b) relationships with Target Companies as holders of equity interests and (c) as disclosed in Section 3.1.22 of the Company
Disclosure Schedule, none of the officers, directors, consultants or equity interest holders, or to Company’s or Seller’s
Knowledge, any member of any of their immediate families, is presently a party to, or was a party to since inception of such Target
Company, any transaction with a Target Company, including any Contract, agreement, or other arrangement (x) providing for the
furnishing of services to or by, (y) providing for lease or sublease of real or personal property to or from, or (z) otherwise
requiring payments to or from, any such Person or any corporation, partnership, trust, or other entity in which any such Person
has or had a 5% or more interest (as a member, partner, beneficiary, or otherwise) or is or was an officer, director, employee,
consultant, vendor or customer of any Target Company.
3.1.23 Absence of Certain
Changes. Except as set forth in Section 3.1.23 of
the Company Disclosure Schedule, since the Latest Balance Sheet Date, each Target Company has (a) conducted its business
only in the ordinary course of business consistent with past practice, (b) not been subject to a Company Material Adverse
Effect and (c) has not taken any action or committed or agreed to take any action that would be prohibited by Section 4.1.1
of this Agreement if such action were taken on or after the date hereof without the consent of Buyer.
3.1.24 Disclosure.
No representation or warranty made by any Target Company in this Agreement or the other
Transaction Documents contains any untrue statement of a material fact, or omits to state a material fact necessary to make the
statements or facts contained herein or therein, in light of the circumstances under which they were made, not misleading. Company
and Sellers have provided to Buyer or its counsel each document listed in the Company Disclosure Schedule.
3.1.25 Independent Investigation.
Company has conducted its own independent investigation, review and analysis of the business,
results of operations, prospects, condition (financial or otherwise) or assets of Buyer, and acknowledges that it has been provided
adequate
access to the personnel,
properties, assets, premises, books and records, and other documents and data of Buyer for such purpose. Company acknowledges and
agrees that: (a) in making its decision to enter into this Agreement and to consummate the Transactions contemplated hereby, it
has relied solely upon its own investigation and the express representations and warranties of Buyer set forth in this Agreement
(including the related portions of the Buyer Disclosure Schedule and the SEC Documents), and in any certificate delivered to Company
pursuant hereto; and (b) neither Buyer nor any of its Representatives have made any representation or warranty as to Buyer or this
Agreement, except as expressly set forth in this Agreement (including the related portions of the Buyer Disclosure Schedule and
the SEC Documents), or in any certificate delivered to Company pursuant hereto.
3.1.26 Information Supplied.
None of the information supplied or to be supplied by Company expressly for inclusion
or incorporation by reference, and ultimately included or incorporated by reference: (a) in any current report on Form 8-K,
and any exhibits thereto or any other report, form, registration or other filing made with any Governmental Entity or stock exchange
with respect to the Transactions contemplated by this Agreement; (b) the Proxy Statements; or (c) in the mailings or other distributions
to Buyer’s stockholders and/or prospective investors with respect to the consummation of the Transactions contemplated by
this Agreement, or in any amendment to any of the documents identified in (a) through (c), will, when filed, made available, mailed
or distributed, as the case may be, contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are
made, not misleading; provided, however, that neither Company, nor any Seller, make any representation with respect
to any forward-looking statements. None of the information supplied or to be supplied by Company expressly for inclusion or incorporation
by reference in any of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing Filing will, when
filed or distributed, as applicable, contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are
made, not misleading. Notwithstanding the foregoing, Company makes no representation, warranty or covenant with respect to any
information supplied by or on behalf of Buyer or its Affiliates.
3.2 Representations
and Warranties of Buyer. Except: (a) as disclosed in SEC
Documents and to the extent that is reasonably apparent on the face of such disclosure to be applicable to the representation
and warranty set forth herein (other than any disclosures contained or referenced therein under the captions “Risk Factors,”
“Forward-Looking Statements,” “Quantitative and Qualitative Disclosures About Market Risk,” and any other
disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking
in nature) (it being acknowledged that nothing disclosed in such an SEC Documents will be deemed to modify or qualify the Buyer
Fundamental Representations); or (b) as provided in a correspondingly numbered disclosure schedule delivered by Buyer to Company
pursuant to Section 6.10 (the “Buyer Disclosure Schedule”), Buyer, represents to Company as follows:
3.2.1 Organization;
Standing and Power.
(a) Buyer is a corporation
duly incorporated, validly existing, and in good standing under the laws of the State of Delaware. Each other member of the Renovaro
Group is a corporation or other entity duly formed, validly existing and in good standing under the Laws of its jurisdiction of
organization. Each member of the Renovaro Group has all requisite corporate power and authority to own, lease, hold its Assets,
and operate its properties and to carry on its business as now being conducted. Each member of the Renovaro Group is duly qualified
or licensed and in good standing in the jurisdiction in which it is incorporated or registered and in each other jurisdiction where
it does business or operates to the extent that the character of the property owned, leased, or operated by it or the nature of
the business conducted by it makes such qualification or licensing necessary, except where the failure to be so qualified has not
and would not have a Buyer Material Adverse Effect. Section 3.2.1(a) of the Buyer Disclosure Schedule lists all jurisdictions
in which any member of the Renovaro Group is qualified to conduct business and all names other than its legal name under which
any member of the Renovaro Group does business.
(b) Buyer has provided
to Sellers and Company correct and complete copies of Buyer’s Organizational Documents, and minute books and the comparable
governing instruments and minutes, as amended as of the date of this Agreement. The minute books of Buyer contains correct and
materially complete records of all material proceedings and actions taken at all meetings of, or effected by written consent of
the stockholders and its board of directors, and the stock records of Buyer contain correct and complete records of all original
issuances, transfers, repurchases, and cancellations of Buyer Common Stock. Except for Buyer’s ownership of other Renovaro
Group members, neither Buyer nor other Renovaro Group members own or Control, directly or indirectly, shares of capital stock of
any other corporation, or any interest in any partnership, joint venture, or other non-corporate business entity or enterprise.
No member of the Renovaro Group is in violation of any provision of its Organizational Documents in any material respect.
3.2.2 Capitalization.
(a) The authorized capital
stock of Buyer consists of (i) 100,000,000 shares of Buyer Common Stock, with a par value of $0.0001 per share, of which 65,698,144
shares are issued and outstanding as of the date of this Agreement, and (ii) 10,000,000 shares of Buyer’s preferred stock,
par value $0.0001 per share, of which 1,000,000 shares have been classified as Series A Convertible Stock (the “Preferred
Stock”, and together with the Buyer Common Stock, the “Buyer Stock”), of which 561,010 shares are
issued and outstanding as of the date of this Agreement. All of the outstanding Buyer Stock has been duly authorized, validly issued,
fully paid, nonassessable, have not been issued in violation of any purchase option, right of first refusal, preemptive right,
subscription right or any similar right under any provision of applicable Law, the Buyer Organizational Documents or any contract
to which Buyer is a party or by which it or its securities are bound, and are not subject to any preemptive rights or similar rights
or Liens under applicable law, Buyer’s Organizational Documents, or any agreement to which Buyer is a party or by which Buyer
may be bound. Section 3.2.2(a) of the Buyer Disclosure Schedule sets forth a list of all instruments that describe the rights
of the holders of Buyer Stock. True and complete copies of all instruments describing the rights of all holders of Buyer Stock
have been provided to or made available to Company.
(b) Buyer owns all of
the equity interest in Renovaro Denmark, organized under the Danish Act on Limited Companies of the Kingdom of Denmark, and all
of the share capital of the Renovaro Biopharma, Inc., a Delaware corporation, organized under the laws of Delaware, and Renovaro
Technologies, Inc., a Nevada corporation, organized under the laws of Nevada, in each case free and clear of any Liens. Other than
as reflected in the previous sentence, Buyer has no other direct or indirect subsidiary, Buyer does not own or Control, directly
or indirectly, an interest in any Person, Buyer does not have any rights to acquire, directly or indirectly, any equity interests
of any Person, and Buyer is not a participant in any joint venture, partnership, or limited liability company. There are no outstanding
contractual obligations of Buyer or its subsidiaries to provide funds to, or make any investment (in the form of a loan, capital
contribution or otherwise) in, any other Person.
(c) Except as disclosed
in the Buyer’s financial statements included in the SEC Documents, since June 30, 2021, Buyer has not declared or paid any
distribution or dividend in respect of its equity interests and has not repurchased, redeemed or otherwise acquired any equity
interests of Buyer, and the board of directors of Company has not authorized any of the foregoing.
(d) All of the outstanding
equity securities of each subsidiary of Buyer are duly authorized and validly issued, fully paid and non-assessable, and were offered,
sold and delivered in compliance with all applicable securities Laws. There are no Contracts to which Buyer or any of its Affiliates
is a party or bound with respect to the voting (including voting trusts or proxies) of the equity interests of any subsidiary of
Buyer other than the Organizational Documents of any such subsidiary. There are no outstanding or authorized options, warrants,
rights, agreements, subscriptions, convertible securities or commitments to which any subsidiary of Buyer is a party or which are
binding upon any subsidiary of Buyer providing for the issuance or redemption of any equity interests of any subsidiary of Buyer.
There are no outstanding equity appreciation, phantom equity, profit participation or similar rights granted by any subsidiary
of Buyer. No subsidiary of Buyer has any limitation, whether by Contract, Order or applicable Law, on its ability to make any distributions
or dividends to its equity holders or repay any debt owed to another member of the Renovaro Group.
(e) Other than Buyer,
the Renovaro Group members do not (i) own, directly or indirectly, any outstanding securities or other equity interests in, any
other Person or (ii) hold the right to acquire any security or interest in any other person.
(f) Buyer has reserved
4,000,000 shares of Buyer Common Stock for issuance pursuant to its 2019 Equity Incentive Plan duly adopted by Buyer’s Board
of Directors and approved by Buyer’s stockholders (the “2019 Equity Incentive Plan”).
(g) Except as set forth
on Section 3.2.2(g) of the Buyer Disclosure Schedule, there are no Convertible Securities of Buyer, or preemptive rights
or rights of first refusal or first offer, nor are there any Contracts, commitments, orally or in writing, arrangements or restrictions
to which Buyer is a party or bound relating to any equity interests of Buyer, whether or not outstanding. To Buyer’s Knowledge,
there are no voting trusts, proxies, shareholder/stockholder agreements or any other agreements or understandings with respect
to the voting of Buyer’s equity interests. Except as set forth in the Buyer Organizational Documents, the SEC Documents or
Section 3.2.2(g) of the Buyer Disclosure Schedule, there are no outstanding contractual obligations of Company to repurchase,
redeem or otherwise acquire any equity interests or securities of Buyer, nor has Buyer granted any registration rights to any Person
with respect to Buyer’s equity interests. All of Buyer’s securities (including Buyer Stock) have been granted, offered,
sold and issued in compliance with all applicable securities Laws. As a result of the consummation of the Transactions contemplated
by this Agreement, no equity interests of Buyer are issuable and no rights in connection with any interests, warrants, rights,
options or other securities of Buyer accelerate or otherwise become triggered (whether as to vesting, exercisability, convertibility
or otherwise). There are no accrued and unpaid dividends with respect to any outstanding shares of Buyer Common Stock. There are
no accrued and unpaid dividends with respect to any outstanding Buyer Stock. To Buyer’s Knowledge, the Buyer Stock is free
and clear of any Liens.
(h) All outstanding
Buyer Stock are duly authorized, validly issued, fully paid, and not subject to any preemptive rights or similar rights or Liens
under applicable Law, Buyer’s Organizational Documents, or any agreement to which Buyer is a party or by which Buyer may
be bound.
(i) Except as set forth
on Section 3.2.2(i) of the Buyer Disclosure Schedule, Buyer does not have outstanding:
(i) any debt, the holders
of which (A) have the right to vote (or are convertible or exercisable into securities having the right to vote) with Buyer stockholders
on any matter, or (B) are or will become entitled to receive any payment as a result of the execution of this Agreement or the
completion of the Transactions; or
(ii) any restricted
stock units, stock appreciation rights, stock performance awards, dividend equivalents, or other stock-based or equity-linked securities
of a similar nature.
3.2.3 Authority.
Buyer has all requisite corporate power and authority to execute and deliver this Agreement
and each Transaction Document. The execution, delivery and performance by Buyer of this Agreement and the Transaction Documents
have been duly and validly authorized by all requisite corporate action on the part of Buyer and upon receipt of Stockholder Approval,
no other proceedings on the part of Buyer are necessary for Buyer to perform its obligations under this Agreement and the Transaction
Documents and to consummate the Transactions contemplated hereby and thereby. This Agreement has been, and upon execution and
delivery thereof, the other Transaction Documents will be, duly and validly executed and
delivered by Buyer, and (assuming due authorization, execution and delivery thereof
by the other parties hereto and thereto) this Agreement constitutes, and upon execution and delivery thereof, the other Transaction
Documents will constitute, the legal, valid and binding obligations of Buyer, enforceable against Buyer in accordance with their
respective terms, except to the extent that enforceability may be limited by the effect of (a) any applicable bankruptcy, insolvency,
reorganization, moratorium, or other similar laws affecting the enforcement of creditors rights generally, and (b) general equitable
principles, regardless of whether such enforceability is considered in a proceeding at law or in equity.
3.2.4 Valid Issuance
of Shares. The Exchange Consideration being issued in accordance
with this Agreement when issued, sold, and delivered in accordance with the terms and for the consideration set forth in this
Agreement, will be validly issued, fully paid, and nonassessable, and free and clear of any Liens (other than those imposed by
applicable securities Laws and the Amended Buyer Organizational Documents). Assuming the accuracy of the representations and warranties
of Sellers herein and subject to any filings described in Section 3.2.5 of this Agreement, the Exchange Consideration
being issued in accordance with this Agreement will be issued in compliance with all Federal Securities Laws and state securities
Laws.
3.2.5 No Conflicts;
Consents, Notices and Approvals. The execution and delivery
of this Agreement and the other Transaction Documents do not, and after receipt of Stockholder Approval, the consummation of the
Transactions will not cause a Violation, and Buyer has not received written notice that it would be, with the passage of time,
in Violation under: (a) any provision of Buyer’s Organizational Documents (b) any loan or credit agreement, note, bond,
mortgage, indenture, or other agreement or instrument including, without limitation each Buyer Material Contract; or (c) Law applicable
to any Renovaro Group member or its respective properties or assets. Except as set forth in Section 3.2.5 of the Buyer
Disclosure Schedule and for the Stockholder Approval, no Consent of or with any (y) third party or (z) Governmental Entity is
required by or with respect to Buyer in connection with the execution, delivery or performance of this Agreement, the Transaction
Documents or the consummation by Buyer of the Transactions other than any filings under any applicable state securities laws.
3.2.6 SEC Documents;
Financial StatementsIn the two (2) years preceding the
date hereof, Buyer has filed all registration statements, prospectuses, reports, schedules, forms, statements and other documents
(including exhibits and schedules thereto and all other information incorporated by reference) required to be filed or furnished
by Buyer with or to the SEC, including pursuant to Section 13(a) or 15(d) of the Exchange Act, together with any amendments, restatements
or supplements thereto (collectively referred to herein as the “SEC Documents”). As of their respective dates,
the SEC Documents complied in all material respects with the applicable requirements of the Securities Act and the Exchange Act,
and the rules and regulations promulgated thereunder. None of the SEC Documents, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. Each of the consolidated financial statements
of Buyer (including, in each case, any notes thereto) included in the SEC Documents comply in all material respects with applicable
accounting requirements and the rules and regulations of the
SEC with respect thereto as in effect at the time of filing. Such consolidated financial statements have been prepared in accordance
with US GAAP during the periods involved (except as may be otherwise specified in such financial statements or the notes thereto,
or, in the case of unaudited financial statements may not contain all footnotes required by US GAAP), and fairly present in all
material respects the financial position of Buyer and its consolidated subsidiaries as of and for the respective dates thereof
and the results of operations and cash flows for the respective periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. Except as set forth in Section 3.2.6 of the Buyer Disclosure Schedule,
Buyer has received no notices or correspondence from the SEC for the two (2) years preceding the date hereof.
(b) As
of the date of this Agreement, except as set forth on Section 3.2.6(b)
of the Buyer Disclosure Schedule, (A) the Buyer Common Stock is registered pursuant to Section 12(b) of the Exchange Act and
is listed for trading on the Nasdaq Capital Market under the symbol “RENB”, (B) Buyer has not received any written
deficiency notice from Nasdaq relating to the continued listing requirements of such Buyer Common Stock, (C) there are no
Proceedings pending or, to the Knowledge of Buyer, threatened against Buyer by Nasdaq, the SEC or the Financial Industry Regulatory
Authority with respect to any intention by such entity to suspend, prohibit or terminate the quoting of such Buyer Common Stock
on the Nasdaq Capital Markets, and (D) Buyer is in compliance with all of the applicable corporate governance rules of
the Nasdaq. None of Buyer or any of its Affiliates has taken any action in an attempt to terminate the registration of the Buyer
Common Stock under the Exchange Act.
3.2.7 Litigation.
Except as disclosed in SEC Documents or on Section 3.2.7 of the Buyer Disclosure
Schedule, there is no (a) Proceeding of any nature currently outstanding or, to the Buyer’s Knowledge, threatened (and
no such Proceeding has been brought or, to the Buyer’s Knowledge, threatened since June 30, 2021); or (b) Order now
pending or outstanding or that was rendered by a Governmental Entity, in either case of (a) or (b) by or against any
member of the Renovaro Group, any of its current or former directors, officers or equity holders, except for any Proceeding or
Order involving any such director, officer or equity interest holder of a member of the Renovaro Group that is not related to
a Renovaro Group member’s business, equity interests or assets. In the past five (5) years, none of the current or
former officers or directors of any member of the Renovaro Group have been charged with, indicted for, arrested for, or convicted
of any felony or any crime involving Fraud.
3.2.8 Absence of Undisclosed
Liabilities. Except as disclosed in SEC Documents, no Renovaro
Group member is subject to any Liabilities or obligations which would be required to be reflected or reserved against in Buyers
consolidated financial statements prepared in accordance with US GAAP, except for those that are either (i) adequately reflected
or reserved on or provided for in the financial statements included in the SEC Documents or (ii) not material and that were incurred
after the date of the most recent financial statements included in the SEC Documents in the ordinary course of business consistent
with past practice (other than Liabilities for breach of any Contract or violation of any Law).
3.2.9 No Violations.
(a) No Renovaro Group
member is or has not been in material conflict or material non-compliance with, or in material default or violation of, nor has
any Renovaro Group member received, since June 30, 2021, any written or, to the Knowledge of Buyer, oral notice of any material
conflict or non-compliance with, or material default or violation of, any applicable Laws by which it or any of its properties,
assets, employees, business or operations are or were bound or affected.
(b) All Permits required
for the Renovaro Group members to conduct their respective business have been obtained by them and are valid and in full force
and effect. All fees and charges with respect to such Permits as of the date hereof have been paid in full. Section 3.2.9(b)
of the Buyer Disclosure Schedule lists all current Permits issued to the Renovaro Group members, including the names of the Permits
and their respective dates of issuance and expiration. No loss or expiration of any such Permit is pending or, to the Knowledge
of the Buyer, threatened, other than expiration in accordance with the terms thereof.
3.2.10 Compliance with
Healthcare Laws.
(a) The Renovaro Group
members are and have been since June 30, 2021, in compliance in all material respects with all applicable Healthcare Laws.
The Renovaro Group members (i) have not received any material written notice of adverse finding, warning letter, untitled
letter or other correspondence or notice from the U.S. Food and Drug Administration or any other Governmental Entity alleging or
asserting material noncompliance with any Laws or any licenses, certificates, approvals, clearances, authorizations, permits and
supplements or amendments thereto required by any such Laws (“Authorizations”); (ii) possess all
material Authorizations and such material Authorizations are valid and in full force and effect and, to Buyer’s knowledge,
are not in violation of any term of any such material Authorizations; (iii) have not received written notice of any Proceeding
or other action from any Governmental Entity or third party alleging that any product, operation or activity is in violation of
any Laws or Authorizations and Buyer has no Knowledge that any such Governmental Entity or third party is considering any such
Proceeding; (iv) have not received written notice that any Governmental Entity has taken, is taking or intends to take action to
limit, suspend, modify or revoke any Authorizations and Buyer has no Knowledge that any such Governmental Entity is considering
such action; and (v) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Laws or material Authorizations and that all such
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and
correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission). During the two
year period immediately preceding the date hereof, to Buyer’s Knowledge, the studies, tests and preclinical studies conducted
by or on behalf of the Renovaro Group were and, if still pending, are, in all material respects, being conducted in accordance
with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable
Laws, including, without limitation, the United States Federal Food, Drug, and Cosmetic Act or any other federal, state, local
or foreign Governmental.
Entity or quasi-governmental body exercising comparable authority. The descriptions of the results of such
studies and tests contained in the SEC Documents are accurate and complete in all material respects and fairly present the data
derived from such studies and tests in all material respects; and to Buyer’s Knowledge there are no other studies whose results
are materially inconsistent with or otherwise materially call into question the results described or referred to in the SEC Documents.
Buyer uses commercially reasonable efforts to review, from time to time, the progress and results of the studies, tests and preclinical
studies that are described in the SEC Documents and, based upon (i) the information provided the Renovaro Group members by the
third parties conducting such studies, tests, and preclinical studies and Buyer’s review of such information, and (ii) Buyer’s
Knowledge, Buyer believes that the descriptions of the results of such studies, tests, and preclinical studies are accurate and
complete in all material respects.
3.2.11 Ethical Practices.
(a) No Renovaro Group
member, nor, to the Knowledge of Buyer, any of their respective Representatives acting on their behalf, has (i) used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees, to foreign or domestic political parties or campaigns
or violated any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended or any other local or foreign anti-corruption
or bribery Law, or (iii) made any other unlawful payment. No Renovaro Group member, nor, to the Knowledge of Buyer, any of
their respective Representatives acting on their behalf has, directly or indirectly, given or agreed to give any unlawful gift
or similar benefit in any material amount to any customer, supplier, governmental employee or other Person who is or may be in
a position to help or hinder a Renovaro Group member or assist any Renovaro Group member in connection with any actual or proposed
transaction.
(b) The operations of
the Renovaro Group are and have been conducted at all times in compliance with money laundering statutes in all applicable jurisdictions,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any Governmental Entity, and no Proceeding involving the Renovaro Group with respect to any of the foregoing is pending
or, to the Knowledge of Buyer, threatened.
(c) No Renovaro Group
member, nor any of its directors or officers, or, to the Knowledge of Buyer, any other Representative acting on behalf of Buyer
is currently identified on the specially designated nationals or other blocked person list or otherwise currently subject to any
U.S. sanctions administered by OFAC, and Buyer has not in the last five (5) fiscal years, directly or indirectly, used any funds,
or loaned, contributed or otherwise made available such funds to any subsidiary, joint venture partner or other Person, in connection
with any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar, Russia or any other country sanctioned by OFAC or for
the purpose of financing the activities of any Person currently subject to, or otherwise in violation of, any U.S. sanctions administered
by OFAC.
3.2.12 Employment Matters.
(a) Section 3.2.12(a)
of the Buyer Disclosure Schedule contains a list of all persons who are employees of any Renovaro Group member as of the date hereof,
including any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for
each such individual the following: (i) name; (ii) title or position (including whether full-time or part-time); (iii) hire or
retention date; (iv) current annual base compensation rate or contract fee; and (v) commission, bonus or other incentive-based
compensation. As of the date hereof, all compensation, including wages, commissions, bonuses, fees and other compensation, payable
to all employees, independent contractors or consultants of the Renovaro Group for services performed on or prior to the date hereof
have been paid in full and there are no outstanding agreements, understandings or commitments of the Renovaro Group with respect
to any compensation, commissions, bonuses or fees.
(b) No Renovaro Group
member is, nor has been for the past five (5) years, a party to, bound by, or negotiating any collective bargaining agreement or
other Contract with a Union, and there is not, and has not been for the past five (5) years, any Union representing or purporting
to represent any employee of the Renovaro Group, and no Union or group of employees is seeking or has sought to organize employees
for the purpose of collective bargaining. There has never been, nor has there been any threat of, any strike, slowdown, work stoppage,
lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting a Renovaro Group member or any
of its employees. No Renovaro Group member has a duty to bargain with any Union.
(c) Each Renovaro Group
member (i) is and has been in compliance in all material respects with all applicable Laws pertaining to employment and employment
practices to the extent they relate to employees, volunteers, interns, consultants and independent contractors of such Renovaro
Group member, including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment
discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime
compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy,
health and safety, workers’ compensation, leaves of absence, paid sick leave and unemployment insurance. All individuals
characterized and treated by the Renovaro Group as independent contractors or consultants are properly treated as independent contractors
under all applicable Laws (ii) is not liable for any material past due arrears of wages or any material penalty for failure
to comply with any of the foregoing, and (iii) is not liable for any material payment to any Governmental Entity with respect
to unemployment compensation benefits, social security or other benefits or obligations for employees, independent contractors
or consultants (other than routine payments to be made in the ordinary course of business and consistent with past practice). All
employees of the Renovaro Group classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws
are properly classified in all material respects. Each Renovaro Group member is in compliance with and has complied with all immigration
laws, including Form I-9 requirements and any applicable mandatory “E-Verify” obligations. There are no Proceedings
against any Renovaro Group member pending, or to Buyer’s Knowledge, threatened to be brought or filed, by or with any Governmental
Entity or arbitrator in
connection with the employment of any current or former applicant, employee, consultant, volunteer, intern
or independent contractor of the Renovaro Group, including, without limitation, any charge, investigation or claim relating to
unfair labor practices, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation,
reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, employee classification,
child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety,
workers’ compensation, leaves of absence, paid sick leave, unemployment insurance or any other employment related matter
arising under applicable Laws.
(d) Section 3.2.12(d)
of the Buyer Disclosure Schedule contains a list of all independent contractors (including consultants) currently engaged by any
Renovaro Group member, along with the position, the entity engaging such Person, date of retention and rate of remuneration, most
recent increase (or decrease) in remuneration and amount thereof, for each such Person. Except as set forth on Section 3.2.12(d)
of the Buyer Disclosure Schedule, all of such independent contractors are a party to a written Contract with a Renovaro Group member.
Except as set forth on Section 3.2.12(d) of the Company Disclosure Schedule, each such independent contractor has entered
into customary covenants regarding confidentiality, non-solicitation and assignment of inventions and copyrights in such Person’s
agreement with a Renovaro Group member, a copy of which has been provided to Company by Buyer.
3.2.13 Employee Benefit
Plans. Section 3.2.13 of the Buyer Disclosure Schedule,
contains a true and complete list of each pension, benefit, retirement, compensation, employment, consulting, profit-sharing,
deferred compensation, incentive, bonus, performance award, phantom equity, stock or stock-based, change in control, retention,
severance, vacation, paid time off (PTO), medical, vision, dental, disability, welfare, fringe benefit and other similar agreement,
plan, policy, program or arrangement (and any amendments thereto), in each case whether or not reduced to writing and whether
funded or unfunded, including each “employee benefit plan” within the meaning of Section 3(3) of ERISA, whether or
not tax-qualified and whether or not subject to ERISA (each a “Benefit Plan”), which is or has been maintained,
sponsored, contributed to, or required to be contributed to by Buyer or any of its subsidiaries for the benefit of any current
or former employee, officer, director, retiree, independent contractor or consultant of Buyer, or any of its subsidiaries, or
any spouse or dependent of such individual, or under which Buyer, any of its subsidiaries, or any of its ERISA Affiliates has
or may have any Liability. Each Benefit Plan is and has been operated at all times in compliance with all applicable Laws
in all material respects.
3.2.14 Real Property;
Lease. Neither Buyer nor any Renovaro Group member own,
or have ever owned, real property. Section 3.2.14 of the Buyer Disclosure Schedule sets forth each lease and sublease in
effect on the date of this Agreement under which any Renovaro Group member leases or subleases (a) real property (as either a
tenant or subtenant), or (b) personal property (in case of either clause (a) or (b), a “Buyer Lease”). No default
by any Renovaro Group member, or to Buyer’s Knowledge, by any lessor, or sublessor, exists under any Buyer Lease, and all
payments of rent, operating expenses, and other sums due under each Buyer Lease are current as of the date hereof. No Buyer Lease
is terminable because of the execution of this Agreement or
the consummation
of the Transactions. Each Buyer Lease is in full force and effect in accordance with its respective terms. No consent is required
from any party under any Buyer Lease in connection with the completion of the Transaction. Buyer has not received notice that a
party to any Buyer Lease intends to cancel, terminate, or refuse to renew any Buyer Lease or to exercise any option or other right
under such Buyer Lease, except where the failure to receive such consent, or where such cancellation, termination, or refusal,
would not result, or reasonably be expected to result, individually or in the aggregate, in a Buyer Material Adverse Effect.
3.2.15 Environmental.
(a) Each Renovaro Group
member has complied in all material respects with all Environmental Law in effect on or before the date hereof in respect of any
real property leased or subleased by any Renovaro Group member.
(b) No Proceeding is
pending and, to Buyer’s Knowledge, no Proceeding has been threatened by any Governmental Entity against any Renovaro Group
member concerning any Environmental Law in respect of any real property leased or subleased at any point in time by any Renovaro
Group member.
3.2.16 Buyer Material
Contracts.
(a) Section 3.2.16(a)
of the Buyer Disclosure Schedule lists all of the following Contracts to which Buyer or which a Renovaro Group member is a party
(the “Buyer Material Contracts”):
(i) any Contract with
an annual payment obligation by the Buyer of more than $300,000 (A) relating to the performance of services by, any employee, consultant,
or other Person, (B) in accordance with which Buyer or any Renovaro Group member is or may become obligated to make any severance,
termination, incentive, or similar payment to any current or former officer, director, or employee, or (C) in accordance with which
Buyer or a Renovaro Group member may be required to provide, or accelerate the vesting of, any payments, benefits, or equity rights
upon the occurrence of any of the Transactions;
(ii) any Contract imposing
any restriction on the right or ability of Buyer or any Renovaro Group member, or that, after consummation of the Transactions,
would impose a restriction on the right or ability of Buyer or any Renovaro Group member, to compete in any line of business or
in any geographic region with any other Person or to transact business or deal in any other manner with any other Person;
(iii) any Contract that
provides for indemnification of any officer, director, employee, agent of Buyer or any Renovaro Group member;
(iv) any Contract with
a third party in accordance with which Buyer (A) has paid or received $300,000 or more annually;
(v) any Contract or
agreement of partnership or joint venture, limited liability company or operating agreement that would give rise to an obligation
on the part of Buyer or any Renovaro Group member to form a joint venture or to acquire securities of, or any other equity interest
in, a third party;
(vi) any Buyer Lease;
(vii) any Contract providing
for the development of any Technology or other Intellectual Property, independently or jointly, by or for Buyer or any Renovaro
Group member (other than agreements with employees and independent contractors of Buyer or any Renovaro Group member);
(viii) any settlement,
conciliation or similar agreement under which Buyer, any Renovaro Group member or any counterparty to any such agreement has any
outstanding obligations in excess of $200,000;
(ix) any Contract relating
to the distribution, reselling, whole selling, advertising, marketing or sales of Buyer’s or any Renovaro Group member’s
services or products, if any;
(x) any Contract that
grants any right of first refusal or right of first offer or similar right or that limits or purports to limit the ability of Buyer
or any Renovaro Group member to own, operate, sell, transfer, pledge or otherwise dispose of any material amount of its assets
and properties or their respective businesses;
(xi) any Contract entered
into since the date of Buyer’s most recent financial statements included in the SEC Documents providing for the acquisition
or sale, directly or indirectly, by merger or otherwise of all or substantially all of the assets of another Person, the equity
interests of another Person, or a business or division of another Person;
(xii) any Contract between
Buyer or any Renovaro Group member, on the one hand, and an Affiliate, on the other hand that provides for consideration in excess
of $120,000;
(xiii) any Contract
with any Governmental Entity;
(xiv) any Contract with
a vendor to which total amounts payable exceed $300,000;
(xv) except for trade
indebtedness incurred in the ordinary course of business and except as disclosed in the financial statements included in the SEC
Documents, any instrument evidencing or related in any way to indebtedness for borrowed money (either owed by or to Buyer or any
Renovaro Group member) by way of direct loan, sale of debt securities, purchase money obligation, conditional sale, guarantee,
or otherwise; and
(xvi) Any In-Licenses
or IP Assignments.
(b) Each Buyer Material
Contract is in full force and effect and is a valid and binding obligation of Buyer or such Renovaro Group member, and, to Buyer’s
Knowledge, against any other party to such Buyer Material Contract, except to the extent that enforceability may be limited by
the effect of (a) any applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws affecting the enforcement
of creditors rights generally, and (b) general equitable principles, regardless of whether enforceability is considered in a Proceeding
at law or in equity. Neither Buyer, any Renovaro Group member, nor, to Buyer’s Knowledge, any other party to any Buyer Material
Contract, is in material breach of or default under, any Buyer Material Contract. None of the parties to the Buyer Material Contracts
has expressed intent in writing to cancel, terminate, or refuse to renew any Buyer Material Contract. Buyer has made available
to Company complete copies of all Buyer Material Contracts.
3.2.17 Tax Returns and
Payments.
(a) Buyer has or will
have filed, or caused to be filed, all income and other material Tax Returns required to be filed by it or any Renovaro Group member
(taking into account all available extensions), which Tax Returns are true, accurate, correct and complete in all material respects,
and has paid, collected or withheld, or caused to be paid, collected or withheld, all Taxes required to be paid, collected or withheld,
other than such Taxes for which adequate reserves in the Company Financials have been established.
(b) There is no Proceeding
currently pending or, to the Knowledge of Buyer, threatened against a member of the Renovaro Group by a Governmental Entity in
a jurisdiction where a Renovaro Group member does not file Tax Returns that it is or may be subject to taxation by that jurisdiction.
(c) No member of the
Renovaro Group is being audited by any Tax authority or has been notified in writing by any Tax authority that any such audit is
contemplated or pending. There are no claims, suits, assessments or, to the Knowledge of Buyer, audits, examinations, investigations
or other Proceedings, pending against a member of the Renovaro Group in respect of any Tax, and no member of the Renovaro Group
has been notified in writing of any proposed Tax claims or assessments against it (other than, in each case, claims or assessments
for which adequate reserves in the financial statements included in the SEC Documents have been established).
(d) There are no Liens
with respect to any Taxes upon any Renovaro Group member’s assets, other than Liens with respect to Taxes not yet due and
payable or Taxes being contested in good faith and for which adequate reserves in Buyer’s financial statements included in
the SEC Documents have been established.
(e) No Renovaro Group
member has any outstanding waivers or extensions of any applicable statute of limitations to assess any amount of Taxes. There
are no outstanding requests by any Renovaro Group member for any extension of time within which to file any Tax Return or within
which to pay any Taxes shown to be due on any Tax Return.
(f) No Renovaro Group
member has made any change in accounting method (except as required by a change in Law) or received a ruling from, or signed an
agreement with, any taxing authority that would reasonably be expected to have a material impact on its Taxes following the Closing.
(g) No Renovaro Group
member has any Liability for the Taxes of another Person (other than another member of the Renovaro Group) that are not adequately
reflected in the financial statements included in the SEC Documents (i) under any applicable Tax Law, (ii) as a transferee
or successor, or (iii) by Contract or indemnity (excluding commercial agreements entered into in the ordinary course of business
the primary purpose of which is not the sharing of Taxes). No member of the Renovaro Group is a party to or bound by any Tax indemnity
agreement, Tax sharing agreement or Tax allocation agreement or similar agreement (excluding commercial agreements entered into
in the ordinary course of business the primary purpose of which is not the sharing of Taxes) with respect to Taxes (including advance
pricing agreements, closing agreements or other agreements relating to Taxes with any Governmental Entity) that will be binding
on any member of the Renovaro Group with respect to any period following the Closing Date.
(h) No Renovaro Group
member has requested, or is the subject of or bound by any private letter ruling, technical advice memorandum, closing agreement
or similar ruling, memorandum or agreement with any Governmental Entity with respect to any Taxes, nor is any such request outstanding.
3.2.18 Intellectual
Property Rights.
(a) Section 3.2.18(a)
of the Buyer Disclosure Schedule attached hereto contains a true and complete list of (i) the Buyer Patent Rights existing on the
Effective Date that are registered and applied-for with a Governmental Entity and owned by a Renovaro Group member and (ii) In-Licenses
relating to the Buyer Technology as of the Effective Date, excluding any licenses or sublicenses entered with any Renovaro Group
member’s suppliers or customers. The Buyer Patent Rights listed in Section 3.2.18(a) of the Buyer Disclosure Schedule
include all of the Patent Rights owned by the Renovaro Group members and licenses relating to the Buyer Technology as of the Effective
Date that relate to the Renovaro Group’s business and its operations.
(b) Buyer is the owner
or exclusive licensee of all Buyer Patent Rights listed in Section 3.2.18(b) of the Buyer Disclosure Schedule and, to Buyer’s
Knowledge as of the Effective Date, and Buyer has no Knowledge that the Buyer Patent Rights are not unpatentable or unenforceable.
(c) Buyer (i) is, as
of the Effective Date, the sole and exclusive owner or licensee of all right, title and interest in and to Buyer IP Rights and
as of the Effective Date free and clear of any Liens; (ii) has not granted to any third party any license or other right with respect
to Buyer IP Rights that conflicts with or limits in any way the licenses and rights granted to Buyer in or by any license; and
(iii) to the Buyer’s Knowledge has not disclosed to any third party any confidential Trade Secrets or Know-how listed in
Section 3.1.17(b) of the Buyer Disclosure Schedule.
(d) The manufacture,
use, sale, offer for sale or import of any Buyer Technology does not, to Buyer’s Knowledge as of the Effective Date, Infringe
any Patent, Trade Secret, or any other Intellectual Property or proprietary right of any third party, and no Renovaro Group member
has received written, oral or other notice from any third party claiming that the manufacture, use, sale, testing, offer for sale
or import of any Product to the extent practicing Buyer Technology Infringes any Patent or other Intellectual Property rights of
any third party, nor to Buyer’s Knowledge as of the Effective Date is there any reasonable basis for such a claim.
(e) There are no claims,
judgments or settlements against or owed by Buyer (or any of their Affiliates) with respect to Buyer IP Rights, and Buyer is not
a party to any legal action, suit or proceeding relating to Buyer IP Rights, nor has Company received any written, oral or other
communication from any third party, including, without limitation, any Regulatory Authority or other Governmental Entity, threatening
such action, suit or proceeding or any other claim or proceeding alleging the unpatentability or unenforceability of any Buyer
Patent Rights; in each case, as of the Effective Date.
3.2.19 Privacy and
Information Security.
(a) The Renovaro Group
members are in compliance with all Privacy Laws in the Processing of Personal Information (including employee information) applicable
to the its business;
(b) The Renovaro Group
members have not experienced any Security Breach, where such Security Breach resulted in the provision of notice to any Person
as required by applicable Privacy Laws;
(c) The Renovaro Group
members maintain commercially reasonable security measures, controls, technologies, policies and safeguards designed to protect
Personal Information and any proprietary information in possession of the Renovaro Group members.
(d) The Renovaro Group
members have established one or more incident response and disaster recovery and business continuity plans to address any actual
or threatened Security Breach or other security incident or data breach.
3.2.20 Brokers and Other
Fees. Neither Buyer, nor any of its officers, directors,
or employees has employed any investment banker, broker, finder, or other intermediary that has been retained by, or is authorized
to act on behalf of, Buyer that would be entitled to any fee or commission from any of the Renovaro Group members in connection
with or upon consummation of the Transactions.
3.2.21 Insurance.
Section 3.2.21 of the Buyer Disclosure Schedule lists all insurance policies (by
policy number, insurer, coverage period, coverage amount, annual premium and type of policy) held by the Renovaro Group members
relating to the Renovaro Group or its business, properties, assets, directors, officers and employees, copies of which have been
provided to Company. All premiums due and payable under all such insurance policies have been timely paid and the Renovaro Group
members are otherwise in material compliance with the terms of such insurance policies. Each such insurance policy (i) is
legal, valid, binding, enforceable and in full force and effect and (ii) will continue to be legal, valid, binding, enforceable,
and in full force and effect on identical terms following the Closing. No the Renovaro Group member has any self-insurance or
co-insurance programs. Since June 30, 2021, no the Renovaro Group member has received any written notice from, or on behalf of,
any insurance carrier relating to or involving any adverse change or any change other than in the ordinary course of business,
in the conditions of insurance, any refusal to issue an insurance policy or non-renewal of a policy.
3.2.22 D&O Policy.
Buyer has previously provided to Company (through counsel) a copy of its current directors
and officers insurance policy (“D&O Policy”). Neither Buyer nor any of its subsidiaries is in default with
respect to its obligations under any such insurance policy. Such policy is in full force and effect, all premiums due and payable
thereon have been paid, and no notice of cancellation or termination has been received with respect to such policy and, to the
Knowledge of Buyer, no cancellation or termination of such policy is pending or threatened by the current insurer. All of Buyer’s
officers and directors (including those who shall assume such positions in accordance with this Agreement and/or the other Transaction
Documents) shall be covered by the D&O Policy, as amended prior to Closing pursuant to Section 5.7 hereof.
3.2.23 Affiliate Transactions.
Except for (a) relationships with any Renovaro Group member as an officer, director,
employee or consultant (and compensation by a Renovaro Group member in consideration of such services), (b) relationships with
Buyer as an equity interest holder and (c) except as set forth in Section 3.2.24 of the Buyer Disclosure Schedule or as
disclosed in the SEC Documents, none of the officers, directors, consultants or equity interest holders, or to Buyer’s Knowledge,
any member of any of their immediate families, is presently a party to, or was a party to since June 30, 2021, any transaction
with Buyer or Renovaro Group, including any Contract, agreement, or other arrangement (x) providing for the furnishing of services
to or by, (y) providing for lease or sublease of real or personal property to or from, or (z) otherwise requiring payments to
or from, any such Person or any corporation, partnership, trust, or other entity in which any such Person has or had a 5% or more
interest (as a member, partner, beneficiary, or otherwise) or is or was an officer, director, employee, Buyer vendor.
3.2.24 Absence of Certain
Changes. Except as set forth in Section 3.2.24 of the Buyer Disclosure Schedule, since
the date of the most recent financial statements included in the SEC Document, each Renovaro Group member has (a) conducted
its business only in the ordinary course of business consistent with past practice,
(b) not been subject to a Buyer Material Adverse Effect and (c) has not taken any action
or committed or agreed to take any action that would be prohibited by Section 5.1.1 if such action were taken on or
after the date hereof without the consent of Company.
3.2.25 Compliance with
Regulation S. Neither Buyer, nor any of its Affiliates
nor any person acting on its or their behalf has engaged or will engage in any form of general solicitation, general advertising
or “directed selling efforts” (as defined in Rule 902 of Regulation S promulgated under the Securities Act) in connection
with the offering of the Exchange Consideration. Buyer has complied and will comply with the offering restrictions requirement
of Regulation S promulgated under the Securities Act.
3.2.26 Disclosure.
No representation or warranty made by Buyer in this Agreement or the other Transaction Documents contains any untrue statement
of a material fact, or omits to state a material fact necessary to make the statements or facts contained herein or therein, in
light of the circumstances under which they were made, not misleading. Buyer has made available to Company or its counsel each
document listed in the Buyer Disclosure Schedule.
3.2.27 Independent Investigation.
Buyer has conducted its own independent investigation, review and analysis of the business,
results of operations, prospects, condition (financial or otherwise) or assets of the Target Companies, and acknowledges that
it has been provided adequate access to the personnel, properties, assets, premises, books and records, and other documents and
data of the Target Companies for such purpose. Buyer acknowledges and agrees that: (a) in making its decision to enter into
this Agreement and to consummate the Transactions contemplated hereby, it has relied solely upon its own investigation and the
express representations and warranties of Company and Sellers set forth in this Agreement (including the related portions of the
Company Disclosure Schedules) and in any certificate delivered to Buyer pursuant hereto, and the information provided by or on
behalf of Company or Sellers for any registration statement; and (b) none of Company, Sellers nor any of their respective
Representatives have made any representation or warranty as to the Target Companies, Sellers or this Agreement, except as expressly
set forth in this Agreement (including the related portions of the Company Disclosure Schedules) or in any certificate delivered
to Buyer pursuant hereto, or with respect to the information provided by or on behalf of Company for any registration statement.
3.2.28 Liens on
Company and Company Shares. The purchase of the Company Shares by Buyer and the consummation
of the Transactions contemplated hereby shall not result in the creation of any Lien on any assets of the Target Companies or on
any Company Shares under the terms of any loan or credit agreement, note, bond, mortgage, indenture, or other agreement or instrument
including, without limitation each Buyer Material Contract, to which any Renovaro Group member is a party, or any Order or decree
by any Governmental Authority imposed on any Renovaro Group member.
3.2.29 Information SuppliedNone
of the information supplied by Buyer expressly for inclusion or incorporation by reference, and ultimately included or incorporated
by reference in any of the Proxy Statements, Signing Press Release,
Signing Filing, Closing Press Release and Closing Filing will,
when filed, made available, mailed or distributed, as the case may be, contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading; provided, however, that Buyer makes no representation with
respect to any forward-looking statements supplied by or on behalf of Buyer for inclusion in, or relating to information to be
included in the Proxy Statements, Signing Press Release, Signing Filing, Closing Press Release or Closing Filing. Notwithstanding
the foregoing, Buyer makes no representation, warranty or covenant with respect to any information supplied by or on behalf of
the Company, Sellers or their Affiliates.
3.3 Representations
and Warranties with respect to Sellers. Each Seller represents
to Buyer, with respect to such Seller and not with respect to any Seller, as follows:
3.3.1 Organization,
Standing, and Power. Such Seller, if not an individual
person, is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its formation
and has all requisite power and authority to own, lease and operate its properties and to carry on its business as now being conducted.
3.3.2 Authority.
(a) Seller has all requisite
power and authority to execute and deliver this Agreement and to consummate the Transactions. The execution and delivery by Seller
of this Agreement and any other Transaction Document to which said Seller is a party and the performance of any Seller’s
obligations under this Agreement and the other Transaction Documents to which such Seller is a party have been duly and validly
authorized by all necessary action on the part of said Seller and no other action on the part of Seller, or its members or manager,
are necessary to authorize this Agreement or to consummate the Transactions. This Agreement has been duly executed and delivered
by Seller and (assuming due authorization, execution and delivery by Buyer and Company) constitutes a valid and binding obligation
of said Seller enforceable in accordance with its terms, except to the extent that enforceability may be limited by the effect
of (a) any applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws affecting the enforcement of creditors
rights generally, and (b) general equitable principles, regardless of whether enforceability is considered in a Proceeding at law
or in equity.
(b) The execution and
delivery of this Agreement and compliance with the provisions of this Agreement do not and will not (i) conflict with, or result
in any material violation or breach of, or default (with or without notice) under, any provision of the Organizational Documents
of such Seller, (ii) violate any Law or Order to which such Seller is subject, or (iii) violate any agreement or instrument to
which said Seller is a party or by which said Sellers assets are bound, except, in the case of items (ii) and (iii) above, for
any violation that individually or in the aggregate, would not materially and adversely affect the ability of such Seller to consummate
the Transactions contemplated hereby, and discharge its obligations under, this Agreement and the Transaction Documents to which
such Seller is a party.
(c) Such Seller owns
good, valid and marketable title to the Company Shares set forth opposite such Seller’s name on Exhibit B, free and
clear of any and all Liens, other than those imposed under applicable securities Laws. There are no proxies, voting rights, shareholders’/stockholders’
agreements or other agreements or understandings, to which such Seller is a party or by which such Seller is bound, with respect
to the voting or transfer of any of such Seller’s Company Shares other than this Agreement. Upon delivery of such Seller’s
Company Shares to Buyer on the Closing Date in accordance with this Agreement, the entire legal and beneficial interest in such
Company Shares and good, valid and marketable title to such Company Shares, free and clear of all Liens (other than those imposed
under applicable securities Laws or those incurred by Buyer), will pass to Buyer.
(d) There is no Proceeding
pending or, to the Knowledge of such Seller, threatened, nor any Order is outstanding, against or involving such Seller, whether
at law or in equity, before or by any Governmental Entity, which would reasonably be expected to materially and adversely affect
the ability of such Seller to consummate the Transactions contemplated by, and discharge its obligations under, this Agreement
and the Transaction Documents to which such Seller is a party.
3.3.3 Investment Representations.
Such Seller, as identified on the signature pages hereto: (a) either is (i) an “accredited
investor” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) not
a “U.S. person” as such term is defined in Rule 902 of Regulation S promulgated under the Securities Act, is not acquiring
the Exchange Shares for the account or benefit of any U.S. person, is not, at the time of the execution of this Agreement, and
will not be at the time of Closing, in the United States and is not a “distributor” (as defined in Regulation S);
(b) is acquiring its portion of the Exchange Shares for itself for investment purposes only, and not with a view towards any resale
or distribution of such Exchange Shares; (c) has been advised and understands that the Exchange Shares (i) are being issued in
reliance upon one or more exemptions from the registration requirements of the Securities Act and any applicable state securities
Laws and (ii) have not been and shall not be registered under the Securities Act or any applicable state securities Laws and,
therefore, must be held indefinitely and cannot be resold unless such Exchange Shares are registered under the Securities Act
and all applicable state securities Laws, unless exemptions from registration are available; (d) is aware that an investment in
Buyer is a speculative investment and is subject to the risk of complete loss; and (e) acknowledges that except as set forth in
the Seller Registration Rights Agreement, Buyer is under no obligation hereunder to register the Exchange Shares under the Securities
Act. Such Seller does not have any Contract with any Person to sell, transfer, or grant participations to such Person, or to any
third Person, with respect to the Exchange Shares. By reason of such Seller’s business or financial experience, or by reason
of the business or financial experience of such Seller’s “purchaser representatives” (as that term is defined
in Rule 501(i) under the Securities Act), such Seller is capable of evaluating the risks and merits of an investment in
Buyer and of protecting its interests in connection with this investment. Such Seller has carefully read and understands all materials
provided by or on behalf of Buyer or its Representatives to such Seller or such Seller’s Representatives pertaining to an
investment in Buyer and has consulted, as such Seller has deemed advisable, with its own attorneys, accountants or investment
advisors with respect to the investment contemplated hereby and its suitability for such Seller.
Such Seller acknowledges that the Exchange Shares are subject to dilution for events not under
the control of such Seller. Such Seller has completed its independent inquiry and has relied fully upon the advice of its own legal
counsel, accountant, financial and other Representatives in determining the legal, tax, financial and other consequences of this
Agreement and the Transactions contemplated hereby and the suitability of this Agreement and the Transactions contemplated hereby
for such Seller and its particular circumstances, and, except as set forth herein, has not relied upon any representations or advice
by Buyer or its Representatives. Such Seller acknowledges and agrees that, except as set forth in Section 3.2 (including
the related portions of the Buyer Disclosure Schedules and the SEC Documents), no representations or warranties have been made
by Buyer or any of its Representatives, and that such Seller has not been guaranteed or represented to by any Person, (i) any specific
amount or the event of the distribution of any cash, property or other interest in Buyer or (ii) the profitability or value of
the Exchange Shares in any manner whatsoever. Such Seller: (A) has been represented by independent counsel (or has had the opportunity
to consult with independent counsel and has declined to do so); (B) has had the full right and opportunity to consult with such
Seller’s attorneys and other advisors and has availed itself of this right and opportunity; (C) has carefully read and fully
understands this Agreement in its entirety and has had it fully explained to it or him by such counsel; (D) is fully aware of the
contents hereof and the meaning, intent and legal effect thereof; and (E) is competent to execute this Agreement and has executed
this Agreement free from coercion, duress or undue influence.
Article
IV
COVENANTS OF COMPANY AND SELLER
During the period from the
date of this Agreement and continuing until the earlier of the termination of this Agreement pursuant to Article X or the
Closing, Company agrees (except as expressly contemplated by this Agreement or as otherwise consented to in advance in writing
by Buyer, which consent shall not be unreasonably delayed, conditioned or withheld) as follows:
4.1 Conduct of Business.
4.1.1 Ordinary Course.
Company shall, and shall cause each of the other Target Companies to, carry on its business
in the ordinary course consistent with past practice, will continue to observe its obligations to comply with the requirements
of all applicable Laws and regulations, and will use commercially reasonable efforts to (i) preserve intact its present business
organization and its assets, (ii) keep available the services of its officers, consultants, and employees (other than termination
of such services for cause), (iii) maintain and preserve the goodwill and relationships with manufacturers, customers, suppliers,
contractors, distributors, and others having business relationships with it and (iv) maintain its books, records and financials
in accordance with applicable Accounting Principles. Company will promptly notify Buyer of any event or occurrence not in the
ordinary course of business of any Target Company that would result, or could reasonably be expected to result, individually or
in the aggregate, in a Company Material Adverse Effect. Without limiting the above, prior to the earlier of the termination of
this Agreement pursuant to Article X or the Closing Date, the Company shall not, and shall cause its
subsidiaries to not (except as (i) expressly contemplated by this Agreement, (ii)
as required by applicable Law, or (iii) as otherwise consented to in advance in writing by Buyer, which consent shall not be unreasonably
delayed, conditioned or withheld):
(a) except as required
under the terms of any agreement existing as of the date of this Agreement as disclosed in the Company Disclosure Schedule, (i)
increase the compensation or benefits of any of the current or former directors, officers, employees or consultants of any Target
Company (collectively, “Employees”), (ii) establish or amend any Benefit Plan, (iii) terminate the employment
of any Employee (other than due to terminations for cause), or (iv) grant any severance or termination pay to any Employee, other
than in such Target Company’s ordinary course of business and consistent with past practices;
(b) assign, transfer,
dispose of, or license ownership of Company IP Rights or any other assets;
(c) authorize for issuance,
issue, grant, sell, dispose of or propose to issue, grant, sell or dispose of any of its equity interests, Convertible Securities
or any commitments, subscriptions or rights of any kind to acquire or sell any of its equity interests, Convertible Securities
or other securities, including any securities convertible into or exchangeable for any of its shares or other equity interests
or securities of any class and any other equity-based awards, or engage in any hedging transaction with a third Person with respect
to such securities;
(d) abandon or permit
to lapse any Company IP Rights;
(e) disclose any of
Company’s Trade Secrets to any third party, other than pursuant to confidentiality agreements;
(f) declare, set aside,
or pay any distribution with respect to any Company Shares, or repurchase, redeem, or acquire any outstanding Company Shares or
other ownership interests in Company, or otherwise change the capitalization of any Target Company in any manner from the way it
existed on the date of this Agreement;
(g) amend Company’s
Organizational Documents or comparable charter or governance documents of any Target Company;
(h) incur,
create, assume, prepay or otherwise become liable for any Indebtedness (directly, contingently or otherwise), make a loan or advance
to or investment in any third party (other than advancement of expenses to employees in the ordinary course of business), or guarantee
or endorse any Indebtedness, Liability or obligation of any Person;
(i) commence a lawsuit,
or settle, compromise, or otherwise terminate any litigation, claim, investigation, or other settlement negotiation;
(j) make any payments
to any third parties in excess of $100,000;
(k) extend an offer
of employment to a candidate whose annual compensation shall be in excess of $300,000;
(l) enter into any joint
venture, partnership, limited liability company, or operating agreement with any Person;
(m) enter into any Company
Material Contract or breach, modify, amend, or terminate any Company Material Contracts (including insurance policies covering
Company’s properties or assets), or waive, release, or assign any rights or claims under any Company Material Contracts,
except as expressly required or permitted by this Agreement;
(n) voluntarily
incur any Liability or obligation (whether absolute, accrued, contingent or otherwise) in excess of $300,000 individually or $600,000
in the aggregate other than pursuant to the terms of a Company Material Contract;
(o) adopt a plan of
complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization, or other reorganization;
(p) acquire or dispose
of capital stock of any third party or merge or consolidate with any third party;
(q) establish any subsidiary
or enter into any new line of business;
(r) fail to use commercially
reasonable efforts to keep in force insurance policies or replacement or revised policies providing insurance coverage with respect
to its assets, operations and activities in such amount and scope of coverage substantially similar to that which is currently
in effect;
(s) sell,
lease, license, transfer, exchange or swap, mortgage or otherwise pledge or encumber (including securitizations), or otherwise
dispose of any material portion of its properties, assets or rights;
(t) knowingly take any
action that would or is reasonably likely to (i) make any representation or warranty of Company contained in this Agreement inaccurate,
(ii) result in any of the conditions in Article VII not being satisfied, or (iii) impair the ability of Company to consummate
the Transactions in accordance with the terms of this Agreement; or
(u) authorize, commit,
or agree to take any of the foregoing actions.
4.1.2 Seller Transfers. Without
limiting Section 4.1.1, except as set forth in Section 4.1.2 of the Company Disclosure Schedule, prior to Closing
or termination of this Agreement, without the prior written consent of Buyer, which consent shall not be unreasonably withheld,
delayed, or conditioned (i) Company shall not issue any Company Securities, and (ii) no Seller shall sell, transfer or dispose
of any Company Securities owned by such Seller, in either case of clauses (i) and (ii), unless the recipient or transferee of
such Company Securities (A) becomes a Joining Seller hereunder by executing and delivering to Buyer and Company a Seller
Joinder, which
Seller Joinder is accepted in writing and executed and delivered by Buyer, Company and Seller Representative, and (B) executes
and delivers to Buyer and Company any Transaction Documents which such transferee would have been required to be a party or bound
if such transferee were a Signing Seller on the date of this Agreement or to which the transferring Seller is otherwise bound.
Notwithstanding anything to the contrary in this Agreement, the Parties shall make any appropriate adjustments to Exhibit B
and each Seller’s Pro Rata Share and Earnout Stock to account for any such new Seller.
4.1.3 Exclusivity; Acquisition
Proposals.
(a) For purposes of
this Agreement, an “Alternative Transaction” means (A) with respect to Company, Sellers and their respective
Affiliates, a transaction (other than the Transactions contemplated by this Agreement) concerning the sale of (x) all or any material
part of the business or assets of the Target Companies (other than in the ordinary course of business consistent with past practice)
or (y) any of the shares or other equity interests or profits of the Target Companies, in any case, whether such transaction takes
the form of a sale of shares or other equity interests, assets, merger, consolidation, issuance of debt securities, management
Contract, joint venture or partnership, or otherwise and (B) with respect to Buyer and its Affiliates, a transaction (other than
the Transactions contemplated by this Agreement) concerning a merger, consolidation or other business combination involving Buyer,
the issuance of equity interests in Buyer resulting in a change of Control of Buyer, or the sale of all or a substantial portion
of the assets of the Renovaro Group.
(b) Prior to the earlier
of the termination of this Agreement pursuant to Article X or the Closing, in order to induce Buyer to continue to commit
to expend management time and financial resources in furtherance of the Transactions contemplated hereby, the Target Companies
and Sellers shall not, and shall cause their Representatives to not, without the prior written consent of Buyer, directly or indirectly,
(i) solicit, assist, initiate or facilitate the making, submission or announcement of, or intentionally encourage, any Acquisition
Proposal, (ii) furnish any non-public information regarding the Target Companies or their Affiliates or their respective businesses,
operations, assets, Liabilities, financial condition, prospects or employees to any Person or group of Persons (other than a Party
to this Agreement or their respective Representatives) in connection with or in response to an Acquisition Proposal, other than
as required by applicable Law, (iii) engage or participate in discussions or negotiations with any Person or group of Persons
with respect to, or that could reasonably be expected to lead to, an Acquisition Proposal, (iv) approve, endorse or recommend,
or publicly propose to approve, endorse or recommend, any Acquisition Proposal, (v) negotiate or enter into any letter of intent,
agreement in principle, acquisition agreement or other similar agreement related to any Acquisition Proposal, or (vi) release any
third Person from, or waive any provision of, any confidentiality agreement to which such Party is a party.
(c) Company and any
Seller shall notify Buyer as promptly as practicable (and in any event within three (3) business days) in writing of the receipt
by such Party or any of its Representatives of (i) any bona fide inquiries, proposals or offers,
requests for information or requests
for discussions or negotiations regarding or constituting any Acquisition Proposal or any bona fide inquiries, proposals or offers,
requests for information or requests for discussions or negotiations that could be expected to result in an Acquisition Proposal,
and (ii) any request for non-public information relating to the Target Companies or their Affiliates in connection with any Acquisition
Proposal, specifying in each case, the material terms and conditions thereof (including a copy thereof if in writing or a written
summary thereof if oral) and the identity of the party making such inquiry, proposal, offer or request for information. Each Party
shall keep the others promptly informed of the status of any such inquiries, proposals, offers or requests for information. Prior
to Closing, each Target Company shall, and shall cause its Representatives to, immediately cease and cause to be terminated any
solicitations, discussions or negotiations with any Person with respect to any Acquisition Proposal and shall, and shall direct
its Representatives to, cease and terminate any such solicitations, discussions or negotiations.
4.1.4 Company Financial Statements.
(a) Company shall
deliver to Buyer as promptly as reasonably practicable (but in any event no later than October 30, 2023) following the date of
this Agreement, (i) the audited consolidated financial statements of the Target Companies (including any related notes thereto)
for the years ended December 31, 2022 and 2021, consisting of the audited consolidated balance sheets of the Target Companies as
of December 31, 2022 and 2021, and the related audited consolidated income statements, changes in shareholder/stockholder
equity and statements of cash flows for the fiscal years then ended, audited by a Public Company Accounting Oversight Board (“PCAOB”)
qualified auditor in accordance with US GAAP and PCAOB standards (the “2022 Company Financials”), and (ii) interim
unaudited consolidated financial statements of the Target Companies for the six months ended June 30, 2023 and 2022, consisting
of the interim unaudited consolidated balance sheet of the Target Companies as of June 30, 2023 and 2022, prepared in accordance
with US GAAP and PCAOB standards, subject to year-end audit adjustments and excluding footnotes (the “2023 Interim Company
Financials”). Company shall cause (A) the 2022 Company Financials and the 2023 Interim Company Financials to be prepared
in accordance with US GAAP applied on a consistent basis throughout the periods indicated (except as may be specifically indicated
in the notes thereto), (B) the 2022 Company Financials to be audited in accordance with the standards of the PCAOB and to
contain a report of Company’s auditor and (C) the 2022 Company Financials and the 2023 Interim Company Financials to
comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC,
the Exchange Act and the Securities Act in effect as of date of delivery (including Regulation S-X or Regulation S-K, as applicable).
(b) In the event the
Closing does not occur prior to November 15, 2023, the Company shall deliver to Buyer as promptly as reasonably practicable (but
in any event no later than November 15, 2023) interim unaudited consolidated financial statements of the Target Companies for the
nine months ended September 30, 2023 and 2022, consisting of the interim unaudited consolidated balance sheet of the Target Companies
as of September 30, 2023 and 2022, prepared in accordance with US GAAP and PCAOB standards, subject to year-end audit adjustments
and excluding footnotes (the “September Company Financials”).
The Parties agree the term “2023 Interim
Company Financials” shall be modified to include the September Company Financials if their delivery is required prior to
Closing. As used herein, the defined term “Latest Balance Sheet Date” shall mean the date of the balance sheet
contained in the 2023 Interim Company Financials, as modified by the previous sentence.
(c) Prior to Closing,
and beginning with the month ended October 31, 2023, within thirty (30) calendar days following the end of each calendar month
and within thirty (45) calendar days following the end of each three-month quarterly period, Company shall deliver to Buyer an
interim unaudited consolidated income statement and an interim unaudited consolidated balance sheet of the Target Companies for
the period from the Latest Balance Sheet Date through the end of such calendar month or quarterly period and the applicable comparative
period in the preceding fiscal year, in each case accompanied by a certificate of the Chief Financial Officer of Company to the
effect that all such financial statements fairly present the consolidated financial position and results of operations of the Target
Companies as of the date or for the periods indicated, in accordance with US GAAP, subject to year-end audit adjustments and excluding
footnotes. From the date hereof through the Closing Date, Company will also promptly deliver to Buyer copies of any audited consolidated
financial statements of the Target Companies that the Target Companies’ certified public accountants may issue.
4.1.5 No Trading.
Each of Company and Sellers acknowledges and agrees that it is aware, and that their respective Affiliates are aware (and each
of their respective Representatives is aware or, upon receipt of any material nonpublic information of Buyer, will be advised)
of the restrictions imposed by U.S. federal securities laws and the rules and regulations of the SEC and Nasdaq (or other
applicable national exchange) promulgated thereunder or otherwise (the “Federal Securities Laws”) and other applicable
foreign and domestic Laws on a Person possessing material nonpublic information about a publicly traded company. Each of Company
and Sellers hereby agrees that, while it is in possession of such material nonpublic information, it shall not purchase or sell
any securities of Buyer (other than to engage in the Transactions contemplated by this Agreement), communicate such information
to any third party, take any other action with respect to Buyer in violation of such Laws, or cause or encourage any third party
to do any of the foregoing.
4.2 Notification; Access to
Information.
4.2.1 Cooperation.
From the date of this Agreement to the earlier of the Closing Date or the termination of this Agreement in accordance with Article
X, Company will (i) confer with Buyer and its Representatives, at such times as they may request, during normal business hours and
upon reasonable advance notice, about operational and integration matters to the extent permitted by Law, (ii) in the event of, and promptly
after becoming aware of, the occurrence of or the pending or threatened occurrence of any event that would cause or constitute a material
breach of any of the representations and warranties in Section 3.1, give detailed written notice to Buyer and use commercially
reasonable efforts to prevent or promptly remedy such breach or inaccuracy, (iii) promptly notify Buyer if it fails to comply with or
satisfy any covenant, condition or agreement
to be complied with or satisfied by it or its
Affiliates or any Seller hereunder in any material respect; and (iv) promptly notify Buyer of any change in the normal course of
any business, operations, or financial condition of the Target Companies or their respective Assets or properties, or any emergency
related to the same.
4.2.2 Access to Information.
Company will, subject to applicable Law, afford Buyer and its Representatives reasonable access during normal business hours during the
period before the Closing to all information concerning the business, properties, and personnel of the Target Companies, as Buyer may
reasonably request that is necessary to complete the Transactions and prepare for an orderly transition of operations after the Closing;
provided that such access does not disrupt the normal operations of the Target Companies and does not contravene applicable Law.
4.3 Consents and Notices.
Company will use its commercially reasonable efforts, and each Seller will cooperate with Buyer and Company, to promptly (a) apply for
or otherwise seek, and use commercially reasonable efforts to obtain, all consents included in Section 3.1.4 of the Company Disclosure
Schedule (if any), (b) provide all notices included in Section 3.1.4 of the Company Disclosure Schedule (if any), and (c) make
all filings required with respect to any Target Company for the consummation of the Transactions (if any).
4.4 Commercially Reasonable
Efforts. Each Target Company will use commercially reasonable efforts to effect the Transactions applicable
to such Party, including the satisfaction of the respective conditions set forth in Article VII, applicable to Company, and including
to execute and deliver such other instruments and do and perform such other acts and things as may be reasonably necessary for effecting
completely the consummation of the Transactions applicable to Company (including making all filings (if any), giving all notices (if
any) required to be made and given by Company in connection with the Transactions and using commercially reasonable efforts to obtain
each consent (if any) required to be obtained (pursuant to any applicable Law, Contract or otherwise) by such Party in connection with
the Transactions).
4.5 Proxy Statement.
Company and Sellers shall, and shall cause the Target Companies to, furnish all information concerning the Target Companies and Sellers
as Buyer may reasonably request in connection with the preparation of the Proxy Statements, including, without limitation, any information
in response to comments received from the SEC, if applicable.
4.6 Issuance of
Company Ordinary Shares to Consultant. Immediately prior to Closing, Company shall (i) issue
to Consultant that number of Company Ordinary Shares that would result in Consultant receiving 1,000,000 Exchange Shares at Closing
pursuant to Section 2.2 and (ii) use commercially reasonable efforts to cause the Consultant to become a Joining Seller.
Article
V
COVENANTS OF BUYER
During the period from the
date of this Agreement and continuing until the earlier of the termination of this Agreement pursuant to Article X or the
Closing, Buyer agrees (except as expressly contemplated by this Agreement or as otherwise consented to in advance in writing by
Company, which consent shall not be unreasonably delayed, conditioned or withheld) as follows:
5.1 Conduct of Business.
5.1.1 Ordinary Course.
Buyer shall, and shall cause each of the other Renovaro Group members to, carry on its business in the ordinary course consistent with
past practice, will continue to observe its obligations to comply with the requirements of all applicable Laws and regulations, and will
use commercially reasonable efforts to (i) preserve intact its present business organization and its assets, (ii) keep available the
services of its officers, consultants, and employees (other than termination of such services for cause), (iii) maintain and preserve
the goodwill and relationships with manufacturers, customers, suppliers, contractors, distributors, and others having business relationships
with it and (iv) maintain its books, records and financials in accordance with US GAAP. Buyer will promptly notify Sellers and Company
of any event or occurrence not in the ordinary course of business of any Renovaro Group member that would result, or could reasonably
be expected to result, individually or in the aggregate, in a Buyer Material Adverse Effect. Without limiting the above, prior to the
earlier of the termination of this Agreement pursuant to Article X or the Closing Date, Buyer shall not, and shall cause its subsidiaries
to not (except as (i) expressly contemplated by this Agreement, (ii) as required by applicable Law, or (iii) as otherwise consented to
in advance in writing by Company and Sellers, which consent shall not be unreasonably delayed, conditioned or withheld):
(a) except as required
under the terms of any agreement existing as of the date of this Agreement as disclosed in the Buyer Disclosure Schedule, (i) increase
the compensation or benefits of any of the current or former directors, officers, or employees of any Renovaro Group member (collectively,
“Buyer Employees”), (ii) establish or amend any Benefit Plan, (iii) terminate the employment of any Buyer Employee
(other than due to terminations for cause) or (iv) grant any severance or termination pay to any Buyer Employee, other than in
Buyer’s ordinary course of business and consistent with past practices;
(b) assign, transfer,
dispose of, or license ownership of Buyer IP Rights or any other assets;
(c) abandon or permit
to lapse any Buyer IP Rights;
(d) disclose any Buyer’s
Trade Secrets to any third party, other than pursuant to confidentiality agreements;
(e) declare, set aside,
or pay any distribution with respect to any Buyer Common Stock, or repurchase, redeem, or acquire any outstanding Buyer Common
Stock or other ownership interests in Buyer, or otherwise change the capitalization of Buyer in any manner from the way it existed
on the date of this Agreement;
(f) amend the Organizational
Documents of Buyer;
(g) incur,
create, assume, prepay or otherwise become liable for any Indebtedness (directly, contingently or otherwise), make a loan or advance
to or investment in any third party (other than advancement of expenses to employees in the ordinary course of business), or guarantee
or endorse any Indebtedness, Liability or obligation of any Person;
(h) commence a lawsuit,
or settle, compromise, or otherwise terminate any litigation, claim, investigation, or other settlement negotiation;
(i) make any payments
to any third parties in excess of $100,000 outside of the ordinary course of business;
(j) extend an offer
of employment to a candidate whose annual compensation shall be in excess of $300,000;
(k) enter into any joint
venture, partnership, limited liability company, or operating agreement with any Person;
(l) enter into any Buyer
Material Contract or breach, modify, amend, or terminate any Buyer Material Contracts (including insurance policies covering Buyer’s
properties or assets), or waive, release, or assign any rights or claims under any Buyer Material Contracts, except as expressly
required or permitted by this Agreement;
(m) voluntarily
incur any Liability or obligation (whether absolute, accrued, contingent or otherwise) in excess of $300,000 individually or $600,000
in the aggregate other than pursuant to the terms of a Company Material Contract;
(n) adopt a plan of
complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization, or other reorganization;
(o) acquire or dispose
of capital stock of any third party or merge or consolidate with any third party;
(p) establish any subsidiary
or enter into any new line of business;
(q) fail to use commercially
reasonable efforts to keep in force insurance policies or replacement or revised policies providing insurance coverage with respect
to its assets, operations and activities in such amount and scope of coverage substantially similar to that which is currently
in effect;
(r) sell,
lease, license, transfer, exchange or swap, mortgage or otherwise pledge or encumber (including securitizations), or otherwise
dispose of any material portion of its properties, assets or rights;
(s) knowingly take any
action that would or is reasonably likely to (i) make any representation or warranty of Buyer contained in this Agreement inaccurate,
(ii) result in any of the conditions in Article VII not being satisfied, or (iii) impair the ability of Buyer to consummate
the Transactions in accordance with the terms of this Agreement; or
(t) authorize, commit,
or agree to take any of the foregoing actions.
5.1.2 Exclusivity; Acquisition
Proposals.
(a) Prior to the earlier
of the termination of this Agreement pursuant to Article X or the Closing, in order to induce Company and Sellers to continue
to commit to expend management time and financial resources in furtherance of the Transactions contemplated hereby, Buyer shall
not, and shall cause its Representatives to not, without the prior written consent of Company, directly or indirectly, (i) solicit,
assist, initiate or facilitate the making, submission or announcement of, or intentionally encourage, any Acquisition Proposal,
(ii) furnish any non-public information regarding Buyer or its Affiliates or their respective businesses, operations, assets, Liabilities,
financial condition, prospects or employees to any Person or group of Persons (other than a Party to this Agreement or their respective
Representatives) in connection with or in response to an Acquisition Proposal, other than as required by applicable Law, (iii)
engage or participate in discussions or negotiations with any Person or group of Persons with respect to, or that could reasonably
be expected to lead to, an Acquisition Proposal, (iv) approve, endorse or recommend, or publicly propose to approve, endorse or
recommend, any Acquisition Proposal, (v) negotiate or enter into any letter of intent, agreement in principle, acquisition
agreement or other similar agreement related to any Acquisition Proposal, or (vi) release any third Person from, or waive any provision
of, any confidentiality agreement to which such Party is a party.
(b) Buyer shall notify
Company and the Sellers’ Representative as promptly as practicable (and in any event three (3) business days) in writing
of the receipt by Buyer or any of its Representatives of (i) any bona fide inquiries, proposals or offers, requests for information
or requests for discussions or negotiations regarding or constituting any Acquisition Proposal or any bona fide inquiries, proposals
or offers, requests for information or requests for discussions or negotiations that could be expected to result in an Acquisition
Proposal, and (ii) any request for non-public information relating to Buyer or its Affiliates in connection with any Acquisition
Proposal, specifying in each case, the material terms and conditions thereof (including a copy thereof if in writing or a written
summary thereof if oral) and the identity of the party making such inquiry, proposal, offer or request for information. Each Party
shall keep the others promptly informed of the status of any such inquiries, proposals, offers or requests for information. Prior
to Closing, Buyer shall, and shall cause its Representatives to, immediately cease and cause to be terminated any solicitations,
discussions or negotiations with any Person with respect to any Acquisition Proposal and shall, and shall direct its Representatives
to, cease and terminate any such solicitations, discussions or negotiations.
5.1.3 Buyer Public Filings
(a) From the date of
this Agreement to the earlier of the Closing Date or the termination of this Agreement in accordance with Article X, Buyer
will keep current and timely file all of the forms, reports, schedules, statements and other documents required to be filed by
Buyer with the SEC, including all necessary amendments and supplements thereto, and otherwise comply in all material respects with
applicable securities Laws (the “Additional SEC Documents”). All such Additional SEC Documents (including any
financial statements or schedules included therein) shall be prepared in all material respects in accordance with either the requirements
of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act, as the case may be, and the rules and regulations promulgated
thereunder. As used in this Section 5.1.3, the term “file” shall be broadly construed to include any manner
in which a document or information is furnished, supplied or otherwise made available to the SEC or Nasdaq. Any Additional SEC
Documents which discuss or refer to this Agreement or the Transactions shall be subject to the prior review and approval of Company
(not to be unreasonably withheld, delayed or conditioned).
(b) From the date of
this Agreement to the earlier of the Closing Date or the termination of this Agreement, Buyer shall promptly notify the Sellers’
Representative of the filing of any Additional SEC Documents.
(c) From the date of
this Agreement to the earlier of the Closing Date or the termination of this Agreement in accordance with Article X, Buyer
shall use its best efforts to maintain the listing of the Buyer Common Stock on the Nasdaq.
5.2 Notification; Access to
Information.
5.2.1 Cooperation.
From the date of this Agreement to the earlier of the Closing Date or the termination of this Agreement in accordance with Article
X, Buyer will (i) confer with Company, Sellers, and their Representatives, at such times as they may request, during normal business
hours and upon reasonable advance notice, about operations and integration matters to the extent permitted by Law, (ii) in the event
of, and promptly after becoming aware of, the occurrence of or the pending or threatened occurrence of any event that would cause or
constitute a material breach of any of the representations and warranties in Section 3.2, Buyer will give detailed written notice
to Company and will use commercially reasonable efforts to prevent or promptly remedy such breach or inaccuracy; (iii) promptly notify
Company if it fails to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it or its Affiliates
hereunder in any material respect; and (iv) promptly notify the Sellers’ Representative of any change in the normal course of any
business, operations, or financial condition of the Renovaro Group or their respective Assets or properties, or any emergency related
to the same.
5.2.2 Access to Information.
Buyer will, subject to applicable Law, afford Company and Sellers and their respective Representatives reasonable access during normal
business hours during the period before the Closing to all information concerning the business, properties, and personnel of Buyer, as
Company and any Seller may reasonably request that is necessary to complete the Transactions and prepare for an orderly transition of
operations after the Closing; provided that such access does not disrupt the normal operations of the Renovaro Group and does
not contravene applicable Law.
5.3 Consents and Notices.
Buyer will use its commercially reasonable efforts, and will cooperate with Company and Seller, to promptly (a) apply for or otherwise
seek, and use commercially reasonable efforts to obtain, all consents included in Section 3.2.5 of the Buyer Disclosure Schedule,
including Stockholder Approval, (b) provide all notices included in Section 3.2.5 of the Buyer Disclosure Schedule (if any), and
(c) make all filings required with respect to Buyer for the consummation of the Transactions (if any).
5.4 Commercially Reasonable
Efforts. Buyer will use commercially reasonable efforts to effect the Transactions and to fulfill and
cause to be fulfilled the conditions to Closing under this Agreement, including the satisfaction of the respective conditions set forth
in Article VII, applicable to Buyer, and including to execute and deliver such other instruments and do and perform such other
acts and things as may be reasonably necessary for effecting completely the consummation of the Transactions applicable to Buyer (including
making all filings (if any), giving all notices (if any) required to be made and given by Buyer in connection with the Transactions and
using commercially reasonable efforts to obtain each consent (if any) required to be obtained (pursuant to any applicable Law, Contract
or otherwise) by such Party in connection with the Transactions).
5.5 Proxy Statements; Buyer
Stockholder Meeting.
5.5.1 Proxy Statements
As promptly as practicable after the date of this Agreement and in any event no later than fifteen (15)
days from the delivery of the 2022 Company Financials and the 2023 Company Interim Financials, Buyer shall prepare and file with the
SEC a notice of meeting and preliminary proxy statement (“Notice of Meeting and Preliminary Proxy Statement”) relating
to a meeting of Buyer’s stockholders (the “Buyer Stockholder Meeting”) to be held for the purpose of voting
on the matters requiring Stockholder Approval. As promptly as practicable after filing such Notice of Meeting and Preliminary Proxy Statement,
but in any event subject to the rules and regulations of the SEC, Buyer shall prepare and file with the SEC, and mail to its stockholders
of record as of the close of business on the Record Date (the “Record Stockholders”), a notice of meeting and definitive
proxy statement relating to the Buyer Stockholder Meeting (the “Notice of Meeting and Definitive Proxy Statement”).
The Notice of Meeting and Preliminary Proxy Statement and Notice of Meeting and Definitive Proxy Statement are hereinafter referred to
as the “Proxy Statements.”
5.5.2 Buyer Stockholder
Meeting The Buyer Stockholder Meeting shall be called for a date which, after taking into consideration
the provisions of the Buyer Organizational Documents, the Delaware General Corporation Law,
the rules and regulations of the SEC and the NASDAQ Listing Rules and the recommendations
of any proxy solicitor engaged by Buyer with respect to the Buyer Stockholder Meeting and the Transactions, is as prompt as practicable
after the Notice of Meeting and Definitive Proxy Statement is filed with the SEC and mailed to the Record Stockholders. Buyer shall
consult with Company in fixing the record date for the Buyer Stockholder Meeting (the “Record Date”) and the
date of the Buyer Stockholder Meeting, give notice to Company of the Buyer Stockholder Meeting and allow Company’s Representatives
to attend the Buyer Stockholder Meeting. Buyer shall use its reasonable best efforts to obtain the approval of the holders of Buyer
Common Stock at Buyer Stockholder Meeting, including by soliciting from its shareholders proxies as promptly as possible in favor
of the matters to be approved by the Stockholder Approval, and shall take all other action necessary or advisable to secure the
required vote or consent of its shareholders therefor. Buyer shall provide the Company with updates with respect to the tabulated
vote counts received by Buyer; provided, however, that Buyer shall not be permitted to postpone the Buyer Stockholder Meeting
more than the earlier of (i) ten (10) business days prior to the Outside Date and (ii) ten (10) calendar days from the date of
the first Buyer Stockholder Meeting without the prior written consent of Company (not to be unreasonably withheld, delayed or conditioned),
and (c) the right to review and comment on all communication sent to holders of Buyer Common Stock and/or proxy solicitation firms.
5.5.3 Stockholder Approval
of Amendment If the Buyer’s stockholders approve the matters to be approved by the Stockholder
Approval at the Buyer Stockholder Meeting, then promptly after the Buyer Stockholder Meeting and prior to the Closing, Buyer shall amend
the Buyer’s Organizational Documents in accordance with the amendments contemplated by the Proxy Statements as described in Section
2.3.
5.6 Fairness Opinion.
Buyer will use its commercially reasonable efforts to cause an investment bank to issue to Buyer an opinion to the effect that, as of
the Closing Date, the consideration to be paid to the Sellers pursuant to the terms of this Agreement is fair, from a financial point
of view, to Buyer.
5.7 D&O Policy.
Buyer shall amend the D&O Policy in form reasonably satisfactory to Company in order to provide the members of the Post-Closing Buyer
Board and any new officers of Buyer appointed after the date hereof with at least as favorable terms and scope of coverage as those of
the D&O Policy covering Buyer’s officers and directors on the date hereof.
Article
VI
ADDITIONAL AGREEMENTS
Buyer and Company each agree
to take the following actions after the execution of this Agreement:
6.1 Confidentiality Agreement.
Company and Buyer agree that the Confidential Disclosure Agreement dated July 17, 2023, by and between Gedi Health Group, Ltd. and Buyer
(“Confidentiality Agreement”) will continue in full force and effect and will be applicable to all “Confidential
Information” (as such term is defined in the Confidentiality Agreement) exchanged in connection with this Agreement and the Transactions.
6.2 Expenses.
All costs and expenses incurred in connection with this Agreement and the Transactions will be paid by the Party incurring such cost
or expense; provided, however, that Buyer shall pay for all costs and expenses of the Company in connection with the preparation
and audit of the 2022 Company Financials, including engaging an accounting firm to assist the Company in the preparation of the 2022
Company Financials and the 2023 Interim Company Financials. For the avoidance of doubt, all expenses in connection with the Signing Press
Release, the Signing Filing, the Closing Press Release, the Closing Filing, the Buyer Stockholder Meeting and all Buyer related disclosure
included in the Proxy Statements shall be borne by Buyer.
6.3 Further Assurances.
Prior to Closing, Buyer, Company, and Sellers, as applicable, shall sign and deliver any documents and instruments and take any further
action that is reasonably necessary or desirable to effect the Closing and to carry out the purposes of this Agreement.
6.4 Public Announcements.
6.4.1 Prior Written Consent
The Parties agree that prior to Closing, no public release, filing or announcement concerning this
Agreement or the Transaction Documents or the Transactions contemplated hereby or thereby, including the existence or status thereof,
shall be issued by any Party or any of their respective Affiliates without the prior written consent of Buyer and Company (which consent
shall not be unreasonably withheld, conditioned or delayed), except as such release or announcement may be required by applicable Law
or the rules or regulations of Nasdaq, in which case the applicable Party shall promptly notify Buyer and Company (as applicable)
of such obligations and shall use its commercially reasonable efforts to allow Buyer and Company (as applicable) reasonable time to review
and comment on, and arrange for any required filing with respect to, such release or announcement in advance of such issuance.
6.4.2 Press Releases and Filings
Buyer and Company shall mutually agree upon and, as promptly as practicable after the execution of
this Agreement (but in any event within four (4) business days thereafter), issue a press release announcing the execution of this Agreement
(the “Signing Press Release”). Promptly after the issuance of the Signing Press Release, Buyer shall file a current
report on Form 8-K (the “Signing Filing”) with the Signing Press Release and a description of this Agreement
and the Transaction Documents as required by Federal Securities Laws, which Company shall review, comment upon and approve (which approval
shall not be unreasonably withheld, conditioned or delayed) prior to filing (with Company reviewing, commenting upon and approving such
Signing Filing in any event no later than the third (3rd) business day after the execution of this Agreement, provided that Company receive
a substantially complete draft of the Signing Press Release and Signing Filing no more than one (1) business day after the date of this
Agreement). Buyer, Company and the Sellers’ Representative shall mutually agree upon and, as promptly as practicable after the
Closing (but in any event within four (4) business days thereafter), issue a press release announcing the consummation of the Transactions
contemplated by this Agreement (the “Closing Press Release”). Promptly after the issuance of the
Closing Press Release, Buyer shall file a current report on Form 8-K (the “Closing Filing”) with
the Closing Press Release and a description of the Closing as required by Federal Securities Laws which the Sellers’ Representative
shall review, comment upon and approve (which approval shall not be unreasonably withheld, conditioned or delayed) prior to filing.
In connection with the preparation of the Signing Press Release, the Signing Filing, the Closing Filing, the Closing Press Release,
or any other report, statement, filing notice or application made by or on behalf of a Party to any Governmental Entity or other
third party in connection with the Transactions contemplated hereby, each Party shall, upon request by any other Party, furnish
the Parties with all information concerning themselves, their respective directors, officers and equity holders, and such other
matters as may be reasonably necessary or advisable in connection with the Transactions contemplated hereby, or any other report,
statement, filing, notice or application made by or on behalf of a Party to any third party and/or any Governmental Entity in connection
with the Transactions contemplated hereby.
6.5 Post-Closing Board of Directors.
The Parties shall take all necessary action, including causing certain directors of Buyer to resign, so that effective as of the Closing,
Buyer’s board of directors (the “Post-Closing Buyer Board”) will consist of nine (9) individuals (such persons,
the “Directors”): (i) one (1) of which shall be the Chief Executive Officer of Buyer, (ii) the four (4) persons that
are designated by Buyer prior to the Closing, at least three (3) of whom shall qualify as an “independent director” under
NASDAQ Listing Rule 5605(a), and (iii) the four (4) persons that are designated by Company prior to the Closing, at least two (2) of
whom shall be required to qualify as an “independent director” under NASDAQ Listing Rule 5605(a); provided that the
Post-Closing Buyer Board will meet all diversity and other requirements under applicable Law and the NASDAQ Listing Rules. The board
of directors of Company immediately after the Closing shall be the same as the Post-Closing Buyer Board. At or prior to the Closing,
Buyer will provide each Director with a customary director indemnification agreement, in form and substance reasonably acceptable to
such Director, to be effective upon the Closing (or if later, such Director’s appointment).
6.6 Indemnification of Company’s
Board and Officers The Parties agree that all rights to exculpation, indemnification and advancement
of expenses existing in favor of the current or former directors and officers of Buyer or Company and each Person who served as a director,
officer, member, trustee or fiduciary of another corporation, partnership, joint venture, trust, pension or other employee benefit plan
or enterprise at the request of Buyer or Company (the “D&O Indemnified Persons”) as provided in its Organizational
Documents or under any indemnification, employment or other similar agreements between any D&O Indemnified Person and Buyer or Company,
in each case as in effect on the date of this Agreement, shall survive the Closing and continue in full force and effect in accordance
with their respective terms to the extent permitted by applicable Law. For a period of six (6) years after the Closing, Buyer and Company
shall cause the Organizational Documents of Buyer and Company to contain provisions no less favorable with respect to exculpation and
indemnification of and advancement of expenses to D&O Indemnified Persons than are set forth as of the date of this Agreement in
the Organizational Documents of, as applicable, Buyer or Company to the extent permitted by applicable Law. The provisions of this Section 6.6
shall survive the Closing and are intended to be for the benefit of, and shall be enforceable by, each of the D&O Indemnified
Persons and their respective heirs and representatives.
6.7 Post-Closing Tax
Matters.
6.7.1 Returns Filed.
Following the Closing, Buyer will prepare and timely file, or cause to be prepared and timely filed, any Tax Return with respect
to a Pre-Closing Tax Period with a due date (including any applicable extensions) after the Closing Date (including any Tax Returns
with respect to a Straddle Period). Such Tax Returns will be prepared in a manner consistent with past practice, except to the
extent otherwise required under applicable law. Buyer will provide all such Tax Returns that are income Tax Returns to the Sellers’
Representative for review at least fifteen (15) days prior to the due date for such Tax Returns (including any applicable extensions),
and Buyer will reasonably and in good faith consider any comments made by the Sellers’ Representative before the due date
for such Tax Returns with respect to such Tax Returns that are consistent with the standard set forth in the preceding sentence.
6.7.2 Tax Cooperation.
Each of Buyer and each Seller will cooperate fully, as and to the extent reasonably requested by any of the others, in connection
with the filing of Tax Returns and any Tax Contest with respect to Pre-Closing Tax Periods.
6.7.3 No Amendments.
Following the Closing Date, Buyer will not amend or cause to be amended any Tax Return, make or change any Tax election, agree
to the extension or waiver of the statute of limitations period or take any other action that has the effect of extending the
period of assessment or collection, initiate discussions or examinations with any Governmental Entity, or make any voluntary disclosures,
in each case with respect to Taxes of Company that relates to a Pre-Closing Tax Period, and in each case except (i) as required
by applicable law as mutually agreed by Buyer and Sellers, (ii) with the consent of the Sellers’ Representative, which consent
will not be unreasonably withheld, delayed, or conditioned, or (iii) if the Buyer, in its sole and absolute discretion, makes
or causes to be made any Section 338 Election.
6.7.4 Transfer Taxes.
All Taxes and fees (including any penalties and interest) incurred in connection with the Transactions shall be borne and paid
by the Party to which it accrues under applicable Law.
6.7.5 Election Under
Section 338 of the Code. Each Party hereto acknowledges and agrees that the Buyer, in its sole
and absolute discretion, may (but is not obligated to) make or cause to be made an election under Section 338(g) of the Code (and
any comparable provision of applicable U.S. state or local Tax Law) with respect to the purchase of the equity interests of one
or more of the Target Companies and if the Buyer so makes, or causes to be made, such an election, each party hereto shall cooperate
with each other and take all actions necessary and appropriate (including filing such additional forms, returns, elections schedules
and other documents as may be required) to effect and preserve a timely election, in accordance with Section 338(a) of the Code
and the applicable Treasury Regulations promulgated thereunder (each such election, a “Section 338 Election”).
6.8 Efforts to Consummate;
Regulatory Matters and Approvals.
6.8.1 Defense of Proceedings.
Except as otherwise provided in this Agreement, each of the Parties agrees to use its commercially reasonable efforts to defend
against any Proceedings challenging this Agreement or the consummation of the Transactions, seeking to have any preliminary injunction,
temporary restraining order, stay or other legal restraint or prohibition entered or imposed by any court or other Governmental
Entity that is not yet final and nonappealable vacated or reversed, and executing any additional instruments reasonably requested
by another Party (without cost or expense to the executing Party) necessary to carry out the Transactions and to fully carry out
the purposes of this Agreement.
6.9 Securities Laws
Compliance. Buyer covenants to take all actions, make all filings and transmit all documents
required under all Federal Securities Laws and state securities laws and regulations with respect to the Transactions contemplated
by this Agreement, the Transaction Documents and all related agreements.
6.10 Delivery of Disclosure
Schedules. Buyer shall deliver the Buyer Disclosure Schedules and Exhibit 2.2.1 to Sellers
and Company, and Sellers and Company shall deliver the Company Disclosure Schedules to Buyer, within ten (10) Business Days from
the date of this Agreement.
6.11 Additional Sellers.
Company and the Signing Sellers shall use commercially reasonable efforts to cause all other holders of Company Ordinary Shares
to become Parties to this Agreement as a “Joining Seller” by executing and delivering to Buyer and Company (i) a Seller
Joinder to this Agreement, which joinder is accepted in writing and executed and delivered by Buyer and Company, and (ii) any
Transaction Documents which such transferee would have been required to be a party or bound if such transferee were a Seller on
the date of this Agreement. Notwithstanding anything to the contrary in this Agreement, the Parties shall make any appropriate
adjustments to Exhibit B and each Seller’s Pro Rata Share and Earnout Stock to account for any such new Seller.
6.12 Seller Registration
Rights Agreement. Sellers and Buyer shall enter into a Registration Rights Agreement, in the
form attached as Exhibit C hereto (the “Seller Registration Rights Agreement”), which Seller Registration
Rights Agreement shall become effective as of the Closing.
6.13 Issuance of Company
Ordinary Shares to Employee. Immediately prior to Closing, pursuant to its contractual obligation,
Company shall (i) issue to an employee that number of Company Ordinary Shares required to be issued pursuant to such contractual
obligation, and (ii) use commercially reasonable efforts to cause such employee to become a Joining Seller. Upon the exchange
of Company Shares for Exchange Shares pursuant to Section 2.2, Buyer shall cause any reverse vesting, forfeiture provision
or any other restrictions applicable to such Company Ordinary Shares issued to such employee prior to Closing to apply to such
Exchange Shares received by such employee.
Article
VII
CONDITIONS PRECEDENT
7.1 Conditions to Each
Party’s Obligation to Effect the Transactions. The respective obligations of each Party
to consummate the Transactions are subject to the satisfaction, or to the extent permitted by applicable law, the written waiver
at or before Closing, of each of the following conditions:
7.1.1 Buyer
Stockholder Approval. Buyer shall have received Stockholder Approval at the Buyer
Stockholder Meeting in accordance with the Proxy Statements.
7.1.2 Consents.
Each Consent listed on Section 3.1.4 of the Company Disclosure Schedule (if any) and Section 3.2.5 of the Buyer
Disclosure Schedule will have been obtained or provided, other than such Consents (a) as Buyer and Company agree Company will
not seek to obtain, or (b) the failure of which to obtain would not result, or reasonably be expected to result, individually
or in the aggregate, in a Company Material Adverse Effect, Buyer Material Adverse Effect, or as a result of the Transactions,
a Buyer Material Adverse Effect or Company Material Adverse Effect.
7.1.3 No Order.
No Governmental Entity of competent jurisdiction will have enacted, issued, promulgated, enforced, or entered any statute, rule,
regulation, executive order, decree, injunction, or other Order (whether temporary, preliminary, or permanent) that (a) is in
effect and (b) has the effect of making the Transactions illegal or otherwise prohibiting consummation of the Transactions (which
illegality or prohibition would have a Company Material Adverse Effect or Buyer Material Adverse Effect if the Transactions were
consummated).
7.1.4 Nasdaq Listing.
Buyer shall have received evidence reasonably satisfactory to Buyer, the Sellers’ Representative and Company that immediately
after the Closing and after giving effect to the issuance of the Exchange Shares and any of the other Transactions contemplated
by this Agreement, the shares of Buyer Common Stock shall remain listed on Nasdaq.
7.2 Conditions to Obligations
of Buyer. In addition to the conditions specified in Section 7.1, the obligations
of Buyer to consummate the Share Exchange and the other Transactions contemplated by this Agreement are subject to the satisfaction
or written waiver (by Buyer) of the following conditions:
7.2.1 Representations
and Warranties of Company and Sellers.
(a) The representations
and warranties of Company and Sellers contained in Section 3.1.1, Section 3.1.2, Section 3.1.3, Section 3.1.4(a), Section 3.1.17,
Section 3.1.18 and Section 3.1.20 (the “Company Fundamental Representations”) shall be true and correct in all
respects as of the Closing Date with the same force and effect as if made on the Closing Date (except to the extent that any such
representation and warranty speaks as of an earlier date, in which case such representation and warranty shall be true and correct
in all respects as of such date). All other representations and warranties of Company and Sellers in this Agreement shall be true
and correct in all respects as of the Closing Date with the same force and effect as if made on the Closing Date (except to the
extent that any such representation and warranty speaks as of an earlier date, in which case such representation and warranty shall
be true and correct in all respects as of such date), except where the failure to be true and correct (without regard to any materiality
or Company Material Adverse Effect qualifiers set forth therein) would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect.
(b) The representations
and warranties of Sellers contained in Section 3.3.1, Section 3.3.2(a), Section 3.3.2(b), and Section 3.3.2(c) (the “Seller
Fundamental Representations”) shall be true and correct in all respects as of the Closing Date with the same force and
effect as if made on the Closing Date (except to the extent that any such representation and warranty speaks as of an earlier date,
in which case such representation and warranty shall be true and correct in all respects as of such date). All other representations
and warranties of Sellers in this Agreement shall be true and correct in all respects as of the Closing Date with the same force
and effect as if made on the Closing Date (except to the extent that any such representation and warranty speaks as of an earlier
date, in which case such representation and warranty shall be true and correct in all respects as of such date), except where the
failure to be true and correct (without regard to any materiality or Company Material Adverse Effect qualifiers set forth therein)
would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.
7.2.2 Agreements and
Covenants. Company and Sellers shall have performed in all material respects all of their respective
obligations and complied in all material respects with all of their respective agreements and covenants under this Agreement to
be performed or complied with by them on or prior to the Closing Date.
7.2.3 No Company Material
Adverse Effect. No Company Material Adverse Effect shall have occurred with respect to the Target
Companies since the date of this Agreement which is continuing and uncured.
7.2.4 Return of All
Distributions. All distributions made by any Target Company to any Affiliate since August 1,
2023, shall have been repaid to the Target Company.
7.2.5 Certain Transaction
Documents. Each (i) Seller shall have duly executed and delivered to Buyer the Seller Registration
Rights Agreement, and (ii) Seller that Buyer and Company mutually agree upon, in good faith, that is to be a party to a non-competition
agreement shall have duly executed and delivered to Buyer a non-competition agreement.
7.2.6 Seller’s
and Company’s Closing Deliverables(a) Officer’s Certificate. Buyer will
have received from Company a certificate, dated the Closing Date, signed by an executive officer of Company certifying as to the
Company’s satisfaction of the conditions specified in Sections 7.2.1(a), 7.2.2, 7.2.3 and 7.2.4.
(b) Sellers’
Certificates. Buyer will have received a certificate from each Seller, dated the Closing Date, signed by such Seller, certifying
as to such Seller’s satisfaction of the conditions specified in Sections 7.2.1(b), and 7.2.2.
(c) Secretary’s
Certificate. Company shall have delivered to Buyer a certificate from its secretary or other executive officer certifying as
to the validity and effectiveness of, and attaching, (A) copies of Company’s Organizational Documents as in effect as of
the Closing Date (immediately prior to the Closing), (B) the requisite resolutions of Company’s board of directors authorizing
and approving the execution, delivery and performance of this Agreement and each of the Transaction Documents to which Company
is a party or by which it is bound, and the consummation of the Transactions contemplated hereby and thereby, and (C) the
incumbency of officers of Company authorized to execute this Agreement or any Transaction Document to which Company is or is required
to be a party or otherwise bound.
(d) Good Standing.
Company shall have delivered to Buyer good standing certificates (or similar documents applicable for such jurisdictions, in the
case of the Netherlands, such similar document being an excerpt of the Trade Register of the Dutch Chamber of Commerce) for each
Target Company certified as of a date no earlier than thirty (30) days prior to the Closing Date from the proper Governmental Entity
of the Target Company’s jurisdiction of organization, in each case to the extent that good standing certificates or similar
documents are generally available in such jurisdictions.
(e) Share Certificates
and Transfer Instruments. Buyer shall have received from each Seller share certificates representing the Company Shares (or
duly executed affidavits of lost share certificates in form and substance reasonably acceptable to Buyer and consistent with the
Laws of England and Wales), if applicable, together with executed instruments of transfer in respect of Company Shares in favor
of Buyer and in form reasonably acceptable for transfer on the books of Company.
7.2.7 Legal Action.
Since the date of this Agreement, there will not be pending or threatened any Proceeding (a) challenging or seeking to restrain
or prohibit the consummation of the Transactions, or seeking to obtain any material damages, or any award of attorney fees in
connection with the Transactions; or (b) seeking to prohibit or impose any material limitations on Buyer’s ownership or
operation of all or any portion of any Target Company’s respective businesses, or to compel Buyer to dispose of or hold
separate all or any material portion of the assets of Target Company as a result of the Transactions.
7.2.8 Financial Statements.
Company shall have delivered to Buyer the 2022 Company Financials and 2023 Interim Company Financials in the form required for
Buyer’s independent public accounting firm to prepare financial statements in accordance with Buyer’s filing requirements
with the SEC in respect to the Transactions.
7.2.9 Fairness Opinion.
The board of directors of Buyer shall have received an opinion from an investment bank to the effect that, as of the Closing Date,
the consideration to be paid to the Sellers pursuant to the terms of this Agreement is fair, from a financial point of view, to
Buyer.
7.2.10 Termination of
Certain Agreements. All agreements listed in Section 7.2.10 of the Company Disclosure
Schedule (if any) will have been terminated by the parties thereto, if any.
7.2.11 Joinder to this
Agreements. All holders of Company Ordinary Shares immediately prior to the Closing shall have
become Parties to this Agreement as a “Signing Seller” or a “Joining Seller” by executing and delivering
to Buyer and Company a Seller Joinder to this Agreement so that immediately following the Closing, Buyer shall be the sole holder
of Company Ordinary Shares.
7.3 Conditions to Obligation
of Company and Sellers. In addition to the conditions specified in Section 7.1,
the obligations of Company and Sellers to consummate the Share Exchange and the other Transactions contemplated by this Agreement
are subject to the satisfaction or written waiver (by Company) of the following conditions:
7.3.1 Representations
and Warranties of Buyer. The representations and warranties of Buyer contained in Section 3.2.1,
Section 3.2.2, Section 3.2.3, Section 3.2.4, Section 3.2.5(a) and Section 3.2.20 (the “Buyer Fundamental Representations”)
shall be true and correct in all respects as of the Closing Date with the same force and effect as if made on the Closing Date,
except to the extent that any such representation and warranty speaks as of an earlier date, in which case such representation
and warranty shall be true and correct in all respects as of such date. All other representations and warranties of Buyer in this
Agreement shall be true and correct in all respects as of the Closing Date with the same force and effect as if made on the Closing
Date (except to the extent that any such representation and warranty speaks as of an earlier date, in which case such representation
and warranty shall be true and correct in all respects as of such date), except where the failure to be true and correct (without
regard to any materiality or Buyer Material Adverse Effect qualifiers set forth therein) would not, individually or in the aggregate,
reasonably be expected to have a Buyer Material Adverse Effect.
7.3.2 Agreements and
Covenants. Buyer shall have performed, in all material respects, all of Buyer’s obligations
and complied, in all material respects, with all of Buyer’s agreements and covenants under this Agreement to be performed
or complied with by it on or prior to the Closing Date.
7.3.3 No Buyer
Material Adverse Effect. No Buyer Material Adverse Effect shall have occurred with respect
to Buyer since the date of this Agreement which is continuing and uncured.
7.3.4 Certain Transaction
Documents. Buyer shall have duly executed and delivered
to the Sellers’ Representative: (i) the Seller Registration Rights Agreement, and (ii) each non-competition agreement.
7.3.5 Buyer Organizational
Documents. Buyer shall have amended its Organizational
Documents to reflect the Stockholder Approval as described in Section 2.3.
7.3.6 Appointment to
the Board. The members of the Post-Closing Buyer Board shall have been elected or appointed
as of the Closing consistent with the requirements of Section 6.5.
7.3.7 Buyer Closing
Deliverables.
Officer’s Certificate.
Company will have received from Buyer a certificate, dated the Closing Date, signed by an executive officer of Buyer certifying
as to the satisfaction of the conditions specified in Sections 7.3.1, 7.3.2 and 7.3.3.
Secretary’s Certificate.
Buyer shall have delivered to Company a certificate from its secretary or other executive officer certifying as to, and attaching,
(A) copies of the Buyer’s Organizational Documents as in effect as of the Closing Date, (B) the resolutions of Buyer’s
board of directors authorizing and approving the execution, delivery and performance of this Agreement and each of the Transaction
Documents to which it is a party or by which it is bound, and the consummation of the transactions contemplated hereby and thereby,
(C) evidence that the Stockholder Approval has been obtained and (D) the incumbency of officers authorized to execute this Agreement
or any Transaction Document to which Buyer is or is required to be a party or otherwise bound.
Good Standing.
Buyer shall have delivered to Company a good standing certificate (or similar documents applicable for such jurisdictions) for
Buyer certified as of a date no earlier than thirty (30) days prior to the Closing Date from the proper Governmental Entity of
Buyer’s jurisdiction of organization.
(d) Exchange Shares.
Buyer shall have delivered to each Seller, such Seller’s Exchange Shares, in book entry form, in the name of such Seller,
and promptly thereafter on the Closing Date a copy of the records of Securities Transfer Corporation, transfer agent for Buyer,
showing such Seller as the owner of such Exchange Shares.
7.4 Frustrations of
Conditions. Notwithstanding anything contained herein to
the contrary, no Party may rely on the failure of any condition set forth in this Article VII to be satisfied if such failure
was caused by the failure of such Party or its Affiliates (or with respect to Company, any Target Company or any Seller) failure
to comply with or perform any of its covenants or obligations set forth in this Agreement.
Article
VIII
INDEMNIFICATION
8.1 Indemnification
by Sellers. Subject to the limitations in this Article
VIII, if the Closing of the Transactions occurs, from and after Closing, each Seller (the “Indemnifying Seller”)
will defend, indemnify, and hold Buyer and its respective officers, directors, agents, consultants, advisors, Representatives
and equity holders (each of the foregoing being referred to individually as a “Buyer Indemnified Person” and
collectively as “Buyer Indemnified Persons”) harmless from and reimburse Buyer (on behalf of Buyer Indemnified
Persons), without duplication, for all documented and out-of-pocket costs or expenses (including without limitation, reasonable
attorney’s fees), judgments, levies, losses, damages, fines, Liens, Taxes and penalties, except for any punitive, consequential,
indirect or exemplary damages (except, in each case, to the extent reasonably foreseeable) or losses or damages on account of
loss of future opportunities (collectively, “Losses”), incurred by Buyer Indemnified Persons arising out of,
relating to or resulting from any of the following:
(a) any inaccuracy in
or breach of any representation or warranty of Company or Sellers contained in Section 3.1 of this Agreement (as modified
by the Company Disclosure Schedule);
(b) any breach or non-fulfillment
of any covenant, agreement, or obligation to be performed by such Seller under this Agreement (other than as a direct result of
the failure of Buyer to perform its agreements under this Agreement);
(c) any inaccuracy in
or breach of any representation or warranty of such Seller contained in Section 3.3 of this Agreement (as modified by the
Company Disclosure Schedule);
(d) any breach or non-fulfillment
of any covenant, agreement, or obligation to be performed on or prior to Closing by the Company under this Agreement (other than
as a direct result of the failure of Buyer to perform its agreements under this Agreement);
(e) any claims by (A)
any then current or former holder or alleged then-current or former holder of any Company Securities, arising out of, resulting
from or in connection with (I) the Transactions or this Agreement, or (II) such Persons status or alleged status as a holder of
Company Securities at any time at or prior to the Closing, whether for breach of fiduciary duty or otherwise or (B) any Person
to the effect that such Person is entitled to any Company Securities or any payment in connection with the Transactions by virtue
of such Company Securities; and
(f) any Pre-Closing
Taxes;
provided, that (i) and in the case of
Sections 8.1(a), (b), (c) or (d) above, without giving effect to any “materiality” limitations
or references to “Company Material Adverse Effect” in determining Losses (but not in determining whether any breaches
of representations and warranties have occurred); and (ii) each Seller shall only be liable to Buyer Indemnified Persons for indemnification
under Sections 8.1(a), (d) and (e) above in proportion to such Seller’s Pro Rata Share of such Losses.
Notwithstanding the foregoing, in no event shall any Indemnifying Seller have any liability to a Buyer Indemnified Person with
respect to a breach of representation, warranty or covenant under this Agreement to the extent that Buyer knew of such breach as
of the Closing Date.
8.2 Indemnification
by Buyer. Subject to the limitations in this Article
VIII, if the Closing of the Transactions occurs, from and after Closing, Buyer will defend, indemnify, and hold each Seller
and its respective officers, directors, agents, consultants, advisors, Representatives, equity holders, and successors and assigns
(each of the foregoing being referred to individually as a “Seller Indemnified Person” and collectively as
“Seller Indemnified Persons”, and together with Buyer Indemnified Persons, “Indemnified Persons”)
harmless from and reimburse Seller Indemnified Persons, without duplication, for all Losses incurred by Sellers Indemnified Persons
arising out of, relating to or resulting from any of the following:
(a) any inaccuracy in
or breach of any representation or warranty of Buyer contained in Section 3.2 of this Agreement (as modified by the Buyer
Disclosure Schedule);
(b) any breach or non-fulfillment
of any covenant, agreement, or obligation to be performed by Buyer or the Renovaro Group members under this Agreement (other than
as a direct result of the failure of Company or Seller to perform its agreements under this Agreement);
(c) any breach or non-fulfillment
of any covenant, agreement, or obligation to be performed following the Closing by the Company under this Agreement (other than
as a direct result of the failure of Seller to perform its agreements under this Agreement);
(d) any claims by (A)
any then current or former holder of any Buyer equity interests or Convertible Security, arising out of, resulting from or in connection
with the Transactions or this Agreement or (B) any Person to the effect that such Person is entitled to any Buyer equity interests
or Convertible Securities or any payment in connection with the Transactions by virtue of such Buyer equity interests or Convertible
Securities;
(e) any action, claim
or Proceeding arising out of or relating to Serhat Gumrukcu, William Anderson Wittekind, their Affiliates, or their relationship
with Buyer or the other Renovaro Group members as current or former stockholders;
(f) any legal Proceeding
relating to any inaccuracy, breach, claim or expense of the type referred to in the preceding clauses (a) through (e) (including,
without limitation, any legal Proceeding commenced by a Seller for the purpose of enforcing its rights under this Article
VIII if Seller is the prevailing party in any such legal Proceeding);
provided, that in the case of Sections
8.2(a), (b) or (c) above, without giving effect to any “materiality” limitations or references to
“Buyer Material Adverse Effect” in determining Losses (but not in determining whether any breaches of representations
and warranties have occurred). Notwithstanding the foregoing, in no event shall Buyer have any liability to a Seller Indemnified
Person with respect to a breach of representation, warranty or covenant under this Agreement to the extent that Sellers knew of
such breach as of the Closing Date.
8.3 Third Party Claims.
(a) Whenever an Indemnified
Person receives a written notice that a claim or demand has been asserted or threatened by any Person who is not a Party to this
Agreement for which such Indemnified Person may seek indemnification under Article VIII of this Agreement (other than claims
or demands covered by Section 8.4) (a “Third Party Claim”), the Indemnified Person shall notify the Indemnifying
Party of such Third Party Claim and of the related facts within the Indemnified Person’s knowledge within a reasonable time
after receiving such written notice; provided that no delay on the part of the Indemnified Person in notifying the Indemnifying
Party will relieve the Indemnifying Party from any obligation under this Article VIII, except and only to the extent such
delay actually prejudices the Indemnifying Party.
(b) The Indemnifying
Party shall have the right to participate in the defense of any Third Party Claim that is the subject of a notice given by or on
behalf of any Indemnified Person pursuant to this Section 8.3. In addition, the Indemnifying Party will have the right to
defend the Indemnified Person against the Third Party Claim with counsel of its choice reasonably satisfactory to the Indemnified
Person so long as (i) the Indemnifying Party gives written notice to the Indemnified Person within fifteen (15) business days after
the Indemnified Person has given notice of the Third Party Claim under to this Section 8.3 stating that it has elected to
assume the defense of such Third Party Claim, (ii) the Indemnifying Party provides the Indemnified Person with evidence reasonably
acceptable to the Indemnified Person that the Indemnifying Party will have adequate financial resources to defend against the Third
Party Claim, (iii) the Third Party Claim involves only money damages and does not seek an injunction or other equitable relief
against the Indemnified Person, (iv) the Indemnified Person has not been advised by counsel that an actual or probable conflict
exists between the Indemnified Person and the Indemnifying Party in connection with the defense of the Third Party Claim, (v) the
Third Party Claim does not relate to or otherwise arise in connection with any criminal or regulatory enforcement Proceeding and
(vi) the Indemnifying Party conducts the defense of the Third Party Claim actively and diligently at its expense. In the event
that the Indemnifying Party assumes the defense of any Third Party Claim, subject to Section 8.3(c), it shall have the right
to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third
Party Claim in the name and on behalf of the Indemnified Person. The Indemnified Person may retain separate co-counsel at its sole
cost and expense and participate in the defense of the Third Party Claim; provided that the Indemnifying Party will pay
the fees and expenses of separate counsel retained by the Indemnified Person that are incurred prior to the Indemnifying Party’s
assumption of control of the defense of the Third Party Claim.
(c) Notwithstanding
any other provision of this Agreement, the Indemnifying Party will not consent to the entry of any judgment or enter into any compromise
or settlement with respect to the Third Party Claim without the prior written consent of the Indemnified Person unless such judgment,
compromise or settlement (i) provides for the payment by the Indemnifying Party of money as sole relief for the claimant, (ii)
results in the full and general release of all Indemnified Persons from all liabilities arising or relating to, or in connection
with, the Third Party Claim from the Person with which such settlement is made and (iii) involves no finding or admission of any
violation of Laws or the rights of any Persons.
(d) If the Indemnifying
Party elects not to compromise or defend such Third Party Claim, fails to promptly notify the Indemnified Person in writing of
its election to defend as provided in this Agreement, or otherwise at any time fails to conduct the defense of such Third Party
Claim actively and diligently, the Indemnified Person may defend the Third Party Claim and may consent to the entry of any judgment
or enter into any compromise or settlement with respect to, the Third Party Claim in any manner it may deem appropriate. The Indemnifying
Party shall remain responsible for any Losses of the Indemnified Person the Indemnifying Party would be responsible for pursuant
to this Article VIII in the event that (i) the Indemnifying Party does not elect to defend such Third Party Claim pursuant
to Section 8.3(b) or (ii) the Indemnifying Party and the Indemnified Person are parties to or subject to such Third Party
Claim and conflicts of interest exist between the Indemnified Person and the Indemnifying Party.
8.4 Tax Contests.
Notwithstanding anything to the contrary in this Agreement (including Section 8.3), following the Closing Date, Buyer will
have the right, in Buyer’s sole and absolute discretion, to conduct and control, through counsel of Buyer’s choosing,
the defense of any Tax Contest; provided, however, that to the extent that any Tax Contest could reasonably give rise to
an indemnification claim by Buyer under Article VIII Buyer will (i) provide notice of such Tax Contest to the Sellers’
Representative within thirty (30) days after receiving written notice of the commencement of such Tax Contest from the relevant
Governmental Entity (provided that any failure by Buyer to provide such notice to the Sellers’ Representative within such
period will not relieve Sellers of any obligation or liability to Buyer, except and only to the extent such delay actually prejudices
the Sellers), (ii) provide to the Sellers’ Representative all information reasonably requested by the Sellers’ Representative
regarding such Tax Contest, (iii) permit Sellers to evaluate and comment on such Tax Contest at Sellers’ sole expense, and
(iv) reasonably and in good faith consider any such comments of the Sellers’ Representative. Buyer may settle, adjust, or
compromise any such Tax Contest, in Buyer’s sole and absolute discretion, without the consent of Sellers. In the event that
Sellers consent in writing to any settlement, adjustment, or compromise of any Tax Contest, Sellers will not have any power or
authority to object under any provision of Article VIII to the amount of any claim by Buyer for indemnification under Article
VIII with respect to such settlement, adjustment, or compromise.
8.5 Survival.
All representations, warranties, covenants, and agreements set forth in this Agreement
will survive the Closing, subject to the following:
(a) (i) The Company
Fundamental Representations and the Seller Fundamental Representations shall survive the Closing until the date that is six (6)
years from the Closing Date; (ii) the representations and warranties of the Sellers contained in Section 3.1.16 (Tax Matters)
shall survive until 90 days after the expiration of the applicable statute of limitations; and (iii) all other representations
and warranties of the Company and Sellers contained in Section 3.1 and Section 3.3 shall survive the Closing until
the date that is twenty four (24) months from the Closing Date.
(b) (i) The Buyer Fundamental
Representations shall survive the Closing until the date that is six (6) years from the Closing Date; (ii) the representations
and warranties of the Buyer contained in Section 3.2.17 (Tax Returns and Payments) shall survive until 90 days after the
expiration of the applicable statute of limitations; and (iii) all other representations and warranties of Buyer contained in Section
3.2 shall survive the Closing until the date that is twenty four (24) months from the Closing Date.
(c) The covenants and
other agreements of the Parties set forth herein (other than the covenants which by their terms are to be performed prior to the
Closing) shall survive the Closing until the date that is five (5) years from the Closing Date or for the period explicitly specified
therein.
(d) Notwithstanding
anything in this Section 8.5 to the contrary, in the event a Notice of Claim is asserted by the Buyer Indemnified Persons
or the Seller Indemnified Persons related to or arising out of an inaccuracy or breach in any representation, warranty, covenant
or claim during the time periods provided for in Sections 8.5(a), (b), and (c), such representation, warranty,
covenant or claim will continue to survive until such matter has been resolved by settlement, litigation (including all appeals
related thereto), arbitration or otherwise. For purposes of clarity, only a Notice of Claim needs to be given during the applicable
time period, without a requirement to commence Proceedings.
(e) Notwithstanding
anything in this Section 8.5 to the contrary, in the event a claim is asserted by a Buyer Indemnified Person or Seller Indemnified
Person related to or arising out of an inaccuracy or breach in any representation or warranty that results from or constitutes
Fraud by Sellers or Buyer, respectively, such representation or warranty will survive without any time limitation.
8.6 Limitations.
Indemnified Persons will be entitled to indemnification under Article VIII only
if the following conditions included in this Section 8.6 are met.
8.6.1 Threshold Amounts.
(a) Sellers
shall not be liable for any Losses pursuant to Section 8.1 (a)
or Section 8.1 (c) which, individually
considered, are lower than an amount equal to $250,000 (the “Threshold Amount”). Any Losses pursuant to Section
8.1 (a) or Section
8.1 (c) not exceeding the Threshold Amount shall
be considered non-indemnifiable Losses under this Agreement; provided, however, that a series of claims or multiple claims
for Losses arising out of the same or substantially the same set of facts or circumstances shall be deemed to have arisen from
a single event subject to indemnification for purposes of determining the foregoing Threshold Amount. Notwithstanding anything
contained in this Agreement to the contrary, the Threshold Amount limitation shall not apply to (i) claims for Losses made by the
Buyer Indemnified Persons pursuant to any of the Company Fundamental Representations or Seller Fundamental Representations, (ii)
claims for Losses made by the Buyer Indemnified Persons pursuant to Section 8.1
(b), Section 8.1 (d)
and Section 8.1 (e), and (iii)
claims for Losses arising out of Fraud.
(b) Buyer
shall not be liable for any Losses pursuant to Section 8.2 (a)
which, individually considered, are lower than the Threshold Amount. Any Losses pursuant to Section 8.2
(a) not exceeding the Threshold Amount shall be considered non-indemnifiable Losses under
this Agreement; provided, however, that a series of claims or multiple claims for Losses arising out of the same or substantially
the same set of facts or circumstances shall be deemed to have arisen from a single event subject to indemnification for purposes
of determining the foregoing Threshold Amount. Notwithstanding anything contained in this Agreement to the contrary, the Threshold
Amount limitation shall not apply to (i) claims for Losses made by the Seller Indemnified Persons pursuant to any of the Buyer
Fundamental Representations, (ii) claims for Losses made by the Seller Indemnified Persons pursuant to Section 8.2
(b), Section 8.2 (c),
Section 8.2 (d), Section
8.2 (e) and Section 8.2
(e), and (iii) claims for Losses arising out of Fraud.
8.6.2 Caps.
(a) The Indemnifying
Sellers shall always have the right to satisfy any claim for indemnification hereunder with shares of Buyer Common Stock issued
to it hereunder, and other than in respect of Fraud, shall never be required to make a cash payment to satisfy the indemnification
claims, unless the Indemnifying Seller so elects. Notwithstanding anything herein to the contrary, other than in respect of Fraud:
(i) the
maximum aggregate amount of indemnifiable Losses which may be recovered from any Seller for indemnification by the Buyer Indemnified
Persons pursuant Section 8.1(a) and Section 8.1(c) shall be an amount equal to such Seller’s Pro Rata Share
of fifteen percent (15%) of the Exchange Consideration received at Closing, calculated as of the Closing Date in accordance with
Section 8.8 (the “General Cap”); provided, however, that the General Cap will not apply to claims
for Losses made by the Buyer Indemnified Persons for any breaches of, or inaccuracies in, any of the Company Fundamental Representations,
Company Special Representations or the Seller Fundamental Representations;
(ii) the
maximum aggregate amount of indemnifiable Losses which may be recovered from any Seller for indemnification by the Buyer Indemnified
Persons pursuant any breach or inaccuracy in any of the Company Special Representations shall be an amount equal to such Seller’s
Pro Rata Share of fifty percent (50%) of the Exchange Consideration received at Closing, calculated as of the Closing Date in accordance
with Section 8.8 (the “Special Cap”); provided, however, that Sellers’ liability for Losses
under Section 8.1(a) and Section 8.1(c) (excluding for any breaches of, or inaccuracies in, any of the Company Fundamental
Representations or the Seller Fundamental Representations) collectively, shall not exceed the Special Cap in the aggregate; and
(iii) no
Seller shall have any Liability under Section 8.1 in excess of a maximum aggregate amount equal to such Seller’s Pro
Rata Share of the Exchange Consideration received at Closing, calculated as of the Closing Date in accordance with Section 8.8.
(b) Notwithstanding
anything herein to the contrary, other than in respect of Fraud:
(i) the
maximum aggregate amount of indemnifiable Losses which may be recovered from Buyer for indemnification by the Seller Indemnified
Persons pursuant Section 8.2(a) shall be an amount equal to General Cap; provided, however, that the General Cap
will not apply to claims for Losses made by the Seller Indemnified Persons for any breaches of, or inaccuracies in, any of the
Buyer Special Representations or Buyer Fundamental Representations;
(ii) the
maximum aggregate amount of indemnifiable Losses which may be recovered from Buyer for indemnification by the Seller Indemnified
Persons pursuant any breach or inaccuracy in any of the Buyer Special Representations shall be an amount equal to the Special Cap;
provided, however, that Buyer’s liability for Losses under Section 8.2(a) (excluding for any breaches of, or inaccuracies
in, any of the Buyer Fundamental Representations) shall not exceed the Special Cap in the aggregate; and
(iii) Buyer
shall not have any Liability under Section 8.2 in excess of a maximum aggregate amount equal to the Exchange Consideration
received at Closing, calculated as of the Closing Date in accordance with Section 8.8.
(c) Notwithstanding
anything herein to the contrary, no limitations on indemnification set forth in this Article VIII, including with respect to time
limits, the Threshold Amount, the General Cap and the Special Cap shall apply to any claims for Losses arising out of Fraud.
8.7 Exclusive Remedy.
Subject to Section 11.10, with the exception of claims based upon Fraud,
the Parties acknowledge and agree that their sole and exclusive remedy with respect to claims for any breach of any representation,
warranty, covenant or agreement set forth herein or otherwise relating to the subject matter of this Agreement from and after
the Closing Date shall be pursuant to the indemnification provisions set forth in this Article VIII. In furtherance of
the foregoing, subject to Section 11.10, each Party hereby waives, to the fullest extent permitted under Law, any
and all rights, claims and causes of action for any breach of any representation, warranty, covenant or agreement set forth herein
that it may have against the other Parties hereto arising under or based upon any Law, except pursuant to the indemnification
provisions set forth in this Article VIII. Notwithstanding the foregoing, nothing in this Section 8.7 or elsewhere
in this Agreement will affect an Indemnified Person’s right to equitable remedies to the extent available or to seek any
remedy on account of Fraud.
8.8 Value of Shares.
If a Buyer Indemnified Person makes a claim directly against the Indemnifying Seller
for indemnifiable Losses under this Article VIII, the Indemnifying Seller may elect, at the Indemnifying Sellers sole and
absolute discretion, to satisfy such claim with cash or Buyer Common Stock beneficially owned by the Indemnifying Seller. To the
extent any claim for indemnifiable Losses under this Article VIII is to be satisfied by the return and cancellation of
any Buyer Common Stock paid to the Indemnifying Seller, the per share value of any such Buyer Common Stock at the time of satisfaction,
release and cancellation shall be an amount in U.S. dollars, equal to the Buyer Common Stock’s VWAP for the period of thirty
(30) consecutive trading days ending on the trading day immediately prior to such date of payment. The Buyer Indemnified Persons’
sole recourse against the Indemnifying Seller in respect of any finally resolved indemnification obligations of the Indemnifying
Sellers shall be to seek return and cancellation of a portion of the Buyer Common Stock then held by the Indemnifying Seller,
pursuant to the pricing terms and subject to the limitations of this Article VIII. Notwithstanding the immediately preceding
sentence to the contrary, if an Indemnifying Seller, at the time of payment of a claim for which it is liable hereunder, does
not hold a sufficient number of shares to satisfy the claim because it has previously sold shares of Buyer Common Stock acquired
hereunder, then such Indemnifying Seller may be liable hereunder in cash for an amount up to the lesser of (i) the net proceeds
actually received by him for the sale of its shares of Buyer Common Stock acquired hereunder and (ii) the amounts remaining under
the General Cap or Special Cap to the extent applicable to such indemnifiable claim.
8.9 Losses Net of Insurance
Coverage. In calculating amounts payable to an Indemnified
Person, the amount of any indemnified Losses shall be computed net of (i) payments actually recovered by such Person under any
insurance policy, with respect to such Losses, less any increase in the corresponding premium, and (ii) any prior recovery by
such Person from any third party with respect to such Losses.
8.10 No Duplicative
Recovery. Where substantially the same events or circumstances
qualify under one or more single or multiple claims or under one or more provisions of this Agreement, the Indemnified Person
shall not be entitled to double or duplicative recovery of Losses arising out of such events or circumstances, or to calculate
its Losses by duplicating or double counting its Losses arising out of such events or circumstances. For the avoidance of doubt,
if the Indemnified Person is entitled to bring the claim under more than one provision of this Agreement, such Indemnified Person
may choose at its sole and absolute discretion the provision or provisions under which it seeks indemnification.
8.11 Straddle Period.
In the case of a Straddle Period: (a) the amount of any property or similar ad valorem
Taxes of any Target Company for a Straddle Period that relate to the portion of such Straddle Period through the end of the Closing
Date will be deemed to be the total amount of such Taxes for the Straddle Period multiplied by a fraction, (i) the numerator of
which is the number of days in the Straddle Period up to and including the Closing Date, and (ii) the denominator of which is
the total number of days in such Straddle Period, and (b) the amount of any Taxes based on or measured by income, gains, or receipts
of any Target Company for the portion of such Straddle Period through the end of the Closing Date will be determined based on
an interim closing of the books as of the close of business on the Closing Date.
8.12 Tax Treatment of
Indemnification Payments. All indemnification payments
made under this Agreement shall be treated by the parties as an adjustment to the Exchange Consideration for Tax purposes unless
otherwise required by applicable law.
Article
IX
CLAIMS
9.1 Notice of Claims
and Expenses. Promptly after the receipt by Buyer (on behalf of a Buyer Indemnified Person)
or the Sellers’ Representative (on behalf of a Seller Indemnified Person) of notice or discovery of any Proceeding or other
Loss that such Party believes gives rise to a claim for indemnification (a “Claim”) under Article VIII,
such Party will give the other Party (which will be Buyer or the Sellers’ Representative, as the case may be) (the “Indemnifying
Party”) written notice of such Claim (a “Notice of Claim”). Each Notice of Claim will include the
following: (i) a statement that such Party believes that an Indemnified Person is entitled to indemnification under Article
VIII, (ii) the actual Losses being claimed, and (iii) a summary of known, relevant facts with respect to such Claim; provided
that no defect in the information contained in such Notice of Claim will relieve the Indemnifying Party from any obligation
under Article VIII, except to the extent such failure to include information actually prejudices such Indemnifying Party.
9.2 Resolution of Claims.
Following timely provided notice of a Claim under this Agreement in accordance with Section
9.1 (other than a Third Party Claim which is governed by Section 8.3), the Indemnifying Party will have thirty (30)
days from the date notice was provided of such Claim (the “Dispute Period”) to make such investigation of the
Claim as the Indemnifying Party deems necessary or advisable. For purposes of such investigation, the Indemnified Person will
make available to the Indemnifying Party all the information reasonably related to such Claim relied upon by, or in the possession
or control of, the Indemnified Person to substantiate such Claim. If the Indemnifying Party disagrees with the validity or amount
of all or a portion of such Claim made by the Indemnified Person, the Indemnifying Party will provide to the Indemnified Person
written notice thereof (the “Indemnification Dispute Notice”) prior to the expiration of the Dispute Period.
If the Indemnifying Party provides notice that it does not have a dispute with respect to such Claim for indemnification, then
such Claim will be deemed approved and consented to by the Indemnifying Party (such Claim being referred to herein as an “Approved
Indemnification Claim”). The Indemnifying Party will pay the amount of the Approved Indemnification Claim by wire transfer
of immediately available funds (or, in the case of an Indemnifying Seller, by delivery of its shares of Buyer Common Stock to
the extent applicable under Article VIII) within five (5) business days after such Claim is determined to be an Approved
Indemnification Claim. If no Indemnification Dispute Notice is timely provided to the Indemnified Person within the Dispute Period
or if an Indemnification Dispute Notice is provided to the Indemnified Person within the Dispute Period and the Indemnifying Party
and the Indemnified Person do not agree to the validity and/or amount of such disputed Claim, the Indemnifying Party and the Indemnified
Person shall negotiate in good faith for a period of at least sixty (60) days to resolve the dispute. If the Indemnifying Party
and the Indemnified Person are unable to come to an agreement regarding such disputed Claim during such sixty (60) day period,
such dispute shall be resolved in accordance with Section 9.3.
9.3 Arbitration.
If there is a dispute with respect to a Claim and no settlement agreement is reached
despite negotiations between the Parties in accordance with Section 9.2, then either Party may, by written notice to the
other, submit such dispute to binding arbitration to the American Arbitration Association in Wilmington, Delaware, which will
administer the arbitration in accordance with the American Arbitration Association Commercial Arbitration Rules in effect on the
date of the execution of this Agreement (the “Rules”). Arbitration in accordance with this Section 9.3
will be conducted by a sole arbitrator mutually selected by the Parties; provided that if the Parties fail to mutually
select an arbitrator within fifteen (15) business days after such dispute is submitted to the American Arbitration Association,
then Buyer or Seller will follow the arbitrator selection procedures in accordance with the Rules. The arbitrators’ authority
will be confined to determining (a) whether the Indemnified Person is entitled to recover any indemnifiable Losses and (b) the
prevailing party and any award of fees or costs (or both). The final decision of the arbitrator will include the dollar value
of the award to the Indemnified Person, if any, and will be furnished to both parties in writing. The prevailing party, as determined
by the arbitrator, will be entitled to an award of reasonable attorneys’ fees and costs, and responsibility for all costs
of arbitration paid or payable by the prevailing party, as determined by the arbitrator, will be allocated among the parties in
the discretion of the arbitrator and specified in the arbitrators award. The arbitrator will not have the power to alter, amend,
or otherwise affect the terms of these arbitration provisions or any other provision of this Agreement or any other documents
that are executed in connection with this Agreement. The final decision of the arbitrator will constitute the conclusive determination
of the issues in question, binding upon both parties. Judgment upon any award rendered by the arbitrator may be entered in any
court having jurisdiction.
Article
X
TERMINATION, AMENDMENT, AND WAIVER
10.1 Termination.
This Agreement may be terminated and the Transactions abandoned at any time before the
Closing:
10.1.1 Mutual Written
Consent. By mutual written consent of Buyer and Company
(on behalf of itself and Sellers);
10.1.2 Written Notice
by Buyer or Sellers’ Representatives. By written
notice by Buyer or the Sellers’ Representative if any of the conditions to the Closing set forth in Article VII have
not been satisfied or waived by February 28, 2024 (the “Outside Date”); provided, however, the
right to terminate this Agreement under this Section 10.1.2 shall not be available to a Party if the breach or violation
by such Party or its Affiliates (or with respect to Company, any Seller) of any representation, warranty, covenant or obligation
under this Agreement was the cause of, or resulted in, the failure of the Closing to occur on or before the Outside Date;
10.1.3 Written
Notice of Order. By written notice by either Buyer or Company
if a Governmental Entity of competent jurisdiction shall have issued an Order or taken any other action permanently restraining,
enjoining or otherwise prohibiting the Transactions contemplated by this Agreement, and such Order or other action has become
final and non-appealable; provided, however, that the right to terminate this Agreement pursuant to this Section
10.1.3 shall not be available to a Party if the failure by such Party or its Affiliates (or with respect to Company,
any Seller) to comply with any provision of this Agreement has been a substantial cause of, or substantially resulted in, such
action by such Governmental Entity;
10.1.4 Written Notice
of Breach by Buyer. By written notice by Company to Buyer,
if (i) there has been a breach by Buyer of any of its representations, warranties, covenants or agreements contained in this Agreement,
or if any representation or warranty of Buyer shall have become untrue or inaccurate, in any case, which would result in a failure
of a condition set forth in Section 7.3.1 or Section 7.3.2 to be satisfied (treating the Closing Date
for such purposes as the date of this Agreement or, if later, the date of such breach), and (ii) the breach or inaccuracy is incapable
of being cured or is not cured within the earlier of (A) twenty (20) days after written notice of such breach or inaccuracy is
provided to Buyer or (B) the Outside Date; provided, that Company shall not have the right to terminate this Agreement
pursuant to this Section 10.1.4 if at such time Company or any Seller is in material uncured breach of this Agreement;
10.1.5 Written Notice
of Breach by Company or Seller. By written notice by Buyer
to Company, if (i) there has been a breach by Company or any Seller of any of its representations, warranties, covenants or agreements
contained in this Agreement, or if any representation or warranty of such Parties shall have become untrue or inaccurate, in any
case, which would result in a failure of a condition set forth in Section 7.2.1 or Section 7.2.2 to
be satisfied (treating the Closing Date for such purposes as the date of this Agreement or, if later, the date of such breach),
and (ii) the breach or inaccuracy is incapable of being cured or is not cured within the earlier of (A) twenty (20) days after
written notice of such breach or inaccuracy is provided to Company or (B) the Outside Date; provided, that Buyer shall
not have the right to terminate this Agreement pursuant to this Section 10.1.5 if at such time Buyer is in material
uncured breach of this Agreement;
10.1.6 Written Notice
of Company Material Adverse Effect. By written notice by
Buyer to Company, if there shall have been a Company Material Adverse Effect on the Target Companies taken as a whole following
the date of this Agreement which is uncured and continuing;
10.1.7 Written Notice
of Buyer Stockholder Meeting. By written notice by either
Buyer or Company to the other, if the Buyer Stockholder Meeting is held (including any adjournment or postponement thereof) and
has concluded, Buyer’s stockholders have duly voted, and the Stockholder Approval was not obtained;
10.1.8 Written Notice
of Unsatisfactory Buyer Due Diligence. By written notice
by Buyer to the Sellers’ Representative if Buyer reasonably determines that there has been a material adverse change to
the Target Companies’ AI Technologies, Company IP Rights or capital structure,
except as contemplated by this Agreement on or prior to the date that is five (5) Business Days following the date of
the delivery of the Company Disclosure Schedules to Buyer pursuant to Section 6.10; provided, that Buyer shall not
have the right to terminate this Agreement pursuant to this Section 10.1.8 if at such time Buyer is in material uncured
breach of this Agreement; or
10.1.9 Written Notice
of Unsatisfactory Seller Due Diligence. By written notice
by the Sellers’ Representative to Buyer if the Sellers reasonably determined that there has been a material adverse change
to the Buyer IP Rights or capital structure, except as contemplated by this Agreement on or prior to the date that is five (5)
Business Days following the date of the delivery of the Buyer Disclosure Schedules to the Sellers pursuant to Section 6.10;
provided, that Sellers shall not have the right to terminate this Agreement pursuant to this Section 10.1.9 if
at such time Company or any Seller is in material uncured breach of this Agreement.
10.2 Effect of Termination.
In the event of termination of this Agreement by either Company or Buyer, this Agreement
will become void and have no effect, and there will be no liability or obligation on the part of Buyer, Company, any Seller, or,
as applicable, their respective officers or directors, except that (a) the provisions of Sections 6.1 (Confidentiality
Agreement), 6.4 (Public Announcements), 10.2 (Effect of Termination), Article XI (General Provisions), and the Confidentiality
Agreement will survive any termination, and (b) no Party will be relieved of any liability or damages arising from Fraud or the
willful breach by such Party of any of its representations, warranties, or covenants included in this Agreement. Without limiting
and subject to the foregoing, and except as provided in this Section 10.2 and subject to the right to seek injunctions,
specific performance or other equitable relief in accordance with Section 11.10, the Parties’ sole right prior
to the Closing with respect to any breach of any representation, warranty, covenant or other agreement contained in this Agreement
by another Party or with respect to the Transactions contemplated by this Agreement shall be the right, if applicable, to terminate
this Agreement pursuant to Section 10.1.
Article
XI
GENERAL PROVISIONS
11.1 Notices.
All notices, requests, demands, or other communications required or permitted to be given under this Agreement will be in writing
and deemed given and received upon (a) personal delivery, (b) one business day after being sent, if sent by reputable, nationally
recognized overnight courier service, (c) three (3) business days after being mailed, if sent by registered or certified mail,
pre-paid and return receipt requested, in each case to the applicable Party at the following addresses (or at such other address
for a Party as shall be specified by like notice), or (d) affirmative confirmation of a receipt of an email:
(i) |
if to Buyer, or to Company after Closing: |
Renovaro Biosciences Inc.
Attention: Luisa Puche, Chief Financial Officer
9480 NE 2nd Avenue, #73
Miami, FL 33138
Email: lpuche@renovarobio.com |
|
With a copy (which will not constitute notice) to: |
K&L
Gates LLP
200 South
Biscayne Boulevard
Suite
3900
Miami,
Florida 33131-2399
Attention:
Clayton E. Parker, Esq.
Facsimile
No.: 305-358-7095
Email: clayton.parker@klgates.com
|
(ii) |
if to Company (before Closing), to: |
GEDi Cube
Intl Ltd
71-75
Shelton Street
Covent
Garden
London
WC2H 9JQ
Attn.:
Karen Brink, Statutory Director
E-mail: karen@gedicube.com
|
|
With a copy (which will not constitute notice) to: |
Greenberg Traurig, P.A.
333 S.E. 2nd Avenue
Miami, FL 33131
Attention: John D. Owens, III,
Esq.
Email: owensjohn@gtlaw.com
|
(iii) |
if to Sellers’ Representative to: |
Yalla Yalla Ltd.
Q2, Level 7, Quad Central,
Triq L-Esporaturi
Central Business District,
Birkirkara, CBD 1040, Malta
Attention: Karen Brink
E-mail: kbri@mac.com
|
11.2 Disclosure Schedule.
Certain information set forth in the schedules to the Buyer Disclosure Schedule and the
Company Disclosure Schedule is included solely for informational purposes and may not be required to be disclosed pursuant to
this Agreement. The disclosure of any information shall not be deemed to constitute an acknowledgment that such information is
required to be disclosed in connection with or expand the representations and warranties made by Buyer, Company, or Seller, as
applicable,
in this Agreement or that such information
is material, nor shall such information be deemed to establish a standard of materiality, nor shall it be deemed an admission of
any liability of, or concession as to any defense available to, Buyer, Company, or any Seller, as applicable. Unless this Agreement
specifically provides otherwise, neither the specification of any item or matter in any representation or warranty contained in
this Agreement nor the inclusion of any specific item in any of the schedules to the Buyer Disclosure Schedule or the Company Disclosure
Schedule is intended to imply that such item or matter, or other items or matters, are or are not in the ordinary course of business,
and no Party may use the fact of the setting forth or the inclusion of any such item or matter in any dispute or controversy between
the Parties as to whether any obligation, item or matter not described herein or included in any of the schedules is or is not
in the ordinary course of business for purposes of this Agreement. The section number headings in the schedules to the Buyer Disclosure
Schedule and the Company Disclosure Schedule correspond to the section numbers in this Agreement and any information disclosed
in any section of the schedules shall be deemed to be disclosed and incorporated into any other section of the schedules (and,
for the avoidance of doubt, for purposes of any other representations and warranties in this Agreement) where the relevance of
such disclosure is reasonably apparent on its face. The Parties do not assume any responsibility to any third person other than
to the extent provided in the Agreement for the form or accuracy of any information herein. In disclosing information in the schedules
included in the Buyer Disclosure Schedule and the Company Disclosure Schedule, Buyer, Company, and Sellers have not and do not
waive any attorney-client privilege associated with such information or any protection afforded by the work-product doctrine with
respect to any of the matters disclosed or discussed herein.
11.3 Supplements to
Disclosure Schedule. From time to time before the Closing,
Buyer will promptly supplement or amend the Buyer Disclosure Schedule, and Company and each Seller will promptly supplement or
amend the Company Disclosure Schedule, with respect to any matter, condition, or occurrence arising, which if existing or occurring
at the date of this Agreement that would have been required to be included in such respective Company Disclosure Schedule or Buyer
Disclosure Schedule. No supplement or amendment to the Buyer Disclosure Schedule or Seller Disclosure Schedule, or filing of any
Additional SEC Document, will (a) cure any breach of any representation or warranty made in this Agreement for the purpose of
determining satisfaction of the closing conditions in Article VIII or Article VII, respectively, or (b) be taken
into account for purposes of determining indemnification obligations in Article VIII. No amendment or supplement to such
respective Company Disclosure Schedule or Buyer Disclosure Schedule will be permitted without the written consent of Company or
Buyer, respectively.
11.4 Interpretation.
As used in this Agreement, the term (a) “subsidiary” or “subsidiaries”
means with respect to any Person, any entity or entities of which such Person directly or indirectly owns an amount of the voting
securities or other voting ownership interests sufficient to elect a majority of its board of directors or other governing body
(or, if there are no such interests, 50% or more of the equity interests); (b) “Affiliate” has the meaning
included in Rule 12b-2 promulgated under the Exchange Act; (c) “business day” means any day other than a Saturday,
Sunday, or a day on which banking institutions in New York,
New York, the Netherlands or the United Kingdom are permitted or obligated by law to
be closed for regular banking business; (d) “beneficially owned” or “beneficial ownership”
shall be determined in accordance with Rule 13d-3 promulgated under the Exchange Act; (e) the words “include,”
“includes,” and “including” when used in this Agreement will be treated in each case as followed
by the words “without limitation”; and (f) The respective Parties to this Agreement and their attorneys
have negotiated this Agreement and any ambiguity or uncertainty in the language of this Agreement will not be presumptively construed
for or against a Party as drafter. The table of contents and headings in this Agreement are for reference purposes only and will
not affect in any way the meaning or interpretation of this Agreement. A reference to a section, schedule, or an exhibit means
a section in, or schedule or exhibit to, this Agreement unless otherwise explicitly provided. A reference in this Agreement to
$ or dollars is to U.S. dollars. The definitions of terms herein shall apply equally to the singular and plural forms of the terms
defined. The words “hereof,” “herein,” “hereby,” “hereto,”
and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole
and not to any particular provision of this Agreement. References to “this Agreement” shall include the Company Disclosure
Schedule and the Buyer Disclosure Schedule. References to “made available” or “provided to”
(or words of similar import) when referring to any document or information being made available by Company to Buyer shall mean
posted to the electronic data room established in respect to the Transactions at least two business days prior to the date of this
Agreement.
The Parties have participated
jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation arises,
this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring
or disfavoring any Party by virtue of the authorship of any provision of this Agreement.
11.5 Counterparts.
This Agreement may be executed (a) in one or more partially or fully executed counterparts,
each of which will be deemed an original and will bind the signatory, but all of which together will constitute the same instrument,
and (b) by facsimile or electronic mail. The execution and delivery of a signature page in the form annexed to this Agreement
by any Party who will have been furnished the final form of this Agreement will constitute the execution and delivery of this
Agreement by such Party.
11.6 Entire Understanding;
No Third Party Beneficiaries. This Agreement, the Confidentiality
Agreement, and the Transaction Documents constitute the entire agreement among the Parties with respect to the subject matter
of this Agreement and supersede all prior agreements and understandings, both written and oral, among the Parties with respect
to the subject matter of this Agreement. This Agreement (a) is not intended to confer upon any other Person any rights or remedies
under this Agreement (except as otherwise expressly provided in this Agreement); and (b) will not be assigned by operation of
law or otherwise except as otherwise specifically provided.
11.7 Governing Law.
This Agreement shall be governed by, construed and enforced in accordance with the Laws
of the State of Delaware without regard to the conflict of laws principles thereof.
11.8 Amendment; Waiver.
Except as may otherwise be provided in this Agreement and by applicable law, any provision,
exhibit, or schedule of this Agreement may be amended or modified by the Parties before the Closing Date, if and only if such
amendment or modification is in writing and signed on behalf of each of the Parties to this Agreement. This Agreement may not
be amended, modified or supplemented after the Closing Date except by written agreements of the Parties. No waiver by any Party
of any of the provisions of this Agreement will be effective unless explicitly set forth in writing and signed by the Party so
waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy,
power or privilege arising from this Agreement will operate or be construed as a waiver nor will any single or partial exercise
of any right, remedy, power or privilege arising from this Agreement preclude any other or further exercise of this Agreement
or the exercise of any other right, remedy, power, or privilege.
11.9 Successors and
Assigns. This Agreement shall not be assigned by operation
of Law or otherwise without the prior written consent of Buyer and Company (and after the Closing, Buyer and Sellers), and any
assignment without such consent shall be null and void; provided that no such assignment shall relieve the assigning Party
of its obligations hereunder. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of,
and be enforceable by, the Parties and their respective permitted successors and assigns.
11.10 Specific Performance.
Except as otherwise provided herein, any and all remedies herein expressly conferred
upon a Party hereto shall be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity
upon such Party, and the exercise by a Party hereto of any one remedy shall not preclude the exercise of any other remedy and
nothing herein shall be deemed a waiver by any Party hereto of any right to specific performance or injunctive relief. Except
as otherwise provided herein and specifically subject to Section 8.7, the Parties acknowledge and agree that any breach
of the terms of this Agreement would give rise to irreparable harm for which money damages would not be an adequate remedy. Except
as otherwise provided herein, the Parties agree that, in addition to any other remedies, each will be entitled to an injunction
to prevent breaches of this Agreement and to enforce the terms of this Agreement by a decree of specific performance without the
necessity of proving the inadequacy of money damages as a remedy or posting a bond.
11.11 Severability.
If any term or other provision of this Agreement is invalid, illegal, or incapable of
being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement will nevertheless remain
in full force and effect so long as the economic or legal substance of the Transactions are not affected in any manner materially
adverse to any Party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced,
the Parties will negotiate in good faith to modify this Agreement to effect the original intent of the Parties as closely as possible
in a mutually acceptable manner in order that the Transactions be consummated as originally contemplated to the greatest extent
possible.
11.12 Submission to
Jurisdiction. Subject to the provisions of Section 9.3,
for the purpose of any action arising out of or relating to this Agreement brought by any Party against another Party arising
out of or relating to this Agreement or any of the Transactions (a) each of the Parties irrevocably and unconditionally consents
and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, if (and only if) the
Court of Chancery of the State of Delaware declines to accept jurisdiction over a particular matter, the Superior Court of the
State of Delaware (Complex Commercial Division) or, if (and only if) the Superior Court of the State of Delaware (Complex Commercial
Division) declines to accept jurisdiction over a particular matter, any federal court sitting in the State of Delaware, and any
appellate courts therefrom, (b) irrevocably waives any objection that it may now or hereafter have to the venue of any such action,
dispute or controversy in any such court or that such legal Proceeding was brought in an inconvenient court and agrees not to
plead or claim the same, and (c) agrees that it shall not bring any legal Proceeding relating to this Agreement or the Transactions
in any court other than the aforesaid courts, and (d) each of the Parties irrevocably consents to service of process by first
class certified mail, return receipt requested, postage prepaid, to the address at which such Party is to receive notice in accordance
with Section 11.1; provided, however, that the foregoing shall not limit the right of a Party to effect service
of process on the other Party by any other legally available method.
11.13 Waiver of Jury
Trial. EACH OF THE PARTIES TO THIS AGREEMENT ACKNOWLEDGES
AND AGREES THAT ANY CONTROVERSY ARISING UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES. AS A RESULT
EACH PARTY TO THIS AGREEMENT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT THAT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT
TO LITIGATION ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS. EACH PARTY TO THIS AGREEMENT UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THIS WAIVER AND MAKES THIS WAIVER VOLUNTARILY.
11.14 Sellers’
Representative.
11.14.1 Appointment
of Seller’s Representative. Each Seller does hereby
irrevocably appoint the Sellers’ Representative as its true and lawful attorney-in-fact and agent, with full power of substitution
or re-substitution, to act on behalf of such Seller with respect to this Agreement and the Transaction Documents in accordance
with the terms and provisions of this Agreement, and to take any and all actions and make any decisions required or permitted
to be taken by the Sellers’ Representative pursuant to this Agreement or the Transaction Documents, including the power:
(a) to
give and receive notices and communications;
(b) agree
to, negotiate, enter into settlements and compromises of, and comply with orders or otherwise handle any other matters described
in Section 6.7;
(c) execute
and deliver all documents necessary or desirable to carry out the intent of this Agreement and the Transaction Documents;
(d) make
all elections or decisions contemplated by this Agreement and the Transaction Documents;
(e) engage,
employ or appoint any agents or representatives (including attorneys, accountants and consultants) to assist the Sellers’
Representative in complying with his duties and obligations;
(f) to
receive funds, make payments of funds and give receipts for funds;
(g) to
receive funds for the payment of expenses of Sellers and apply such funds in payment for such expenses; and
(h) take
all actions necessary or appropriate in the good faith judgment of the Sellers’ Representative for the accomplishment of
the foregoing.
Notwithstanding the above,
in case any of the aforementioned actions need to be executed locally in the jurisdictions involved, the Sellers are obliged to
grant the necessary documents, instruments and/or powers of attorney in accordance with the formalities and requirements established
by the correspondent legislation. The appointment of the Sellers’ Representative to act on behalf of Sellers shall be deemed
coupled with an interest and shall be irrevocable, and Buyer, Company and any other Person may conclusively and absolutely rely,
without inquiry, upon any action of the Sellers’ Representative in all matters referred to herein. All notices required to
be made or delivered by Buyer to Sellers shall be made to the Sellers’ Representative for the benefit of Sellers and shall
discharge in full all notice requirements of Buyer to Sellers with respect thereto. The Sellers’ Representative shall act
for Sellers on all of the matters set forth in this Agreement in the manner the Sellers’ Representative believes to be in
the best interest of Sellers and consistent with the obligations of Sellers under this Agreement, but the Sellers’ Representative
shall not be responsible to Sellers for any Losses which Sellers may suffer by the performance of the Sellers’ Representative’s
duties under this Agreement, other than Losses arising from Fraud in the performance of such duties under this Agreement. The Sellers’
Representative shall not have any duties or responsibilities except those expressly set forth in this Agreement, and no implied
covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or shall otherwise
exist against the Sellers’ Representative.
11.14.2 Reliance by
the Sellers’ Representative. The Sellers’ Representative
shall be entitled to rely, and shall be fully protected in relying, upon any statements furnished to him by Sellers or Buyer or
any other evidence reasonably deemed by the Sellers’ Representative to be reliable, and the Sellers’ Representative
shall be entitled to act on the advice of counsel selected by him.
11.14.3 Expenses of
the Sellers’ Representative. The Sellers’ Representative
shall be entitled to retain counsel and to incur such expenses (including court costs and reasonable attorneys’ fees and
expenses) as the Sellers’ Representative deems to be necessary or appropriate in connection with his performance of his
obligations under this Agreement. All fees and expenses incurred by the Sellers’ Representative in performing his duties
shall be borne by the Sellers.
11.14.4 Indemnification
of the Sellers’ Representative. Each Seller hereby
agrees to indemnify the Sellers’ Representative (in its capacity as such) against, and to hold the Sellers’ Representative
(in its capacity as such) harmless from any and all liabilities of whatever kind which may at any time be imposed upon, incurred
by or asserted against the Sellers’ Representative in such capacity in any way relating to or arising out of the Sellers’
Representative’s action or failure to take action pursuant to this Agreement or in connection herewith or therewith in such
capacity; provided, that Sellers shall not be liable for the payment of any portion of such liabilities to the extent resulting
from the Fraud of the Sellers’ Representative. Sellers hereby authorize the Sellers’ Representative to apply proceeds
otherwise distributable to Sellers pursuant to this Agreement to satisfy any of Sellers’ obligations under this Section
11.14.4.
11.14.5 Resignation
of the Sellers’ Representative. The Sellers’
Representative may resign at any time, and may be removed for any reason or no reason by the vote or written consent of a majority
in interest of the Sellers according to each Seller’s Pro Rata Share (the “Majority Sellers”); provided,
however, in no event shall the Sellers’ Representative resign or be removed without the Majority Sellers having first
appointed a new Sellers’ Representative who shall assume such duties immediately upon the resignation or removal of the
Sellers’ Representative. In the event of the death, incapacity, resignation or removal of the Sellers’ Representative,
a new Sellers’ Representative shall be appointed by the vote or written consent of the Majority Sellers. Notice of such
vote or a copy of the written consent appointing such new Sellers’ Representative shall be sent to Buyer, such appointment
to be effective upon the later of the date indicated in such consent or the date such notice is received by Buyer; provided,
that until such notice is received, Buyer, shall be entitled to rely on the decisions and actions of the prior Sellers’
Representative as described in Section 11.14.1.
11.15 Legal Representation
Each Party, on its own behalf and on behalf of its directors, managers, officers, owners, employees
and Affiliates and each of their successors and assigns (all such parties, the “Waiving Parties”), hereby agrees
that. K&L Gates LLP (or any successor thereto) may represent Buyer or any direct or indirect director, manager, officer, owner,
employee or Affiliate thereof, in connection with any dispute, claim, Proceeding or Liability arising out of or relating to this
Agreement, any Transaction Document or the transactions contemplated hereby or thereby (any such representation, the “Buyer
Post-Closing Representation”) notwithstanding its representation (or any continued representation) of Buyer in connection
with the transactions contemplated by this Agreement, and each Party on behalf of itself and the applicable Waiving Parties hereby
consents thereto and irrevocably waives (and will not assert) any conflict of interest or any objection arising therefrom or relating
thereto, even though the interests of the Buyer Post-Closing Representation may be directly adverse to the applicable Waiving
Parties.
[remainder of page intentionally blank]
IN WITNESS WHEREOF, the Parties hereto have
signed or caused their respective duly authorized officers to sign this Agreement, all as of the date first written above.
|
BUYER: |
|
|
|
RENOVARO BIOSCIENCES INC. |
|
|
|
By: |
/s/ Mark Dybul_ |
|
Name: |
Mark Dybul, M.D. |
|
Title: |
Chief Executive Officer |
|
|
|
COMPANY: |
|
|
|
GEDI CUBE INTL LTD. |
|
|
|
By: |
/s/ Frank Van Asch |
|
Name: |
Frank Van Asch |
|
Title: |
Director |
|
|
|
SIGNING SELLERS: |
|
|
|
YALLA YALLA LTD. |
|
|
|
By: |
/s/ Karen Brink |
|
Name: |
Karen Brink |
|
Title: |
Authorized Signature |
|
|
|
SEPA BEHEER BV |
|
|
|
By: |
/s/ F.Y. Van Asch |
|
Name: |
F.Y. Van Asch |
|
Title: |
Director |
|
|
|
CK VA KALKEN BEHEER BV |
|
|
|
By: |
/s/ CK Van Kalken |
|
Name: |
CK Van Kalken |
|
Title: |
Director |
|
|
|
|
SELLERS’ REPRESENTATIVE: |
|
|
|
YALLA YALLA LTD. |
|
|
|
|
By: |
/s/ Karen Brink |
|
Name: |
Karen Brink |
|
Title: |
Authorized Signature |
95
EXHIBIT 99.1
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive
Agreement to Combine
The combined company aims to accelerate precision,
personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted
treatments, and drug discovery
-AI technology products
projected to be in marketplace in 2024
-Phase 1/2 human studies of pancreatic
cancer and other solid tumors with poor longevity projected to begin second half of 2024
LOS ANGELES – Sept. 29, 2023 - Renovaro
Biosciences Inc. (NASDAQ: RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy has signed a definitive
agreement to combine with GEDi Cube Intl Ltd., (GEDi Cube) an AI medical technology company, in which GEDi Cube will become a wholly-owned
subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”).
If completed, the Transaction will result in a combined company that will
offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases
such as pancreatic cancer and other solid tumors with poor life expectancy. It is expected that the combined company will have a unique
advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities
that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance
the fields of diagnosis and treatment with the aim of redefining the future of medicine.
“We believe GEDi Cube’s AI technology
will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic
approaches for cancer and other diseases,” said Dr. Mark Dybul, CEO of Renovaro Biosciences. “The combined company will have
independent operating divisions that will allow each technology to move as quickly as possible to commercialization while the collaboration
between divisions will aim to drive new advances in both AI and medicine.”
“I believe this is a unique opportunity to leverage
the capabilities of our two companies, allowing us to accelerate our product development roadmap and our potential to improve diagnostics
and treatments for many cancers,” said Craig Rhodes, CEO of GEDi Cube. “We expect to begin offering commercial diagnostic
products in 2024 that, in our view, will be comparable or superior to what is currently in the marketplace. We are looking forward to
this exciting new venture.”
GEDi Cube has been developing its innovative technologies
over the last decade and has already validated early diagnosis of lung cancer in humans at a leading university hospital. The company
has also validated technology to target 12 additional cancers, including pancreatic and breast cancer.
Renovaro Biosciences has developed advanced cell,
gene and immunotherapy techniques designed to reignite the body’s natural tumor-fighting capabilities. The company expects to begin
human Phase 1/2 clinical trials of its leading candidate for pancreatic cancer and other solid tumors with poor life expectancy by the
second half of 2024.
About the Transaction
The Transaction is structured as a stock-for-stock
acquisition whereby all of GEDi Cube’s outstanding equity interests will be exchanged for shares of Renovaro common stock. Following
the closing of the Transaction, GEDi Cube equity holders are expected to own approximately 50% of the combined company, subject to certain
adjustments provided for in the definitive agreement. The agreement was executed by a supermajority controlling interest of 78 percent
of GEDi Cube shareholders; it is expected the remaining 22 percent will be included in the agreement prior to closing.
The boards of directors of both companies have unanimously
approved the definitive agreement. The Transaction is expected to close late in the fourth quarter of 2023 or early 2024, subject to satisfying
certain closing conditions, including the receipt of stockholder approval by Renovaro stockholders of the issuance of the shares of Renovaro
common stock in the Transaction and an amendment to its certificate of incorporation to increase the number of authorized shares of common
stock of Renovaro.
Important Additional Information and Where to Find It
In connection with the proposed Transaction, Renovaro
intends to file a proxy statement (the “proxy statement”), and will file other documents regarding the proposed Transaction
with the SEC. INVESTORS AND SECURITYHOLDERS OF RENOVARO ARE URGED TO CAREFULLY AND THOROUGHLY READ, WHEN THEY BECOME AVAILABLE,
THE PROXY STATEMENT, AS MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY RENOVARO WITH THE SEC
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RENOVARO, GEDI CUBE AND THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND
RELATED MATTERS.
Once complete, a definitive proxy statement will be
mailed to stockholders of Renovaro. Investors will be able to obtain free copies of the proxy statement, as may be amended from time to
time, and other relevant documents filed by Renovaro with the SEC (when they become available) through the website maintained by the SEC
at www.sec.gov. Copies of documents filed with the SEC by Renovaro, including the proxy statement (when it becomes available), will be
available free of charge from Renovaro’s website at www.renovarobio.com under the “Financials” tab.
Participants in the Solicitation
Renovaro and its directors and executive officers
may be deemed to be participants in the solicitation of proxies from the stockholders of Renovaro in connection with the proposed Transaction.
Information about Renovaro’s directors and executive officers is set forth in Renovaro’s definitive proxy statement for the
2023 annual meeting of stockholders filed with the SEC on May 16, 2023, and the proxy statement (when it becomes available). Other information
regarding the interests of such individuals, as well as information regarding other persons who may be deemed participants in the proposed
Transaction, will be set forth in the proxy statement and other relevant materials to be filed with the SEC when they become available.
Stockholders of Renovaro, potential investors, and other readers should read the proxy statement carefully when it becomes available before
making any voting or investment decisions.
No Offer or Solicitation
This communication is not intended to and shall not
constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval
with respect to the proposed Transaction or otherwise. No offering of securities shall be made, except by means of a prospectus meeting
the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, or otherwise in accordance with applicable law.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements, other than statements of historical fact, included in this communication that address activities,
events or developments that Renovaro or GEDi Cube expects, believes or anticipates will or may occur in the future are forward-looking
statements. Words such as “estimate,” “project,” “predict,” “believe,” “expect,”
“anticipate,” “potential,” “create,” “intend,” “could,” “would,”
“may,” “plan,” “will,” “guidance,” “look,” “goal,” “future,”
“build,” “focus,” “continue,” “strive,” “allow” or the negative of such terms
or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions,
or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking.
These forward-looking statements include, but are not limited to, statements regarding the proposed Transaction, the expected closing
of the proposed Transaction and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies
and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities
and anticipated future performance. Information adjusted for the proposed Transaction should not be considered a forecast of future results.
There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements
included in this communication. These include the risk that cost savings, synergies and growth from the proposed Transaction may not be
fully realized or may take longer to realize than expected; the possibility that shareholders of Renovaro may not approve the issuance
of new shares of Renovaro common stock in the proposed Transaction or that shareholders of Renovaro may not approve the proposed Transaction;
the risk that a condition to closing of the proposed Transaction may not be satisfied, that either party may terminate the Transaction
Agreement or that the closing of the proposed Transaction might be delayed or not occur at all; potential adverse reactions or changes
to business or employee relationships, including those resulting from the announcement or completion of the proposed Transaction; the
occurrence of any other event, change or other circumstances that could give rise to the termination of the stock purchase agreement relating
to the proposed Transaction; the risk that changes in Renovaro’s capital structure and governance could have adverse effects on
the market value of its securities and its ability to access the capital markets; the ability of Renovaro to retain its Nasdaq listing;
the ability of GEDi Cube to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers
and on GEDi Cube’s operating results and business generally; the risk the proposed Transaction could distract management from ongoing
business operations or cause Renovaro and/or GEDi Cube to incur substantial costs; the risk that GEDi Cube may be unable to reduce expenses;
the impact of the COVID-19 pandemic, any related economic downturn; the risk of changes in regulations effecting the healthcare industry;
and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult
to predict and are beyond Renovaro’s or GEDi Cube’s control, including those detailed in Renovaro’s Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on Renovaro’s website at www.renovarobio.com
and on the website of the Securities and Exchange Commission (the “SEC”) at www.sec.gov. All forward-looking statements are
based on assumptions that Renovaro and GEDi Cube believe to be reasonable but that may not prove to be accurate. Any forward-looking statement
speaks only as of the date on which such statement is made, and neither Renovaro nor GEDi Cube undertakes any obligation to correct or
update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable
law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
About the Companies
GEDi Cube, Intl LTD is pioneering a multi-modal
approach for the early detection of cancer and its recurrence involving blood biopsies, imaging, and multiomic analysis. The company has
a strategic partnership with NVIDIA, the leader in semiconductors for AI. For more information on GEDi Cube Intl LTD, go to their website
at www.gedicube.com
Renovaro Biosciences Inc. has developed advanced cell, gene and immunotherapy
platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information
on Renovaro Biosciences Inc., go to its website at www.renovarobio.com.
Contact: ir@renovarobio.com
Source: Renovaro Biosciences Inc.
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Oct 2023 to Oct 2024